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“The real voyage of discovery consists not in seeking new landscapes, but in having new eyes.” 
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2 Abstract 
 Retinal dystrophies are a large and extremely variegate group of diseases causing 
visual impairments and eventually blindness. As of today, no cures are available for 
such conditions, and the most advanced clinical approaches  are based on classical gene 
transfer techniques. The recent development of genetic tools designed to manipulate 
splicing offers a unique opportunity to target several of these diseases, potentially 
reaching a highly specific and controlled effect in contrast to the more investigated gene 
supplementation therapies. These molecular tools are mainly part of two classes: 
antisense oligonucleotides (AONs) and chimeric or adapted small nuclear RNAs 
(snRNAs). They function by altering how the splicing machinery recognize a target 
sequence, usually an exon, allowing to increase its presence (exon inclusion) or 
decrease it (exon skipping) in mature mRNA.  
 The first aim of this work has been the identification of genes causing retinal 
dystrophies having mutations potentially targetable by splicing-correction approaches. 
Following screening of mutation databases we identified three genes, each of them 
having mutations with  characteristic interesting for a possible application of such 
approaches: CACNA2D4, RPGR, and USH2A.  
 The CACNA2D4 gene encodes for an accessory subunit of high-voltage-activated 
(HVA) calcium channels and, when mutated, causes retinal cone dystrophy 4 (RCD4).  
It was selected because of the presence of a mouse model of retinal dystrophy (Wycisk 
et al., 2006a), allowing an in vivo test of the designed strategy. Since the approach 
consisted in inducing skipping of the exon hosting the mutation, we analysed the 
splicing pattern of the target exon in vivo and in vitro; the functionality of the rescued 
protein resulting from therapeutic exon skipping. The analysis revealed on one side that 
the rescued protein was not functional, therefore showing how the approach was not 
feasible for CACNA2D4. Interestingly, we found evidence of two newly identified 
splicing isoforms of the gene, one of which mimics the effect of the mutation.  
 A mutation in RPGR intron 9 has been shown to cause retinitis pigmentosa by 
increasing the inclusion in mature mRNA of an alternatively spliced exon (E9a) 
(Neidhardt et al., 2007). Using splicing reporter minigene assays, we were able to 
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design efficient chimeric U1snRNAs able to mediate E9a skipping thus correcting the 
genetic defect. In the USH2A gene we instead identified an interesting region hosting 
5% of known mutation which could be approachable with exon skipping. The 
implementation of assays able to assess functionality of USH2A and RPGR will be 
fundamental for the development of new splicing-correction approaches for these genes.  
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3 Introduction1 
 Retinal dystrophies are an extremely diversified group of genetic diseases all 
characterized by visual dysfunctions that, in the worst cases, can lead to blindness. 
Today there are more than 200 genes responsible for syndromic and nonsyndromic 
retinal dystrophies (Daiger et al., 1998), each of them carrying several types of 
mutations leading to very different clinical phenotypes. The development of different 
gene therapy approaches has given a hope for the implementation of therapies for these 
otherwise incurable conditions. Messenger RNA (mRNA) splicing is a fundamental and 
extremely complex cellular process that has been so far barely considered as a 
therapeutic target (Bonnal et al., 2012; Havens et al., 2013), even if it can be considered 
as highly appealing given its importance in the cell. The ability to modulate splicing can 
in fact offer several advantages over other conventional gene replacement approaches, 
especially in the context of retinal dystrophies. By definition, antisense-based 
therapeutic approaches act following base-pairing with their mRNA target, thus giving 
the possibility of obtaining a great specificity of action. Since they act at the mRNA 
level, the endogenous transcriptional regulation of the target gene is always maintained. 
This means that the therapeutic effect is obtained only where and when the target pre 
mRNA is present. In a highly specialized and organized tissue like the retina it is 
particularly important to maintain endogenous gene regulation. Therapeutic 
interventions for delicate processes like the phototransduction cascade would require 
the preservation of this control for desirable outcomes (Smith et al., 2012). Splicing-
correction approaches allow also a fine-tuning over the relative abundance of splicing 
isoforms because, by acting at a pre-mRNA level, it is relatively easy to modulate their 
ratio. The availability of several different molecular tools that can be used to manipulate 
splicing renders these approaches a versatile and promising strategy for the multitude of 
retinal dystrophies known today. Moreover, the retina has some characteristics that 
make it a perfect target tissue for those therapies. First of all it is an easy tissue to 
1 It has been included in the introduction part of the PhD candidate’s review “Splicing-
Correcting Therapeutic Approaches for Retinal Dystrophies: Where Endogenous Gene 
Regulation and Specificity Matter” (Invest Oph- thalmol Vis Sci. 2014;55:3285–3294. 
DOI:10.1167/iovs.14-14544), with the authorisation of the copyright holder ARVO.  
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access, and different drug delivery routes are in use today (Gomes Dos Santos et al., 
2005; Martin et al., 2002). Being that the eye is relatively small, enclosed and separated 
from the rest of the body by the blood-brain barrier, it minimizes both the required dose 
and the unwanted systemic dissemination of the therapeutic agent, thus avoiding 
possible complications due to widespread side effects of the therapy (Surace and 
Auricchio, 2008). The eye is also an immune-privileged organ, limiting the potential 
immune response to the delivered agent (Stein-Streilein, 2008). The retina is composed 
by nondividing cells, it is thus easier to induce prolonged effects or transgene 
expression, without the need of using integrating vectors. Regarding gene delivery, the 
presence of different adeno-associated viral (AAV) vector serotypes able to efficiently 
and stably transduce all retinal layers (Vandenberghe and Auricchio, 2012) is a great 
advantage for splicing–modulating genetic tools.  
 
3.1 The mRNA splicing process  
 Once transcription of a gene begins in the nucleus, the transcript undergoes a 
complex series of co-transcriptional processes all devoted to the production of a mature 
mRNA, collectively dubbed "mRNA processing". One of these events, called mRNA 
splicing, consists in the removal of intervening sequences (introns) and the joining of 
the coding portions of the transcript (exons).  Messenger RNA splicing is a major way 
by which the cell can induce transcriptional diversity, mainly through alternative 
splicing, and apply a fine control on this diversity. The proper recognition of introns and 
exons is mediated by cis-acting sequences and trans-acting factors. The principal cis-
acting elements that spatially organize the splicing reaction consist in the splice donor 
(DS) site (or 5’ splice site), the polypyrimidine tract (Py), the branch-site (BS) and the 
splice acceptor (AS) site (or 3’ splice site). There are also other cis-acting sequences 
that are fundamental for mRNA splicing (Lam and Hertel, 2002): exonic splicing 
enhancers (ESE) or silencers (ESS), that enhance or inhibit recognition of the exon in 
which they lay; intronic splicing enhancers (ISE) or silencers (ISS), intronic sequences 
that promote or suppress recognition of the nearby exons. Trans-acting factors are 
  
 
13 
 
 
instead several proteins and ribonucleoproteins able to recognize the different cis-
elements. Small nuclear RNA (snRNA) are constitutive components of the small 
nuclear ribonucleoproteins (snRNP) U1, U2, U4, U5, U6, and allow them to base-pair 
with the cis-acting sequences that mediate the cascade of events leading to the splicing 
reaction. For example the U1 snRNP recognizes the DS site, whereas U2 binds to the 
branch site. The other two groups of trans-acting splicing factors are represented by 
heterogeneous nuclear ribonucleoproteins (hnRNPs), that mainly have a repressive 
function, and by serine- and arginine-rich (SR) proteins, that play an important role in 
splicing regulations mainly by binding to ESE and ISE, thus promoting splicing (Busch 
and Hertel; Jean-Philippe et al., 2013; Kafasla et al., 2012; Pozzoli and Sironi, 2005; 
Zhou and Fu, 2013). All these factors assemble together in a precise temporal sequence 
in a complex called spliceosome, the cellular machinery devoted to the splicing process. 
For a more exhaustive description of the splicing process we refer the reader to more 
detailed reviews (De Conti et al., 2013; Hoskins and Moore, 2012; Kornblihtt et al., 
2013). 
 
3.2 The retina and photoreceptor cells 
 The retina is a highly structured neural tissue that covers the inner part of the eye 
cup. It is organized in different layers, which carry specific functions. The retina is 
delimited by the retinal pigmented epithelium (RPE), a pigmented non-neuronal tissue 
dedicated to two important functions. The RPE layer absorbs the photons not captured 
by photoreceptor cells, thus improving the quality of vision. It also undertakes several 
metabolic and trafficking functions in support of photoreceptor cells, such as 
performing many biochemical steps of the visual cycle and phagocytizing photoreceptor 
outer membranes. Photoreceptors are the sensory cells of the retina. Phototransduction 
starts in their outer segment, a modified and specialized cilium in close proximity to 
RPE cells, that contains a multitude of tightly-packed membrane disks where the 
different light-sensitive proteins (opsins) are located and where the phototransduction   
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cascade occurs. The connective cilium joins the outer segment of photoreceptors with 
their inner segment, where the nucleus and other organelles are located. Photoreceptors 
are classified into rods and cones. While cones are fundamental for color vision, rods 
are more sensitive to light and are important in dark/dim light conditions. The outer 
nuclear layer (ONL) of the retina consists of the nuclei of rods and cones. 
Photoreceptors make synapses with other 
photoreceptors and second-order neurons 
in the outer plexiform layer (OPL). There 
are three types of second-order neurons in 
the retina: horizontal cells, which are 
interconnecting neurons that integrate the 
visual input horizontally; bipolar cells, 
which are responsible for transferring the 
visual input vertically to third-order 
neurons; and amacrine cells. Cell bodies 
of bipolar, horizontal and amacrine cells 
constitute the inner nuclear layer (INL) of 
the retina. Amacrine cells are another 
class of interneurons that integrate the 
signal laterally, like horizontal cells, 
making synapses with bipolar cells and 
the third-order neurons, the retinal 
ganglion cells. Synapses between bipolar 
cells, amacrine cells and retinal ganglion cells are organized spatially in the inner 
plexiform layer (IPL) of the retina. Retinal ganglion cell axons form the optic nerve and 
reach the visual cortex. Spanning across all retinal layer, Muller glia cells have a 
supportive function for the different retinal neurons. Their connection with 
photoreceptor cell inner segments form the outer limiting membrane (OLM), while their 
more internal protrusions constitute the inner limiting membrane of the retina (ILM), 
where the retina enters in contact with the vitreous humour.  
FIGURE 1. Eye and retina structure 
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3.3 Retinal dystrophies 
 Degeneration of photoreceptor or of RPE cells is the initial sign of most retinal 
dystrophies, which are genetic diseases that affect the eye. Degenerations can start in 
one of the two types of photoreceptors (rods or cones) and later diffuse also the other 
type, or can start in both types from the beginning. Symptoms can be highly variable, 
and generally  depend on which region of the retina is the first to be affected and which 
type of photoreceptor starts degenerating first. They can comprise decrease in central or 
peripheral vision, decrease in visual acuity, problems in photopic (during dark) or 
scotopic (during light) vision, and can lead to blindness in advanced stages. The current 
classification takes into account several aspects: if the disease affects primarily rods 
(rod dominated), cones (cone dominated) or both (generalized degeneration), if the 
degeneration is stationary or progressive, and if it involves only the retina (non 
syndromic) or also other districts of the body (syndromic). Additionally, the different 
dystrophies can be classified following the pattern of inheritance which can be 
autosomal dominant, autosomal recessive, X-linked or mitochondrial. The genetic 
diversity of retinal dystrophies is astonishing, with many different genes accounting for 
different proportion of cases of the same disease, and other situations where one gene 
can be responsible for different diseases. They affect around 2 million people 
worldwide (Berger et al., 2010), and in many patients the genetic cause is still unknown. 
The first gene therapy strategy to enter the clinic aiming to cure a retinal dystrophy was 
designed for Leber congenital amaurosis (LCA), a severe non-syndromic generalized 
photoreceptor diseases caused by mutations in RPE65 and other genes. The therapy was 
based on an AAV serotype 2 (rAAV2)  encoding for human RPE65 (Maguire et al., 
2008). Success in safety and efficacy parameters of the conducted trials for LCA 
(Jacobson et al., 2012; Maguire et al., 2009; Simonelli et al., 2010) makes gene therapy 
the most promising and advanced approach for the cure of retinal dystrophies, and we 
will hopefully see other clinical studies starting in the close future.  
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3.4 Mutations leading to retinal diseases 
 Retinal dystrophies are caused by mutations in many different genes, leading to a 
multitude of disease conditions (Berger et al., 2010; Daiger et al., 1998) (Tab. 1). Today 
there are 219 genes 
identified as causative of 
retinal diseases, and the 
number is still growing 
(Daiger et al., 1998). The 
total number of known 
mutations for 208 of these 
genes, annotated in the 
Human Gene Mutation 
Database (provided in the 
public domain by HGMD 
professional, 
http://www.hgmd.cf.ac.uk/ac
/index.php), is 13.668 (Stenson et al., 2003). The large majority of these are represented 
by missense mutations, accounting for 34% of the total  (Fig. 2). Small deletions follow 
as the second most abundant type of genetic defect (16%). Bona fide splicing mutations 
represent 11% of the total. Generally, mutations residing in introns are categorized as 
splicing mutations because the amino acid sequence of the protein is not altered, thus 
the problem most likely concerns proper splicing. These mutations can be located in any 
of the cis-acting elements present in introns. Splicing mutations can also be found in 
exons, altering or not the coding sequence. In this case their identification as splicing 
mutations is much more difficult, as it requires analysis of the splicing pattern. Today it 
is believed that more than 25% of mutations, normally categorized as missense, 
nonsense, or silent, actually act by altering the splicing pattern (Lim et al., 2011a; 
López-Bigas et al., 2005; Sterne-Weiler et al., 2011). Their effect can be the disruption 
of a cis-acting sequence, or the formation of a new one, resulting in exon skipping, 
intron retention or use of alternative DS and AS sites. Correct identification of these 
mutations is of pivotal importance for the development of therapeutic approaches. Aside 
from splicing mutations, antisense-mediated splicing-correction approaches can 
potentially be utilized for the correction of missense and nonsense mutations, as well as 
FIGURE 2. Mutation pattern of genes causing retinal diseases. 
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for small insertions and deletions. In all cases where a mutation causes the introduction 
of a stop codon or frameshift leading to a premature termination of the transcript, the 
possibility to interfere with the proper recognition, by the splicing machinery, of the 
exon carrying the mutation (therapeutic exon skipping) can be the right strategy to 
follow. The result of this approach is a shorter mature mRNA, missing the portion 
encoded by the skipped exon, but resulting in a restored ORF.  It is then necessary to 
assess the functionality of the rescued smaller protein. This strategy is more easily 
applicable to cases in which the mutated exon encodes for a repetitive structural element 
whose loss in the final protein product is less likely to cause structural and functional 
defects of the protein itself, whereas it is a riskier approach in other cases, where proper 
function of the skipped protein is less predictable. 
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Disease Category Involved Genes  
Cone or cone-rod 
dystrophy/dysfunctions 
ABCA4 ADAM9 AIPL1 BBS12 C2orf71 C8orf37 CA4 CABP4 CACNA1F CACNA2D4 
CDHR1 CERKL CNGA3 CNGB3 CNNM4 CRB1 CRX GNAT2 GUCA1A GUCY2D 
KCNV2 MERTK MKS1 NR2E3 NRL OPN1LW OPN1MW PDE6C PDE6H PITPNM3 
PROM1 PRPH2 RAB28 RAX2 RDH12 RIMS1 RLBP1 RPE65 RPGRIP1 TULP1 UNC119  
Retinitis pigmentosa	   ABCA4 ARL2BP ARL6 BBS1 BEST1 C2orf71 C8orf37 CA4 CEP290 CERKL CLRN1 
CNGA1 CNGB1 CRB1 CRX CYP4V2 DHDDS EMC1 EYS FAM161A FSCN2 GPR125 
GRK1 GUCA1A GUCA1B GUCY2D IDH3B IMPDH1 IMPG2 KIAA1549 KLHL7 LCA5 
LRAT MAK MERTK MFRP MYO7A NR2E3 NRL OFD1 PDE6A PDE6B PDE6G PRCD 
PROM1 PRPF3 PRPF31 PRPF6 PRPF8 PRPH2 RBP3 RDH12 RGR RHO RLBP1 RP1 
RP1L1 RP2 RP9 RPE65 RPGR RPGRIP1 SAG SEMA4A SNRNP200 SPATA7 TOPORS 
TULP1 USH2A VCAN ZNF513  
Leber congenital 
amaurosis 
AIPL1 BBS4 BEST1 CABP4 CEP290 CNGA3 CRB1 CRX DTHD1 GUCY2D IMPDH1 
IQCB1 KCNJ13 LCA5 LRAT MERTK MYO7A NMNAT1 NRL RD3 RDH12 RPE65 
RPGRIP1 RPGRIP1L SPATA7 TULP1  
Macular 
dystrophy/degeneration 
ABCA4 ABCC6 BEST1 CNGB3 CRX EFEMP1 ELOVL4 GUCY2D PAX2 PROM1 
PRPH2 RP1L1 TIMP3  
Stargardt disease  ABCA4 ELOVL4 PRPH2 CFH HMCN1  
Age-related macular 
degeneration  
ABCA4 ARMS2 BEST1 C3 CFH ELOVL4 ERCC6 FBLN5 HMCN1 HTRA1 RAX2 
SLC24A1  
Stationary night blindness CACNA1F CABP4 GNAT1 GPR179 GRK1 GRM6 LRIT3 NYX PDE6B RHO SAG 
SLC24A1 TRPM1  
Color blindness CNGA3 CNGB3 GNAT2 OPN1LW OPN1MW OPN1SW PDE6C PDE6H  
Usher syndrome ABHD12 CACNA1F CDH23 CIB2 CLRN1 DFNB31 GPR98 GUCY2D HARS LRAT 
MYO7A PCDH15 PDZD7 TRIM32 USH1C USH1G USH2A 
Chorioretinal 
atrophy/degeneration  
ABCA4 CRB1 TEAD1  
Retinal dystrophies/ 
dysfunctions/ 
degeneration 
ABCC6 ABCA4 ADAMTS18 AIPL1 BEST1 C1QTNF5 CAPN5 CDHR1 CERKL CHM 
CRB1 CYP4V2 FZD4 GUCA1B KCNV2 LRAT LRP5 MERTK NDP NR2E3 NRL OTX2 
PANK2 PLA2G5 PROM1 PRPH2 RD3 RDH12 RDH5 RGS9 RGS9BP RLBP1 RPE65 
SLC24A1 TSPAN12  
Retinopathy of 
prematurity  
LRP5 NDP FZD4  
Optic atrophy/aplasia  MFN2 OPA1 OPA3 OTX2 SLC24A1 TMEM126A WFS1  
Wagner syndrome  VCAN COL2A1  
Bardet-Biedl syndrome ARL6 BBS1 BBS10 BBS12 BBS2 BBS4 BBS5 BBS7BBS9 CEP290 LZTFL1 MKKS 
MKS1 RPGRIP1L SDCCAG8 TRIM32 TTC8 WDPCP  
Other systemic/syndromic 
diseases involving the 
retina 
ABCC6 ABHD12 ADAMTS18 AHI1 ALMS1 ATXN7 CC2D2A CDH3 CEP290 CISD2 
CLN3 COL11A1 COL2A1 COL9A1 ERCC6 FLVCR1 GNPTG IFT140 INPP5E IQCB1 
ITM2B JAG1 KIF11 LRP5 NPHP1 NPHP4 OFD1 OPA3 OTX2 PANK2 PAX2 PEX1 
PEX2 PEX7 PHYH RBP4 RPGRIP1L SDCCAG8 TIMM8A TMEM237 TREX1 TTPA 
TTPA USH1C WFS1  
TABLE 1. List of genes causing retinal diseases. All RetNet identified genes have been searched and allocated to 
disease categories according to HGMD professional entries at December 2013.  
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3.5 Antisense oligonucleotides 
 A versatile tool to target splicing is represented by antisense oligonucleotides 
(AONs). These are chemically synthesized molecules, generally around 20 nucleotides 
long, able to mimic the RNA structure and bind by reverse complementarity to specific 
cellular RNA targets. Even if they are normally used to block mRNA translation or to 
degrade mRNA by RNase H-mediated cleavage, these effects are unwanted when the 
goal is to interfere with splicing. By the use of several different chemistries (Järver et 
al., 2013; Saleh et al., 2012) available today for their design, it is in fact possible to 
direct AONs toward splicing relevant sequences on the pre mRNA, masking them, and 
to avoid RNase H activity after binding. The first splice-switch oligonucleotides used a 
phosphothioate linkage to join nucleosides (DNA-PS) (De Clercq et al., 1969). 
However, these AONs were retaining undesired RNAse H activity (Saleh et al., 2012). 
A second generation of oligonucleotides was created from the DNA-PS structure. 
Inclusion at the 2’ oxygen of a methyl (2’OMe) or a methoxyethyl (2’MOE) protecting 
group to increase oligonucleotides resistance to degradation and block RNAse H 
activity originates 2’OMe-PS (Sproat et al., 1989) and 2’MOE-PS (Martin P., 1995) 
ribonucleosides, respectively. The third generation comprised locked nucleic acids 
(LNA), peptide nucleic acids (PNA) and phosphorodiamidate morpholino 
oligonucleotides (PMO). Locked nucleic acids derive from the addition of a methylene 
bridge between the 2’ oxygen and the 5’ carbon on a DNA-PS backbone (Koshkin et al., 
1998; Obika et al., 1998). They have an increased affinity to target RNA and do not 
activate RNAse H. In PNAs the DNA backbone is instead substituted by a peptide-like 
mimicry (Nielsen et al., 1991). Peptide nucleic acids do not cause RNAse H degradation 
of their target and show strong affinity to it. Since they are neutrally charged, addition 
of a Lysine residue is commonly used to increase their water solubility and cell-uptake. 
Phosphorodiamidate morpholino oligonucleotides derive from the substitution of the 
ribose rings with morpholine ones, and their joining by phosphorodiamidate groups 
(Summerton and Weller, 1997). PMOs are neutrally charged oligonucleotides that do 
not activate RNAse H and are lowly susceptible  to degradation.  For a comprehensive 
understanding of these chemistries we refer the reader to more specific reviews (Järver 
et al., 2013; Kole et al., 2012; Kurreck, 2003; Saleh et al., 2012). 
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 In order to be able to regulate splicing, AONs must gain access to the cell nucleus. 
There are different splicing regulatory sequences that have been so far targeted with 
AONs on pre-mRNA to achieve splicing modulation (Fig. 3). 
 
FIGURE 3. Possible AONs targets to induce splicing modulation. Schematic representation of cis-acting 
sequences that are possible target of AONs. Cis-acting sequences that  promote exon recognition are reported in 
green, whereas sequences that suppress it are highlighted in red. AONs designed to  induce exon skipping are shown 
in the bottom part. AONs designed to promote proper exon inclusion are shown in the upper part. 
For example, by targeting splicing enhancers or silencers it is possible to induce 
respectively exon skipping or exon retention by blocking access of splicing factors to 
their target sites. Another common target of AONs are splice sites that, when bound by 
an AON, are no longer free to take part in the splicing reaction, thus obliging the 
spliceosome to use alternative “downstream“ sites, again inducing exon skipping. In 
few cases, AONs have also been engineered to carry an additional tail containing cis-
acting sequences that can be bound by splicing factors able to enhance (Baughan et al., 
2006, 2009; Osman et al., 2012; Owen et al., 2011; Skordis et al., 2003) or silence 
(Brosseau et al., 2013; Dickson et al., 2008; Gendron et al., 2006; Villemaire et al., 
2003) splicing of specific exons. In this way, apart from their antisense activity toward a 
splicing-relevant sequence, these bifunctional AONs can induce additional effects 
depending on the sequence they carry on the tail. Since AONs act by base-pairing, they 
are generally believed to allow a high specificity of action for their desired target. No 
undesired mis-spliced products of the target gene or of chosen unrelated genes were in 
fact detected when investigated after therapeutic application of AONs (van Deutekom et 
al., 2007; Kalbfuss et al., 2001). Even if these findings are not generalizable and proper 
design of the antisense molecule should always be considered, they underline the 
potentiality of AONs in the context of target selectivity. Splicing modulation finds its 
more advanced application in the cure of Duchenne muscular dystrophy (DMD). 
Duchenne muscular dystrophy is an X-linked recessive disease caused by mutations in  
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 the dystrophin gene. Dystrophin is an important cellular protein whose main role in 
muscle fibers is the connection of the cellular cytoskeleton with the extracellular matrix. 
Different mutations in the 79 exons of the gene cause protein truncation due to the loss 
of the open reading frame. The majority of these mutations can be addressed by exon 
skipping (Aartsma-Rus et al., 2009). The commonly mutated exon 51 has been the first 
target for exon skipping. In the clinical trials completed so far for exon 51 skipping, the 
different chemistries applied (2’OMe-PS, PMOs) showed overall efficacy and absence 
of serious adverse effects (Cirak et al., 2011; van Deutekom et al., 2007; Goemans et 
al., 2011; Kinali et al., 2009).  
 A phase I clinical trial using a 2’MOE-PS oligonucleotide for splicing modulation 
has also been recently completed for spinal muscular atrophy (SMA), and a phase II 
trial has recently started (Zanetta et al., 2014). Mutations in the survival motor neuron 1 
(SMN1) gene are causative of the disease. In humans, SMN1 has a paralogue, named 
SMN2. The two genes are identical, apart from a silent mutation in exon 7 of SMN2. 
This mutation, however, causes exon 7 of SMN2 to be less recognized by the splicing 
machinery. If exon 7 is not included, the protein is truncated. So a therapeutic strategy 
is to mask exon 7 ESS using AONs, thus promoting exon 7 inclusion, which results in 
the production of a functional full length SMN protein from SMN2, that can compensate 
for mutations on SMN1.  
 Antisense oligonucleotides are known to be able to target all retinal layers following 
intravitreal, subretinal or topical administration (Bhisitkul et al., 2005; Cloutier et al., 
2012; Dvorchik and Marquis, 2000; Shen and Rakoczy, 2001; Shen et al., 1999; Thaler 
et al., 2006). They have long been used to elicit RNAse H degradation or to block 
transcription in the eye for several different diseases, having been applied for example 
against cytomegalovirus (CMV), herpes simplex virus (HSV), vascular endothelial 
growth factor (VEGF), transforming growth factor-β (TGF-G), fibroblast growth 
factor (FGF) (Fattal and Bochot, 2006; Gomes Dos Santos et al., 2005).   
 An example of the use of splice-switch oligonucleotides in the eye is that of vascular 
endothelial growth factor receptor 2 (KDR). The KDR gene has two distinct products: 
membrane-bound KDR (mbKDR), that is prohemangiogenic, and soluble KDR (sKDR), 
antilymphangiogenic. sKDR needs the recognition of an alternative polyadenilation site 
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on KDR intron 13 to be translated. By intravitreal administration of PMO directed 
against murine Kdr exon 13 DS site, it was possible to increase the sKDR/mbKDR ratio 
at mRNA and protein level in the retina and vitreous, interfering with the spliceosome 
ability of mediating intron 13 splicing (Uehara et al., 2013) (Fig. 4). This resulted in a 
block of hemangiogenesis and lymphangiogenesis in a model of choroidal 
neovascularization and corneal injury (Uehara et al., 2013). Another recent example of 
the use of AONs  as splicing regulators to treat a retinal dystrophy is that of the gene 
centrosomal protein 
290kDa, (CEP290). 
CEP290 mutations 
are responsible for 
~15% (den Hollander 
et al., 2008; Perrault 
et al., 2007) of Leber 
congenital amaurosis 
cases, as well as for 
other genetic diseases such as Joubert syndrome, Senior-Løken syndrome, Meckel-
Gruber syndrome and Bardet-Bield syndrome. A transition on intron 26 
(c.2991+1655A>G) is among the most common mutations of CEP290 (den Hollander et 
al., 2006). The mutation introduces a new DS site on intron 26, causing an aberrant 
exon to be included in the mature messenger RNA between exon 26 and 27. This 
aberrant exon carries a stop codon, resulting in a premature truncation of the protein. By 
the design of 2’OMe-PS 
directed towards predicted 
ESE sequences at the 3’ of the 
aberrant exon it was possible 
to demonstrate, on patient 
fibroblasts, its skipping from 
the mature mRNA, so to 
efficiently restore proper 
splicing between exon 26 and 
27 (Collin et al., 2012) (Fig. 5). Another study by Gerard and colleagues, by using 
2’OMe-PS targeting a different predicted ESE sequence, came to similar result. 
FIGURE 4. AONs approach for KDR. Scheme of action of AON against KDR exon 
13 DS site: normally mbKDR, originating from intron 23 splicing, is more abundant 
than sKDR, that is instead generated by the use of an alternative polyadenylation site 
in the retained intron 13. By interfering with the E13 DS site  it was possible to 
increase the sKDR form, and decrease the mbKDR one. 
FIGURE 5. AONs approach for CEP290. (A): Proper joint of CEP290 
exon 26 and 27 (green lines and arrow) is impaired by a mutation in intron 
26 (red star). The mutation causes the aberrant inclusion of a cryptic exon 
in a portion of the mature mRNA (red arrows). (B) Using different AONs 
(black lines) it was possible to augment the fraction of correctly spliced 
mRNA (black arrows). 
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Moreover, they were able to show an increase of full-length protein levels in patient 
fibroblasts following AON administration, as well as a faster ciliation (Gerard et al., 
2012). 
 
 
3.6 Chimeric and adapted snRNAs 
 The use of AONs as a therapeutic approach for genetic diseases poses one major 
problem. Their effect is time-limited, so to have a durable effect, repeated 
administration is required. In this view the use of engineered snRNAs offer a major 
advantage, as they can be delivered in expression cassettes in the same way as it is done 
in conventional gene replacement therapies. By using viral or nonviral delivery systems 
it is in fact possible to transduce or transfect target cells, and then produce the snRNA 
exploiting endogenous transcription. As for AONs, one of the advantages of this class 
of RNA molecules is their specificity of action, as undesired activity of snRNAs has not 
been reported so far when investigated (Pinotti et al., 2008; Schmid et al., 2013). Today 
there are two classes of snRNAs that have been successfully modified to be able to 
modulate splicing: U1 and U7. The first step of spliceosome assembly is mediated by 
U1 recognition of the DS site (Patel and Bellini, 2008). U7 snRNA is instead not 
involved in splicing, but in the processing of the 3’ end of histone mRNA (Dominski 
and Marzluff, 2007).  They both can be used to manipulate splicing exactly as AONs. 
Antisense U1 and U7 snRNA have been applied for masking cis-acting sequences, thus 
inducing therapeutic exon skipping, for Duchenne muscular dystrophy (Denti et al., 
2006, 2008; Goyenvalle et al., 2012). Bifunctional U7 snRNA, acting in a similar way 
as bifunctional AONs, have also been designed for DMD (Goyenvalle et al., 2009) and 
SMA (Marquis et al., 2007; Voigt et al., 2010). snRNAs can also be applied to a 
specific set of mutations not targetable by AONs. When a mutation disrupts a DS site, it  
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 leads to complete or partial loss 
of the ability of the the splicing 
machinery to recognize it. The 
design of mutation-adapted U1 
snRNA able to interact by base 
pairing with the mutated splice 
site can re-establish spliceosome 
recognition (Pinotti et al., 2008; 
Susani et al., 2004). This is 
possible by exploiting U1 natural 
function in splicing. 
Unfortunately the same strategy so far is not applicable in a similar way to mutations of 
the AS site. The only strategy that has been applied to mutations in the polypyrimidine 
tract of the AS site relies on the use of exon-specific U1 snRNAs (ExSpeU1) 
engineered to recognize not the mutation but unconserved intronic sequencies close to 
the DS site, in a mutation-independent way  (Alanis et al., 2012). The  ExSpeU1s have 
been also shown to correct 
DS site and exonic 
mutations (Alanis et al., 
2012). It is also possible to 
engineer any viral vector 
even with a combination of 
different snRNAs, by 
taking advantage of their 
limited size (Goyenvalle et 
al., 2012). Tanner and 
colleagues applied 
mutation-adapted U1 
snRNAs to rhodopsin 
(RHO), one of the genes 
responsible for autosomal 
dominant retinitis pigmentosa. An exonic point mutation interfering with the DS site 
was found responsible for exon 4 mis-splicing. By using minigenes as reporter systems 
FIGURE 7. Mutation-adapted U1 snRNA for BBS1 DS site mutations. 
(A) Normal splicing of BBS1 (green) is altered (red) by a mutation at the end 
of exon 5. The mutation causes exon 6 skipping (bottom, left) or intron 5 
retention (bottom, right). Arrows dimension represent the amount of the 
different splicing products. (B) Black arrows represents the correcting effect 
of the best mutation-adapted U1 snRNA, able to partially restore proper 
splicing. 
FIGURE 6. Mutation-adapted U1 snRNA for RHO and  RPGR 
DS site mutations. The altered splicing pattern caused by the 
different mutations is reported in red. The correct splicing pattern is 
reported in green. The antisense sequence of the best U1 snRNA used 
to correct the effect of each mutation is reported. (A) Mutation at the 
last base of exon 4 of RHO causes skipping of the exon or mis-
splicing due to the use of an alternative DS site. (B) An intronic 
mutation affecting the DS site of exon 10 of RPGR leads to exon 10 
skipping. 
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in COS 7 cells they were able to show rescue of exon 4 proper recognition with an 
average efficiency of 90% after treatment with mutation-adapted U1 snRNAs (Tanner et 
al., 2009) (Fig. 6). The same strategy was used for a splice donor mutation of RPGR 
inducing exon 10 skipping. Proper inclusion of exon 10 was achieved in patient 
fibroblasts using mutation-adapted U1snRNAs (Glaus et al., 2011) (Fig. 6). Mutations 
in BBS1 result in more than 20 % of Bardet–Biedl syndrome (BBS) cases. BBS is a 
ciliopathy characterized by retinal dystrophy, cognitive impairment, obesity, 
polydactyly, hypogonadism and renal disease (Mockel et al., 2011). BBS1 is a member 
of a protein complex called BBSome, involved in trafficking of vesicles to the cilia 
(Nachury et al., 2010). Schmidt and collaborators identified in a family affected by BBS 
a splice donor mutation on exon 5 of BBS1 causing mis-splicing (Schmid et al., 2011).  
They were able to show, after administration of mutation-adapted U1 snRNAs, 
restoration of proper splicing in COS-7 cells, using minigenes as splicing reporter. 
Similar results were obtained in patient-derived fibroblast transduced with lentiviral 
vectors encoding for the modified U1-snRNAs (Fig. 7). A recent innovative approach 
has been developed for the treatment of mutations occurring at position +5 of DS sites 
(Schmid et al., 2013). The synergic use of both mutation-adapted U1 and U6 snRNAs 
was sufficient to achieve efficient correction of aberrant splicing caused by BBS1 
mutations, whereas the only use of mutation-adapted U1 snRNAs resulted in low levels 
of splicing correction. 
 
3.7 Trans-splicing 
 Another correction approach that acts at the splicing level is spliceosome-mediated 
RNA trans-splicing (SMaRT). This technology is based on a cellular process called 
trans-splicing. Initially discovered in trypanosome (Murphy et al., 1986; Sutton and 
Boothroyd, 1986), trans-splicing has also been described in mammals (Caudevilla et al., 
1998; Flouriot et al., 2002). It consists in the ability of two different pre-mRNAs to 
originate a chimeric mature mRNA following a recombination event during splicing. 
Trans-splicing can be exploited to correct aberrant mRNA by using an artificial RNA 
sequence, called pre trans-splicing molecules (PTM). The PTM consists of a correct 
portion of the cDNA of the gene of interest, flanked by a region containing all important 
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elements for splicing and the binding domain (BD), important for specific binding of 
the PTM to the target endogenous pre mRNA, mainly on an intronic sequence. There 
are three types of PTMs that can be exploited to achieve 5’ trans-splicing, 3’ trans-
splicing or internal exon replacement, correcting respectively the 5’, the 3’, or a central 
region of a transcript (Fig. 8). PTMs are delivered in expressing vectors as in a normal 
gene transfer approach. They  have been administered in vivo using different viral 
vectors (Avale et al., 2013; Chao et al., 2003a; Tahara et al., 2004), or non-viral 
delivery sistems (Coady and Lorson, 2010; Coady et al., 2008; Shababi et al., 2011). 
The peculiarity of 
this technique, 
compared to other 
splicing-correction 
approaches, is the 
fact that it is 
mutation-
independent, thus 
the same PTM can 
be used to treat 
different mutations 
located in the same 
region of the transcript.  
 Even if SMaRT has never been applied so far for the correction of a genetic disease 
of the retina, it has been successfully tested in several in vivo models for spinal 
muscular atrophy (Coady and Lorson, 2010),  haemophilia A (Chao et al., 2003b), 
hyper-IgM X-linked immunodeficiency (Tahara et al., 2004) and tauopathy (Avale et al., 
2013). As there are already exhaustive reviews (Mansfield et al., 2004; Wally et al., 
2012) about the first three in vivo approaches, to give an example of a possible 
application of SMaRT, we will spend a few words on the last and more novel one 
regarding tauopathy caused by mutations in MAPT, the gene encoding tau protein. Tau, 
a protein important for microtubule stabilization in the CNS, is subject to active 
alternative splicing as six different isoforms are present in humans (Niblock and Gallo, 
2012). Tau exon 10 encodes for a tandem repeat and by alternative splicing originates  
FIGURE 8. Trans-splicing approaches: Schematic representation of the three 
possible trans-splicing approaches. The different PTMs are constituted  by a region 
harbouring: splicing cis-acting sequences, shown in green; the coding sequence in blue; 
and the binding domain (BD). The mature mRNA resulting from the three trans-splicing 
approaches is shown, with in orange the endogenous sequence, and in blue the sequence 
introduced by the PTMs. 
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two sets of different tau isoforms:  with 4 (4R; +E10) or 3 (3R; -E10) tandem repeats. 
Splicing mutations that lead to a change in the levels of E10 containing transcripts cause 
an imbalance in the 4R/3R isoform ratio, and leads to frontotemporal dementia with 
parkinsonism linked to chromosome 17 (FTDP-17). Avale and colleagues designed a 
PTM for 3’ trans-splicing with the BD binding to intron 9, and carrying the cDNA of 
the last 3 exons of tau  (E10-E11-E12) (Avale et al., 2013). They applied the PTMs to 
Htau mice, that express only human MAPT, resulting in equal amounts of 4R and 3R 
(Andorfer et al., 2003). Since normal adult mice express only the 4R isoform, the model 
recapitulates the effect of a splicing mutation abolishing E10 inclusion. Following 
delivery of the PTM in the prefrontal cortex of Htau mice by stereotaxic injection using 
lentiviral vectors, they were able to show effective trans-splicing at RNA and protein 
level.  
 
3.8 RNA interference 
 RNA interference (RNAi) is a regulatory mechanism used by the cell to silence 
specific transcripts at the post-transcriptional level. The endogenous effectors of this 
mechanism are micro RNAs (miRNAs). They are transcribed into primary precursors 
(pri-miRNA) that are then cleaved first by Drosha into a ~70 bp precursor hairpin (pre-
miRNA), and then by Dicer into a ~22 bp RNA/RNA duplex (Krol et al., 2010). One of 
the two strands (the guide strand) is then loaded into the RNA-induced silencing 
complex (RISC) as a mature miRNA, where it can recognize complementary mRNAs. 
Silencing by RISC is caused by translational repression if the complementarity between 
the miRNA and its target mRNA is not perfect. When the miRNA perfectly matches its 
target, silencing is instead mediated by cleavage and subsequent degradation of the 
mRNA. Small interfering RNAs (siRNAs) are double stranded RNA-molecules that 
result from processing by Dicer of exogenous double strand RNAs. Alternatively they 
can be chemically synthetized and delivered as such for therapeutic purposes. siRNAs 
are directly loaded onto RISC. Another class of interfering RNA is composed by short 
hairpin RNAs (shRNAs), stem-loop structures that enter the miRNA processing 
pathway as substrates for Dicer. shRNAs are often obtained from the transcription of a 
delivered DNA transgene hereby guaranteeing stable expression. On the contrary the 
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effect of siRNAs is transient, even if different chemistries are today available to 
improve their stability. siRNA have been used to treat retinal diseases since already a 
few years. The first RNAi therapeutic applications to enter the clinical phase have in 
fact been two naked siRNAs developed for the treatment of age-related macular 
degeneration (AMD): Bevasiranib, directed against vascular endothelial growth factor 
(VEGF); and AGN211745, targeting VEGF receptor (VEGFR1). Clinical development 
of these two drugs has been discontinued during the last years, mainly because of their 
failure in meeting efficacy endpoints (Vaishnaw et al., 2010). Even if other clinical 
trials are in progress for other naked siRNA (Kanasty et al., 2013), the lessons that we 
can learn from the two described trials is that it is a challenge to deliver naked siRNA 
into cells, even in an easy system such as the eye, and that their efficacy is not mediated 
by RNAi, but via an off-target sequence independent effect on cell surface Toll-like 
receptor-3 (TLR3) (Cho et al., 2009; Kleinman et al., 2008). New chemistries seem to 
overcome these limitations (Byrne et al., 2013), and the availability of different types of 
formulations (polymer or lipid coated nanoparticles, oligonucleotide nanoparticles and 
conjugates delivery systems (Kanasty et al., 2013)) can potentially help in improving 
cellular uptake in the retina. However the current trend for in vivo applications is to 
utilize viral vectors to deliver shRNAs to different retinal layers (Askou et al., 2012; 
Chadderton et al., 2009; Hu et al., 2013; Jiang et al., 2013; Yuan et al., 2010; Zhu et al., 
2013). 
 By exploiting the mechanism of RNAi-mediated gene silencing it is possible to solve 
different situations in which correct splicing is compromised. Mutations that cause 
impairment in the splicing process can lead to mis-spliced products that in some cases 
can show a dominant negative or gain of function effect. If this is the case, the simple 
decrease of the mis-spliced mRNA, without affecting the correctly spliced counterpart, 
can revert the pathological condition. This is possible using RNAi (Seyhan, 2011). A 
recent example of the application of this strategy in the retina has been shown for 
retinitis pigmentosa (Hernan et al., 2011). Mutations in rhodopsin (RHO) are the most 
prevalent cause of autosomal dominant retinitis pigmentosa (adRP), accounting for 25% 
of the cases (Fingert et al., 2008). Two mutations causing adRP (c.531-2A>G and 
c.937-1G>T) generate mis-splicing products. They abolish the proper recognition of the 
DS site of exon 3 and 5 respectively. Mutation c.531-2A>G originates two mis-spliced 
mRNAs with a partial intron 2 retention or a partial deletion of exon 3. Mutation c.937-
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1G>T results in a partial deletion of exon 5. Using RNAi against the mis-spliced mRNA 
their level was succesfully reduced without affecting the properly spliced isoform, with 
the exception of the second product of c.531-2A>G mutation, where the RNAi was not 
able to distinguish between the wild type and the aberrant mRNA (Fig. 9).  
 
3.9 Retinal cone dystrophy and the alpha2deltha subunits of voltage gated 
calcium channels  
3.9.1 Voltage gated calcium channels and phototransduction 
 Voltage gated calcium (Ca2+) channels are a large family of channels found in many 
excitable and non-excitable cells where they are fundamental for different cellular 
processes. They activate upon membrane depolarization and allow calcium influx in the 
cell, which in turn regulates several processes such as neurotransmitter or hormone 
release, cell contraction, gene expression, enzyme activity and many other. Based on 
their biophysical properties, they can be divided in two major subgroups: high voltage-
activated (HVA) and low-voltage activated (LVA) (Fig. 10). Low voltage-activated 
calcium channels show smaller conductance and open in response to a milder 
depolarization of the cell membrane when compared to HVA. Another important   
FIGURE 9. RNAi for adRP splicing mutations. Left: the effect on splicing of the two RHO mutations c.531-2A>G 
and  c.937-1G>T is shown. Mutation c.531-2A>G originates two mis-spliced products (a-b). Right: The different 
mis-spliced products can be selectively recognized by siRNA (black lines) targeting sequencies or exon-exon 
junctions absent in the wt transcript. siRNA directed towards mis-spliced product b of c.531-2A>G mutation was not 
able to discriminate between the wt mature mRNA and the aberrant one. Adapted from Hernan et al., IOVS, 2011. 
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difference between the two groups is their need for auxiliary subunits. While HVA 
calcium channels are heteromultimeric protein complexes constituted of α1, β, α2δ and 
sometime γ subunits, there are today no evidences that this is true also for LVA calcium 
channels (Huc et al., 2009). In HVA channels, the α1 subunit forms the pore, whereas β, 
α2δ and γ subunits conduct ancillary functions related to trafficking and modulation of 
the biophysical properties of the α subunit. Regarding inactivation properties, the major 
subgroup of HVA calcium channels is represented by long lasting calcium channels (L-
type), which show a slow voltage-dependent inactivation. In contrast, LVA calcium 
channels are also called T-type, because they show a faster inactivation resulting in 
transient currents.  
 At the latest step of the phototransduction cascade, L-type calcium channels are 
responsible for the release of the neurotransmitter glutamate at retinal ribbon synapses. 
During light exposure, photoreceptors are hyperpolarized and L-type calcium channels 
are closed. When the light stimulus ends, thus in the dark, photoreceptors depolarize 
and L-type calcium channels open. The influx of calcium stimulates the presynaptic 
release of glutamate, which transfers the signal to bipolar cells. Among the different L-
type calcium channels expressed in the retina there are several lines of evidence 
suggesting that 
Cav1.4α1 subunit 
is the one 
responsible for 
neurotransmitter 
release in 
photoreceptors. 
This channel is 
expressed mainly 
in the retina, 
where it locates to 
the retinal ribbon 
synapse (Knoflach et al., 2013; McRory et al., 2004; Morgans et al., 2005). Mutations 
in this gene result in am X-linked form of night blindness, incomplete stationary night   
FIGURE 10. Voltage gated calcium channels. The classification of the different known 
voltage-gated calcium channels is presented, together with tissue distribution and related 
diseases (Bidaud and Lory, 2011). 
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blindness type 2 (CSNB2) (Striessnig et al., 2010). This disease is characterized by an 
abnormal electroretinogram (ERG) showing a normal a-wave and a reduced b-wave, 
suggesting a defect in connectivity between photoreceptors and secondary neurons like 
bipolar cells. Patients show a normal fundus, and the following symptoms, which may 
not all occur together: problems in visual acuity, night blindness, nystagmus, defects in 
colour vision, and myopia (Striessnig et al., 2010; Zeitz et al., 2014).  
 
3.9.2 Alpha2-delta subunits  
 HVA calcium channels show highly diversified characteristics in different tissues 
and cell types. This property is made possible by the presence of different genes coding 
for the different subunits of the channel, which together form a repertoire of building 
blocks that can be exchanged in order to modulate channel properties. Apart from the 
previously discussed heterogeneity of the α1 subunit, we know today 4 genes encoding 
for β subunits (CACNB1-4), 4 encoding for α2δ subunits (CACNA2D1-4) and 8 
encoding for γ subunits (CACNG1-8). Regarding α2δ subunits, the vast majority of our 
current knowledge refers to studies conducted on α2δ1, encoded by CACNA2D1. 
However, since the four orthologous genes share high similarity, we will refer generally 
to α2δ while describing general characteristics of the family. The α2δ subunits are 
extracellular glycosyl-
phosphatidylinositol (GPI)-
anchored proteins (Davies et al., 
2010). They are translated as a 
single peptide which is then 
cleaved generating a N terminal 
(α2) and a C terminal (δ) 
fragment. The two peptides are 
then joined together by a 
disulfide bond and are subject to 
glycosylation (Sandoval et al., 
2004) (Fig. 11). The δ peptide is 
responsible for membrane anchoring, while the α2 peptide directly interacts with the α1 
FIGURE 11 Subunit organization of HVA calcium channels. 
(Buraei and Yang, 2010) 
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subunit (Gurnett et al., 1997). The α2 peptide hosts different structural domains: a Von 
Willebrand Factor A (VWF-A) (Springer, 2006; Whittaker and Hynes, 2002) domain 
and two Cache domains (Vivek and Aravind, 2000). The VWF-A domain is a common 
domain for extracellular proteins, and is important for protein-protein interactions. The 
Cache domain is found in bacterial chemotaxis receptors and, apart form α2δ, is not 
present in other eukaryotic proteins. The exact role of these domains in α2δ subunits 
have not been elucidated so far.  
 The principal known function of α2δ subunits is to increase the number of functional 
channels on the plasma membrane. The result of this activity is an increase of 2-9 fold 
in current densities originated from HVA calcium channels when a functional α2δ 
subunit is co-expressed (Dolphin, 2013). The mechanism by which α2δ subunits  are 
able to mediate such an effect is probably a combination of trafficking facilitation and 
reduced turnover of α1/β complexes (Bernstein and Jones, 2007; Cantí et al., 2005; 
Hoppa et al., 2012). Another observed characteristics of α2δ subunits is their ability to 
change the voltage-dependency of activation and inactivation of HVA calcium channels 
in some experimental settings. However, the evidence obtained so far does not allow the 
drawing of a precise picture of their effect on such biophysical properties because 
results differ greatly, probably as a consequence of the different combination of α1 and β 
subunit used, and/or of the chosen expression systems (Dolphin, 2013). The α2δ 
subunits are also known to increase the inactivation rate of HVA calcium channels in 
several settings (Felix et al., 1997; Hobom et al., 2000; Shirokov et al., 1998; Sipos et 
al., 2000). Of the different known splice variants of α2δ subunits, all those characterized 
were able to modulate in a similar way HVA calcium channels (Klugbauer et al., 2000; 
Lana et al., 2014).   
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3.9.3 CACNA2D4  
 The last gene of the α2δ family to have been identified is CACNA2D4, encoding for 
α2δ4. First cloned from human brain, α2δ4 was initially identified at protein level in the 
small intestines, liver, adrenal, pituitary gland, and brain (Qin et al., 2002). Cacna2d4 
was subsequently found mutated in a spontaneous strain of mice showing an autosomal-
recessive cone-rod dystrophy. The mice presented an ERG with a reduced b-wave and a 
thinner OPL in the retina. Both characteristics point to a problem in connectivity 
between photoreceptor and second-order neurons (Wycisk et al., 2006a). The mutation 
consists in a single nucleotide insertion on Cacna2d4 exon 25 (E25) and truncates the 
open reading frame (ORF) after the first Cache domain, causing loss of the second 
Cache domain and of the whole δ peptide (Fig. 12). 
 
FIGURE 12. Scheme of Cacna2d4 transcript. Schematic representation of Cacna2d4 transcript (not in scale). 
The various exons are numbered. Positions of the von Willebrand factor A (VWF-A) domain and of the two Cache 
domains of the protein are shown. The murine c.2451insC1  mutation site and the resulting nonsense codon are 
indicated by black arrowheads. 
 
 Animals homozygous for the mutation were showing reduced levels of Cacna2d4 
mRNA in the retina compared to wild types. In humans, CACNA2D4 was found 
mutated in a family affected by autosomal recessive cone dystrophy (RCD4) (Wycisk et 
al., 2006b). Symptoms included a decrease in visual acuity, photophobia and defects in 
colour vision. As in the mouse strain, ERG had a reduced b-wave, a sign of incomplete 
stationary night blindness. Nevertheless the patients were not accusing night blindness, 
and the disease was progressive and not stationary. The causative mutation was found to 
be a substitution in E25 of CACNA2D4 resulting in termination of the ORF, similarly to  
 1 We have changed the annotation of the mutation form c.2367insC to c.2451insC since the trasncription start site of 
Cacna2d4 has been recently moved to an upstream position on the NCBI database.  
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FIGURE 1. Scheme of Cacna2d4 transcript and computational analysis of exon 25 splicing. (A) 
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what was observed in the mouse strain. Different studies have then characterized 
expression of α2δ4 in the retina, where it is found mainly associated with photoreceptors 
terminals, Müller glia cells, bipolar cells, and displaced ganglion cells (Mercer et al., 
2011; De Sevilla Müller et al., 2013). There are today four known splicing isoform of 
CACNA2D4, consisting in two alternative N- and two alternative C-terminals (Qin et 
al., 2002). CACNA2D4 effects on calcium currents have been so far barely 
investigated, and assessed only on one of the identified splicing isoforms. Human α2δ4 
has been found to increase Cav1.2 α1/β3 calcium influx in HEK293 cells (Qin et al., 
2002). More recently, human α2δ4 has been proven to interact with Cav1.4 α1 and β2 
subunits at photoreceptor ribbon synapses (Lee et al., 2014). In comparison to α2δ1, α2δ4 
was found to shift the voltage dependence of activation of Cav1.4 to more positive 
potentials and to evoke smaller current densities when co-expressed with Cav1.4 α1 and 
β2 (Lee et al., 2014). 
 
3.10 The patch clamp technique    
 Patch clamp is a developed of voltage-clamp, first introduced in 1952 by Hodgkin 
and Huxley (Hodgkin and Huxley, 1952) to describe the action potential in axons. 
Voltage-clamp is performed inserting two microelectrodes inside the cell, one for 
applying a certain potential to the cell membrane (clamping), the other for recording 
currents evoked by changes in the membrane potential. A problem of this technique was 
related to the control of the membrane potential at the recording site since the clamping 
and recording sites were not spatially overlapping. Originally invented in 1976 for 
single-channel measurements by Neher and Sakmann (Hamill et al., 1981), patch-clamp 
solved this problem and has revealed to be a very powerful tool in the investigation of 
cell excitability and ionic channel function. The word patch-clamp define the voltage-
clamp of a membrane patch. In other words, it means to set a define voltage on a piece 
of membrane with the goal of measuring the current passing through it. Even if 
clamping can also be referred to the set of a defined current trough the membrane patch, 
with the goal of measuring changes in voltage (current-clamp), we will not consider this 
application further as it is not relevant to the purpose of this work.  
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 The basic components needed in a patch-clamp experiments are an amplifier, a 
reference electrode, a measuring electrode,  an experimental chamber, and a bath 
solution (Fig. 13). The reference electrode, immersed in the bath solution, is grounded 
and keeps the potential outside the cell membrane at 0 mV.  The measuring electrode, 
connected with the amplifier, is inserted into a glass capillary (pipette) filled with a 
solution able to conduct currents (internal solution). In order to patch-clamp a cell, the 
pipette is first heated and pulled several times to obtain a sharp and very small aperture 
(0.5-2 µm). Once the pipette enters the bath solution, the circuit is closed. After having 
moved the pipette in contact with the cell, it is possible to control the electrical potential 
across the cell membrane with the patch-clamp amplifier. The membrane patch is 
formed by the portion of the cell membrane closing the end of the capillary. Only the 
patch is then voltage-clamped trough the capillary, remaining almost completely 
isolated from the rest of the cell membrane.  
 
FIGURE 13. Schematic representation of the basic components of a patch-clamp setup (Gandini et al., 2014).   
 
 An early improvement of this technique has been the introduction of the cell-attached 
mode. By applying suction into the capillary it is in fact possible to obtain a giga-seal, a 
very high resistance between the capillary edge and the plasma membrane. The cell-
attached configuration allows single-channel recordings, and is the starting point to 
obtain all other measurement configurations: whole cell, perforated patch, inside-out 
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and outside-out (Fig. 14). In the whole-cell mode an additional suction is applied, 
resulting in the rupture of the membrane patch closing the end of the capillary. Now the 
solution contained in the capillary (pipette solution) is in contact with the cytoplasm. 
The low resistance between the pipet and the cytoplasm (access resistance) and the 
retention of the giga-seal between the pipet and the membrane allow the clamping of the 
whole cell membrane. This results in the ability of recording currents occurring along 
the whole plasma membrane. The fact that the cytoplasm is now in contact with the 
pipette solution can represent a problem in experiment where the intracellular 
conditions need to be maintained. The perforated-patch configuration permits to 
overcome this issue by adding a pore-forming antibiotic (amphotericin-B or nystatin) to 
the pipette solution (Horn and Korn, 1992). When the cell-attached configuration is 
reached, the antibiotic forms channels in the plasma membrane, providing electrical 
continuity from the pipette to the cytoplasm without breaking the membrane. Additional 
variants of the patch-clamp technique allow the easy exposure to different solutions of 
the interior or exterior of the plasma membrane, as well as a fine control of the 
membrane potential. These single-channel configurations are called inside-out and 
outside-out. If the pipette is withdrawn from the cell after reaching the cell-attached 
configuration, the membrane patch can be detached from the cell obtaining the outside-
out configuration. The inside surface of the plasma membrane is in fact now in contact 
with the bath solution, while the outside faces the pipette solution. The opposite 
situation, or outside-out, is obtained from the whole-cell configuration by slowly 
withdrawing the pipette.   
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FIGURE 14. Different patch-clamp configurations. (Adapetd from Malmivuo and Plonsey, 1995)  
  
3.11 Retinitis pigmentosa and RPGR 
 Among different types of retinal degenerations, retinits pigmentosa (RP) is the most 
common form, affecting one in 4000 individuals (Hartong et al., 2006).  The disease 
commonly manifests during adolescence, and patients experience progressive visual 
impairments. Night blindness and loss of peripheral vision are usually the first 
symptoms, and eventually the disease can evolve into complete blindness due to the 
progressive loss of photoreceptor cells. Generally rods are first affected, and 
subsequently also cones start to degenerate. A typical sign of the disease is the 
appearance in the fundus of a bone-spicule pigmentation caused by migration of RPE 
cells. Although clinical symptoms of RP are similar among RP patients, the pattern of 
inheritance is complex, as mutations in 56 different genes can cause the disease (Daiger 
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et al., 2013). Autosomal recessive RP accounts for 50-60% of the cases, whereas 
autosomal dominant RP for 30-40%, and X-linked RP for 5–20% (Berger et al., 2010). 
Mutations in the retinitis pigmentosa GTPase regulator gene (RPGR) are responsible for 
70% of X-linked RP cases, the most severe form of RP (Petrs-Silva and Linden, 2014). 
RPGR encodes for a protein of still not well-elucidated function. It is known to be 
expressed in several tissues, where it is found associated with the primary cilia (Hong, 
2003; Khanna et al., 2005; Shu et al., 2005). In photoreceptor cells it is localized to the 
transition zone of the connective cilium (Hong and Li, 2002; Mavlyutov et al., 2002), 
where it is known to interact with the RPGR interacting protein 1 (RPGRIP1) (Boylan 
and Wright, 2000; Roepman et al., 2000; Zhao et al., 2003). The constitutive isoform of 
RPGR is encoded by 19 exons and is present in different tissues (Kirschner et al., 2001; 
Meindl et al., 1996; Roepman et al., 1996; Yan et al., 1998). This isoform consist of an 
N-terminal portion, which contain a Regulator of Chromosome Condensation 1 
homologus (RCC1h) protein domain encoded by exon 1 to 11, and a less structured C-
terminal portion (Meindl et al., 1996). The RCC1h domain is important for RPGR 
binding to RPGRIP1 (Roepman et al., 2000). In the retina instead a large subset of 
transcripts contains exon ORF15, that corresponds to the constitutive exon 15 plus a 
portion of intron 15. ORF15 encodes for a purine- rich C terminal, terminates the 
reading frame of the protein and is an hotspot for mutations (Vervoort et al., 2000).  
 A recently discovered splicing isoform of RPGR contains a new exon, exon 9a (E9a), 
downstream of exon 9 (Neidhardt et al., 2007). Exon 9a inclusion in the mature mRNA 
terminates the reading frame of the gene, deleting a portion of the RCC1h domain. This 
deletion modifies how RPGR interact with RPGRIP1, as it has been shown that E9a+ 
protein interacts with different variants of RPGRIP1 (Neidhardt et al., 2007). Moreover 
this isoform has a peculiar expression pattern. It is in fact mainly found in cones rather 
than in rods in human retina, and localizes in the inner segment of cones, whereas 
normally RPGR is present in the connective cilium (Neidhardt et al., 2007). In an RP 
patient a substitution was found 55 bp upstream of exon 9a. This mutation affects exon 
9a recognition by the splicing machinery, increasing the levels of transcripts containing 
the exon (Neidhardt et al., 2007). The elucidation of a splicing-modulating therapy to 
restore the levels of exon 9a can potentially be beneficial for carriers of this mutation.   
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3.12 Usher syndrome and USH2A 
 Usher syndrome (USH) is a disease characterized by deafness and RP, and is 
classified in three clinical types: USH1, USH2 and USH3 (Reiners et al., 2006). The 
three types can be distinguished by disease onset and severity. Patients affected by 
USH1 are congenitally deaf and show sign of RP in childhood. USH2 patients show 
hearing defects from birth, and RP can start during puberty. The most rare form, USH3, 
is also the less severe, and shows progressive hearing impairments, RP, and vestibular 
dysfunctions. Mutations in different genes have been found for each condition. The 
majority of mutations in USH2 patients are located on USH2A gene, encoding for 
usherin (Weston et al., 2000). There are today two known splicing isoforms of usherin: 
a 5Kb transcript that is translated in a 170 kDa protein predicted to be completely 
extracellular (Bhattacharya et al., 2002), and a 15 Kb long transcript, translated in a 600 
kDa protein predicted to be mainly extracellular, but still spanning across the plasma 
membrane (van Wijk et al., 2004). The predictions are based on the presence of several 
domains shared with other extracellular proteins, which are involved in protein-matrix 
and protein-protein interactions. The longer isoform adds several additional domains to 
the C-terminal of the shorter one, and results in having, from N to C terminal: 1 laminin 
G-like domain (LamGL), 1 laminin N-terminal domain (Lam NT), 10 laminin-like 
EGF-like domains (EGF-Lam), 4 fibronectin type 3 domains (FN3), 2 laminin G 
domains (LamG), 28 FN3 domains, 1 transmembrane region and 1 PDZ-1 binding 
domain (Fig. 15). USH2A is expressed in different tissues, but plays a key role mainly 
in the retina and cochlea. In the retina, it was found expressed in Bruch’s membrane, as 
well as at photoreceptor terminals and associated with the connective cilium 
(Bhattacharya et al., 2002; Reiners et al., 2006). A recent study has found that the 
FIGURE 15. Domain organization of USH2A 600kDa and 170KDa isoforms. 
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prevalent form of usherin in the retina is the longer isoform, which is only present 
associated to the membrane just around the connective cilium, which is actually 
wrapped by usherin (Liu et al., 2007). Similar to dystrophin in muscle, USH2A can be 
considered a promising target for exon-skipping strategies due to its modular structure 
of repetitive domains. 
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4 Aims of the PhD project 
 Antisense-mediated splicing-correction approaches have just begun to be applied to 
correct retinal dystrophies. Implementation of new therapeutic strategies in general, and 
for retinal dystrophies more specifically, is however slowed by the difficulty in having 
reliable animal models where to assess the efficacy and safety of the therapeutic 
approach. Such models should in fact not only resemble the human disease phenotype, 
but also its genotype. In particular, the mRNA of the target gene needs to be present in 
the model, and the splicing pattern of the gene, as well as the introduced mutations, 
need to be similar. Moreover not all genes and not all mutations can be effectively 
targeted by splicing-modulating approaches, and a careful evaluation of the type of 
mutation and of the host gene needs to be achieved. A third difficulty in developing 
such therapies is the lack of characterization of disease genes. The function of the 
majority of genes causing retinal dystrophies is in fact not understood or poorly 
characterized.  
 The aims of this project were first of all to analyse existing databases in order to 
identify the most promising genes having mutations targetable with antisense-mediated 
splicing-correction approaches. After identification, the second goal was to design and 
apply such approaches to restore the functionality of the altered proteins. 
 In order to identify new interesting targets for splicing-correction approaches, we 
first undertook a survey of available databases of disease genes and mutations, as well 
as recent literature. We focused our research on disease genes of known function for 
which was available an animal model fitting the previously mentioned characteristics, 
and we identified one potential target for exon-skipping (CACNA2D4). 
Characterization of this model revealed how the protein resulting from exon skipping is 
no more functional, showing the unfeasibility of our therapeutic approach. However we 
identified for the first time two splicing isoform of the gene which do not show the 
same properties as the canonical one. We finally reported an additional effect on 
splicing of the studied mutation.  
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 We thus extended the initial search to other genes not having an animal model, 
identifying other two promising targets for antisense-mediated splicing-correction 
approaches (RPGR and USH2A), and successfully achieving splicing correction in one 
of them (RPGR).  
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5 Results 
5.1 Identification of candidate genes for splicing-correction approaches 
 We started our work with the aim of identifying new candidate genes in which the 
application of antisense splicing-correction approaches would be feasible and 
potentially beneficial for patients affected by retinal dystrophies. We focused our 
attention on genes and mutations that would benefit from strategies aiming at reducing 
or abolishing presence of exons, rather than increasing their recognition. Our choice 
was based on the fact that the design of antisense molecules for such strategies is 
considered easier since more is known about sequences that are fundamental for an 
exon to be recognized as such (SD, SA, ESE, ESS, BS, Py) compared to those 
inhibiting exon recognition (ESS, ISS). Furthermore the correction of splice site 
mutations affecting exon recognition, the most abundant form of identified splicing 
mutations at the moment, is particularly difficult and only mutations in some positions 
have been effectively rescued.  We also decided to prioritize our search to genes for 
which animal models exist, with mutations similar to those encountered in human 
patients.  
 With this goal we started listing all genes present in the RetNet database, a database 
of genes and loci causing retinal diseases (Daiger et al. 1998). Having excluded from 
this list the unidentified genes, we obtained a list of 222 genes out of 269 total entries. 
We then excluded genes present on the mitochondrial genome, which do not undergo 
splicing (7 genes). Of the remaining 215 genes, we selected those causing autosomal 
recessive or X-linked diseases, in order to exclude dominant and multifactorial diseases. 
Even if antisense splicing-correcting approaches can in theory be applied also to 
dominant genetic diseases, the implementation of a therapeutic strategy for those genes 
is considered more risky. In fact in a dominant disease one should be able to selectively 
target the mutant allele and not the correct one, aspect which is rarely feasible with 
splicing-correcting approaches. Moreover, a recessive condition in which the normal 
gene product is absent can benefit more of even a partial restoration of the functional 
protein levels, whereas in a dominant disease, especially in the case of gain of function 
mutations, only a significant reduction of the aberrant gene product can result in a 
beneficial correction of the phenotype. Following this line we thus reduced the 
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candidate genes to 133. A further reduction was obtained by eliminating genes for 
which even a preliminary characterization or an hypothesized function in the retina was 
completely absent. The remaining 100 genes were searched on the Human Genetic 
Mutation Database (HGMD) professional (Stenson et al. 2009) in order to identify all 
known mutations linked to each of them. A list of all identified genes (Tab. S1) as well 
as of all mutations found in all RetNet genes (Tab. S2) is present in the attachments. We 
then started searching the literature for animal models presenting mutations similar to 
any of those listed in the HGMD database. We focused our attention on animal models 
having mutations similar to those observed in human patients, falling in one of the 
following situations: having mutations interrupting the reading frame of an exon which 
is affected also in humans by the same type of mutation; having deep intronic mutations 
in the same intron as the human counterpart; having synonym exonic mutations in the 
same exon as in humans. We were able to identify only one animal model with such 
characteristics. This animal model is a mouse bearing a spontaneous insertion on 
Cacna2d4 exon 25 (K. A. Wycisk et al. 2006) leading to frameshift in a similar way to 
the nonsense mutation on the same exon of CACNA2D4 found in a family affected by 
retinal dystrophy (K. A. Wycisk et al. 2006).  
We then decided to expand our search also to genes lacking an animal model, but 
having a modular structure similar to that of the dystrophin gene. This because in such 
genes an exon-skipping approach can be more feasible since the removal of one domain 
in a protein where such domain is repeated in a series is less likely to severely impact 
protein functionality. We were able to identify a gene with such characteristics, 
USH2A, where many known mutations fall into exons coding for the repeated EGF-
Lam and FN3 domains.  
We finally searched for genes having newly identified mutations in deep intronic 
regions far from the consensus for SD and SA splice sites which increase exon inclusion 
as a pathological mechanism. By this final search we were able to identify a mutation in 
RPGR (Neidhardt et al. 2007). 
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5.2 CACNA2D4 
 
5.2.1 Computational analysis of Cacna2d4 splicing 
 To correct the genetic defects caused by CACNA2D4 mutations on E25 we decided 
to base our strategy on exon-skipping chimeric U1 snRNAs masking sites important for 
splicing. The skipping of E25 alone is not applicable, since the joining of exons 24 and 
26 results in frameshift both in humans and mice. To solve this problem, the minimal 
region that needs to be skipped comprises exons 23-24-25-26 both in humans and mice. 
In mice, also removal of only exons 23-24-25 is enough to restore the reading frame. 
Skipping of these exons would result in a rescued protein that is no more truncated after 
the first Cache domain, since it is retaining all structural domains encoded by the exons 
downstream of the mutation: the second Cache domain and the δ peptide (Fig. 16). For 
the design of a multiexon-skipping approach, U1snRNAs need to be directed against 
splicing-relevant sequences present on all exons that need to be skipped. Alignment of 
both human and mouse coding sequences revealed an overall 85% homology, 
percentage maintained between exons 23-24-25-26 (Fig. S1) and in the alignment of the 
corresponding protein sequences (Fig. S2). The multiexon-skipping strategy has been 
considered for Duchenne muscular dystrophy, in order to expand the pool of patients 
which can be addressed by a single mix of AONs (Aartsma-Rus et al. 2004). In 
alternative to that, a relatively simpler approach consist in targeting only the first and 
last exon. Their targeting by chimeric U1 snRNA can in fact induce the generation of 
splicing events which skip all the four or only three exons.  
               
FIGURE 16. Schematic representation of the effect of the exon-skipping approach on CACNA2D4. The effect 
of the mutation is to truncate the ORF of CACNA2D4 after the first Cache domain (α2δ4 MUT). The rescued 
transcripts, resulting from skipping of exons 23 to 26 or 23 to 25, would encode for  a shorter protein, missing the 
part encoded by the skipped exons, but retaining the domains located downstream of the mutation (α2δ4 ΔE23-26, 
α2δ4 ΔE23-25)  
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 Even if all CACNA2D4 targeted exons are believed to be constitutive exons of 
Cacna2d4, the multiexon-skipping approach is complex, and can potentially generate 
different mis-spliced products. Therefore the design of an exon-skipping strategy must 
envision, at the best approximation possible, how splicing normally occurs among this 
exons in presence and absence of the mutation. In this regard, and focusing first on the 
mouse model, we started applying a bioinformatics strategy aiming at retrieving all 
existing data on Cacna2d4 splicing, with a particular emphasis on the region 
surrounding E25.  
 From a fist analysis of deposited sequences, we realized that an incorrectly annotated 
NCBI entry for Cacna2d4 full-length was actually a potential new splicing isoform, 
missing exon 16 (BC 141091.1). Since nothing is known about murine Cacna2d4 and 
its splicing isoforms, and since there is no indication on which is the functional isoform 
able to increase expression of functional L-type calcium channels in the murine retina, 
we decided to consider also this isoform as relevant to our investigation.  
 We then started searching the Gene Expression Omnibus (GEO) database for next 
generation sequencing (NGS) RNA datasets of wild type mouse eye or retina. We found 
4 RNA-seq datasets of mouse eye and one dataset of mouse retina (dataset ID 
GSE38359: sample IDs GSM945628, GSM945631 and GSM945634; dataset ID 
GSE29752: samples GSM737548 and GSM737550). Alignment of the reads contained 
in each dataset to the genomic sequence of Cacna2d4 revealed the splicing pattern of 
Cacna2d4. Interestingly, when focusing on the region delimited by exons 23 and 26, we 
noticed a significant number of reads covering a portion of intron 25 proximal to the 3' 
end of exon 25 (Fig. 17). Moreover, some of these reads were partially overlapping with 
exon 24 and with exon 26, but not with the canonical E25. Thus the identified region in 
intron 25 can possibly be a new alternatively spliced exon, mutually exclusive with 
exon 25. We named this putative new exon (205bp long) as exon 25b (E25b). Analysing 
the relative coverage levels between E25 and E25b it is possible to predict that 
transcripts containing E25b are less represented than those including E25 (Fig. 17). 
Inclusion of E25b between exon 24 and 26 creates an new stretch of 53 amino acids 
followed by a stop codon, resulting in the termination of the Cacna2d4 reading frame 
between the two Cache domains and thus in a transcript not encoding for the second 
Cache domain and for the whole δ peptide. It is curious to note how the c.2451insC 
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mutation on E25 truncates the reading frame in the same position. We tried to confirm if 
also in humans E25 was alternatively spliced, but recovered human RNA-seq data 
presented low coverage of the region of interest and it was thus not possible to analyse 
the splicing pattern.  
 
FIGURE 17. Integrative Genomic Viewer (IGV) visualization of the RNA-seq eye sample GSM737548 
aligned to Cacna2d4 genomic sequence. Position of E25b has been included. Junctions represent reads spanning 
over two exons: alternative splicing of E25 and E25b can be observed. 
 
 We also analysed the position of exon 16, to assess the presence of mature transcripts 
skipping this exon in the retina. Even if in a few reads skipping of exon 16 was present, 
this isoform does not seem to be the main one present in the eye (Fig. 18).  
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FIGURE 18. IGV visualization of the RNA-seq eye sample GSM737548 aligned to Cacna2d4 genomic 
sequence. It is possible to notice the few reads skipping exon 16.  
 
 To acquire more evidence in support of E25b presence as a putative alternatively 
spliced exon, we performed an analysis of the splice sites of all the exons between exon 
22 and 27 using the splice-site predictor NNSPLICE 0.9 (Reese et al. 1997). The results 
show E25b having stronger 3’ and 5’ splice sites compared to the canonical E25 (Tab. 
2). In particular the 3’ splice site of E25 is very weak, while the 3’ splice site of E25b is 
relatively strong. This strengthens the hypothesis that E25 is alternatively spliced with 
E25b in the retina. 
                           
TABLE 2. Splice site scores of Cacna2d4 exon 22 to 27. The higher is the score, the stronger is the splice site. A 
perfect match to the splice site consensus sequence is indicated with 1.  
 The presence of the putative E25b can give a different light to the effect of the 
mutation found in the murine model. It is in fact possible that the mutation not only 
truncates the reading frame of the protein, but also alters the way E25 is recognized by 
Score Sequence)5')>)3'
E22)5'splice)site 0.52 ctggagtgtgagttc
E23)3'splice)site 0.92 ttcctgtgactttaccctcaggtgacgaggaactggtgcgg
E23)5'splice)site 0.85 tctctgagtacgtac
E24)3'splice)site 0.93 tgttgttgctttgcctcgcagagagtcagagcctggcgtgg
E24)5'splice)site 0.99 ctgacaggtgagccc
E25)3'splice)site 0.43 acatcaatcctactctcacaggaagttcctgacccctgaag
E25)5'splice)site 0.92 ggaccaggtaacgga
E25b)3'splice)site 0.93 cctctctgtgctcttccccagagtggaaaaagggagatgtg
E25b)5'splice)site 0.99 tcccaaggtgagatc
E26)3'splice)site 0.98 caataattctcatttttccagatagcccaggcaagccagtg
E26)5'splice)site 1.00 gcagcaggtaagagc
E27)3'splice)site 0.98 cctccttcctgtttcctgcagctgtgggcatccagatgcaa
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the splicing machinery. We therefore investigated the possible role of this mutation on 
splicing using the webserver spliceAid (Piva et al. 2009). SpliceAid is a regularly 
updated and manually curated tool which predicts cis-acting sequences that enhance or 
inhibit exon recognition, giving positive scores for the first and negative for the second. 
The higher is the absolute value of the score, the better is the prediction presented. The 
analysis of E25 sequence in presence and absence of the mutation (Fig. 19) revealed 
how the mutation is predicted to introduce a new ESS, which may impair recognition of 
the mutated exon 25. Specifically, the mutation creates a sequence of 8 cytosines which 
is predicted to be recognized with high scores by 8 different splicing factors inhibiting 
exon recognition. Only one trans-acting splicing factor improving exon recognition was 
predicted with a low score (Tab. 3).  
 
         
FIGURE 19.  Prediction for ESE and ESS in Cacna2d4 E25. New predictions generated by the c.2451insC 
mutation are reported. The site of the mutation is underlined in black.  
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TABLE 3. Complete list of predicted trans-acting splicing factors binding to mutant E25 only. The higher is the 
absolute value of the score, the better is the binding prediction. The sign of the predicition reveals if the protein is 
believed to impair exon recognition (negative scores, ESS), or promote it (positive scores, ESE). 
 
 Performing the same analysis on human E25, it is possible to predict a similar effect. 
The CACNA2D4 mutation c.2406C→A in fact abolishes an ESE and replaces it with an 
ESS (Fig. 20). If E25 is alternatively spliced also in humans, the mutation could 
therefore change the ratio between the two exons in mature mRNA.  
 
           
FIGURE 20. Prediction for ESE and ESS in CACNA2D4 E25. The figure underlines changes induced by the 
human mutation in E25. The position of the nucleotide substitution is underlined in black. Abolished ESE are 
crossed, new ESS are boxed.  
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5.2.2 In vivo characterization of E25 splicing 
 Following our bioinformatics analysis, we decided to confirm the presence of E25b 
in vivo in mouse retinae and investigate a possible role for the c.2451insC mutation on 
splicing. RT-PCR was conducted on retinae of wild type and mutant animals using 
primers on exon 24 and on exon 26. Discrimination between E25 and E25b containing 
transcripts was possible thanks to the different size of the two alternatively-spliced 
exons (E25: 128bp; E25b: 205bp). By this analysis, we were able to confirm the 
presence of Cacna2d4 E25b alongside the canonical one in the retina of wild type and 
mutant mice (Fig. 21 A). The effect of the mutation was to decrease levels of E25 
containing transcripts, as observed by densitometric analysis of the obtained bands (Fig. 
21 B). Levels of E25b were instead similar in presence or absence of the mutation. For a 
better understanding of how the mutation impacts on the level of the two splicing 
isoforms in the retina, we performed RT-qPCR analysis using specific primers for the 
two splicing isoforms. Our results showed a marked three-fold decrease in the levels of 
E25 in the mutant compared to wild type retinae (Fig. 22 A), in line with what observed 
with densitometric analysis. The reduction in E25 containing transcripts follows the 
general reduction observed in Cacna2d4 mRNA using primers on the 3’ untranslated 
region (UTR) and previously observed with RT-qPCR performed on the last exon of the 
gene (K. A. Wycisk et al. 2006). This reduction could be ascribed, apart from the effect 
of the mutation on splicing, to nonsense mediate decay acting on the mutant transcripts. 
Exon 25b levels are instead much less affected in the mutant (Fig. 22 A). We then 
compared the relative levels of E25 versus E25b in presence and absence of the 
mutation. In normal conditions E25 is three times more abundant in final transcripts 
than E25b. In presence of the mutation in E25, the situation changes dramatically, and 
both exons are present almost at the same levels (Fig. 22 B). 
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FIGURE 21. RT-PCR of wild type and mutant mouse retinae. (A) Numbers represent different pools of wild type 
and mutant retinae. Plasmids containing Cacna2d4 sequence with E25 (pE25) or with E25b (pE25b) were used as 
controls. Presence of both E25 and E25b can be observed. (B) Densitometric analysis of the RT-PCR on wild type 
and mutant mouse retinae reveals a reduction of E25 containing plasmid (P<0.05). 
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FIGURE 22. RT-qPCR of wild type and mutant mouse retinae. (A) Quantification of Cacna2d4 E25, E25b and 
3’ UTR using RT-qPCR on three different pools of mouse retinae. A more pronounced reduction of E25 (p<0.001) 
compared to E25b (p<0.05) containing transcripts was observed. (B) Relative abundance of E25 over E25b 
containing transcripts in mouse retinae. The mutation favours E25b presence (p<0.001). 
 
5.2.3 A splicing-reporter minigene for Cacna2d4  
 Splicing-reporter minigenes are potent instruments for the investigation of the effect 
that mutations have on splicing, and for the validation of different antisense molecular 
tools designed to modulate splicing. In our specific case, a minigene able to recapitulate 
all splicing events between exons 22 and 27 would offer a unique opportunity to better 
understand the effect of the 2451insC mutation on splicing of E25, and to effectively 
screen different chimeric U1snRNAs able to mediate skipping of exons 23 to 25, or 23 
to 26. Since the genomic region spanning from Cacna2d4 exon 22 to exon 27 is too 
large to be cloned in a plasmid (36 Kb), we decided to partially remove introns larger 
than 1.5 Kb, with the precaution of leaving 500 bp of intronic sequence around each 
splice site and the sequence of E25b. A start codon was added at the beginning of exon 
22 and a luciferase reporter was cloned after exon 27 (Fig. 23 A). Proper splicing 
between exon 22 – 23 – 24 – 25 and 27 would permit the ORF between exon 22 and the 
Luc2 reporter to be mantained, resulting in luciferase expression. We also mutagenized 
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the minigene to add the insertion on E25. In the mutant minigene luciferase expression 
would be abolished by presence of the mutant exon, and only rescued by effective 
skipping of exons 23 to 26 or 23 to 25. Since the presence of all spliced exons before 
the luciferase reporter encodes for additional 187 residues, this could result in loss of 
enzymatic activity of the reporter. We thus performed a luciferase assay testing wild 
type and mutant minigenes transfected in HEK293T cells (Fig. 23 B). The wild type 
minigene showed poor luciferase activity, at a comparable level with the mutant 
minigene. This indicates that in fact luciferase can not be the optimal reporter to assess 
splicing with our minigene, and therefore RT-PCR represents a better choice. A 
possible explanation for not having observed luciferase activity from the wild-type 
minigene is that the peptide encoded by Cacna2d4 exons 22 to 27 blocks the enzymatic 
activity of the Luciferase.  
 
FIGURE 23. Cacna2d4 splicing-reporter minigene. (A) Schematic representation of Cacna2d4 splicing-
reporter minigene. The length of the different exons (boxes) and introns (straight lines) is shown. Arrows 
represent the position of the different sets of primers used for the different RT-PCR. The position of the luciferase 
reporter (Luc2) is shown. (B) Luciferase assay of HEK293T cells transfected with wild type minigene, mutant 
minigene, or with vector expressing Luc2 (positive control).  
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5.2.4  In vitro characterization of exon 25 splicing 
 The obtained Cacna2d4 minigenes can be used to better understand the effect of the 
2451insC mutation on splicing of exon 25 and 25b in a different system. We therefore 
transfected HEK293T cells with wild type and mutant minigenes and assessed splicing 
across all exons present on the minigenes by RT-PCR and RT-qPCR. Using primers on 
exon 22 and 27 it was possible to observe how the minigene is able to properly 
recapitulate all splicing events between the different exons, as two bands at around 800 
bp were presents in both wild type and mutant minigenes. The lower band should 
represent transcripts including exon 25, the upper one those containing the larger exon 
25b (Fig. 24 A, first line). It is interesting to note how, with this first PCR, in the mutant 
the upper band is more intense than the lower, whereas using the wild type minigene 
both bands appear to have the same intensity. This finding suggests a role for the 
mutation on splicing of exon 25b also in HEK293T cells, in which it favours exon 25b 
presence. To confirm this data we first performed an additional RT-PCR using primers 
on exon 24 and 26. Two distinct bands were observable: the upper containing exon 25b, 
the lower containing exon 25 (Fig. 24 A, second line). Also with this PCR the mutation 
causes an increase in exon 25b containing trasncripts, as shown by the densitometric 
analysis (Fig. 24 B). We finally confirmed this data by RT-qPCR with specific primers 
for the two splicing isoforms (Fig. 25 A). By direct comparison of the relative 
abundance of the two splicing isoforms it is possible to observe how the mutation 
affects the ratio between exon 25 and 25b, showing a trend that favours exon 25b 
presence (Fig. 25 B). Contrarily to what observed in vivo, where the mutation primarily 
affects exon 25 levels, in transfected cells it  does not significantly impact on exon 25 
recognition. The effect is instead to favour exon 25b presence.  
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FIGURE 24. RT-PCR on wild type and mutant Cacna2d4 minigenes in HEK293T cells. (A) The first line shows 
the occurrence of proper splicing between all exons included in the minigene. Two bands, close to 850 bp, are 
distinguishable. The lower is caused by E25 inclusion (805bp), the upper by E25b (882bp). The second line confirms 
the presence of E25b-containing transcripts alongside E25-containing ones. Wild type minigene (wt mini); mutant 
minigene (mut mini). (B) Densitometric analysis of the RT-PCR on wild type and mutant minigenes. The mutation 
acts on splicing by favouring E25b inclusion.  
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FIGURE 25. RT-qPCR of the two splicing isoforms from HEK293T cells transfected with the different 
minigenes. (A) The mutation causes an increase in the levels of the splicing isoform including E25b (p<0.01). 
(B) Relative abundance of E25 over E25b containing transcripts in HEK293T cells transfected with minigene 
splicing reporter systems. The mutation favours E25b presence. (C) Amplification curves of E25b in presence  
(red, mutant minigene) or absence (green, wild-type minigene) of the mutation.  
 
5.2.5 Analysis of α2δ4 ΔE16 splicing isoform expression in the central nervous system 
(CNS) and neuroendocrine system. 
 From our bioinformatics analysis we noticed the presence of an uncharacterized 
splicing isoform of Cacna2d4 missing exon 16 (α2δ4 ΔE16) coming from a whole brain 
cDNA library. Skipping of exon 16 causes the removal of a consistent portion of the 
first Cache domain of Cacna2d4, and thus this isoform can show different properties 
compared to the full-length one. Aiming at understanding the relevance of this isoform 
in the mouse retina and possibly in other districts, we performed an RT-PCR analysis 
using primers on exon 15 and 17. In line with the analysed RNA-seq data, α2δ4 ΔE16 
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was not detectable in wild type or mutant mouse retinae, where exon 16 is constitutively 
present (Fig. 26 A, B). The same splicing pattern is present in the pituitary gland. 
Interestingly, in the cerebellum (CB), somatosensory cortex (SSC), occipital cortex 
(OC) and hippocampus the only detected isoform is α2δ4 ΔE16, which is present at very 
low levels. The hypothalamus (HPT) is instead the only analysed region where both 
splicing isoform are present.  
                          
FIGURE 26 Analysis of α2δ4 ΔE16 splicing isoform presence in the CNS and neuroendocrine system. (A) 
RT-PCR with primers flanking E16 on mouse hippocampus (HC), pituitary gland (PG), hypothalamus (HPT), 
occipital cortex (OC), somatosensory cortex (SSC), cerebellum (CB), WT (RET WT) and mutant (RET MUT) 
retina. (B) Densitometric analysis of RT-PCR. 
 
5.2.6 Functional characterization of different α2δ4 variants 
 In order to assess the feasibility of the envisioned exon-skipping approach, the 
functionality of the α2δ4 proteins resulting from the removal of exons 23 to 26 (α2δ4 
ΔE23-26) or of exons 23 to 25 (α2δ4 ΔE23-26) needs to be assessed. To achieve this 
goal, the characterization of full length α2δ4 is first needed. Moreover we decided to 
characterize the two newly identified splicing variants α2δ4 ΔE16 and α2δ4 E25b.  
  
  
 
59 
 
 
 The α2δ subunit of HVA calcium channels is known to increase the number of 
functional channel complexes on the plasma membrane, therefore increasing current 
densities of stimulated cells in which the different components of the channel are 
expressed. Another characteristic shared by different members of this protein family is 
to speed up the rate at which HVA calcium channels inactivate after stimulation 
(Dolphin, 2013). To investigate these aspects we exploited the potentiality of whole-cell 
patch clamp applied to an heterologous expression system: tsA-201 cells. We therefore 
cloned in expression vectors the different subunits of the mouse Cav1.4 calcium 
channel, believed to be those interacting in mouse photoreceptors: Cav1.4 α1, β2, and 
α2δ4. We also obtained the different α2δ4 variants, all cloned in pIRES2-EGFP vectors 
for being able to select transfected cells during recordings. A summary of all obtained 
constructs is presented (Fig.27). 
                           
FIGURE 27. Scheme of the different constructs for electrophysiological analysis cloned in pIRES vectors.  
 
 Following transfection of tsA-201 cells with mouse Cav1.4 α1, β2 and α2δ4 we never 
succeeded in obtaining conditions in which transfected cells were recordable. We tried 
different transfection conditions, different amounts of DNA transfected, and we also 
tried to use culture conditions with low calcium. Cells were always very difficult to 
patch, unstable, and those recordable were showing no inducible currents. We therefore 
tried substituting mouse Cav1.4 α1 and β2 with human Cav1.4 α1 (Sinnegger-brauns et 
al. 2009) and rat β3 (Castellano et al. 1993). With this conditions we succeeded in 
having recordable cells, thus we used them in all shown experiments.  
 Since the alteration of the α2δ4 open reading frame due to protein truncation (for α2δ4 
MUT and α2δ4 E25b) or a partial deletion (for α2δ4 ΔE23-25, α2δ4 ΔE23-26 and α2δ4 
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α2δ4 ΔE16) could potentially result in protein instability, we confirmed by Western blot 
the presence of the different α2δ4 variants in tsA-201 cells after transfection. As shown 
in figure 4, α2δ4 is present in all condition tested (lines 2-7) and absent in tsA-201 (line 
1). The α2δ4 MUT and α2δ4 E25b show the smallest dimension, since the protein is 
truncated in both cases after exon 25. The α2δ4 ΔE16 is instead very close to the wild 
type (α2δ4) size, missing only exon 16. The two constructs α2δ4 ΔE23-25, α2δ4 ΔE23-26 
show an intermediate size, since they lack three or four exons compared to the wild-
type, but retain the portion of the protein downstream of them, which is instead not 
present in α2δ4 MUT and α2δ4 E25b. 
       
FIGURE 28. Expression of the different α2δ4 variants in tsA-201 cells after transfection. A specific band for α2δ4 
is visible following tsA-201  transfection with Cav1.4 α1, β3, and constructs encoding all the different α2δ4 variants 
utilized (lanes 2-7). The α2δ4 band changes in size accordingly to the relative length of the expressed variant. In the 
negative control (lane 1) α2δ4 is not detectable, proving the absence of endogenous α2δ4 in tsA-201 cells. A condition 
were human α2δ4  was transfected (α2δ4 human) has been added as an additional positive control (lane 8). 
 We began by analysing current densities evoked by an activation protocol in 
presence of 15mM Ca2+ as charge carrier. The protocol consisted in 50 ms pulses at 
different potentials, ranging from -79 to 52 mV (Fig. 26 A). We first compared full 
length α2δ4 with the more investigated α2δ1 (Koschak et al., 2003) and noticed how α2δ4 
expression is able to mediate an increase in current densities at the different tested 
potentials even if to a lower degree than α2δ1, in a similar way to what has been recently 
shown with human α2δ4 by Lee and collaborators (Lee et al. 2014) (Fig. 29 A-B). We 
then tested the two different splicing isoforms α2δ4 ΔE16 and α2δ4 E25b, and showed 
how they are not able to mediate an increase in current densities, as their effects are 
similar to that of mutant α2δ4 (α2δ4 MUT) or of the empty vector (pIRES) (Fig. 29 A-B-
C). We statistically compared the different tested conditions considering the maximal 
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current densities obtained for each recorded cell. Of the different α2δ4 splice variants, 
only full length α2δ4 was able to mediate a significant increase of about three-folds in 
current densities (Fig. 29 C, Tab. 4). For the condition from which we were able to 
obtain an activation curve, we compared the obtained parameters for the voltage of half-
maximum activation (V0.5, act) and the slope of the curve  (Kact). No differences were 
observable in relation to Cav1.4 α1+ β3 alone, indicating that none of the tested α2δ4 
constructs is able to affect the activation of Cav1.4 calcium channels (Fig. 31 A, Tab 4).  
  
FIGURE 29. Effect of different α2δ4 variants on Cav1.4 mediated current density. (A) Scheme of the 
recording protocol and representative sample traces for some of the different tested conditions. (B) 
Representation of the changes in current density at the different voltages tested for α2δ1, α2δ4, α2δ4 E25b, α2δ4 
MUT (c.2451insC), α2δ4 ΔE16, pIRES (empty vector). Mean values, SEM, and the best fits of the current voltage 
relation are shown. The total number of cells considered for each curve is reported in parentheses. (C) Voltage-
dependent activation curve of α2δ1, α2δ4, α2δ4 E25b, α2δ4 MUT (c.2451insC), α2δ4 ΔE16, pIRES (empty vector). 
(D) Maximal current densities of cells measured in the presence of different α2δ4 subunits in comparison to α2δ1 
and pIRES. For each condition mean and SEM are shown. Selected pairs of conditions were compared using 
Kruskal-Wallis test followed by Dunn’s multiple comparison post-test (p < 0.001 = ***). 
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 Since the purpose of our exon-skipping approach is to resolve the functional problem 
caused by mutations on CACNA2D4 exon 25 which lead to truncation of the gene 
ORF, we tested if the rescued protein α2δ4 ΔE23-26 and α2δ4 ΔE23-26 were able to 
stimulate current densities through Cav1.4 calcium channels more effectively than α2δ4 
MUT. As evident from the comparison of observed maximal current densities, this was 
not the case (Fig. 29 C). This result strongly indicates that the designed therapeutic 
approach is actually unfeasible because the protein region that is deleted as a 
consequence of exon skipping is fundamental for the functionality of the protein. Such a 
conclusion was unpredictable as no characterization of the protein region was available 
before hand. 
 Aiming at better investigating a possible regulatory function of the two splicing 
isoforms α2δ4 ΔE16 and α2δ4 E25b on Cav1.4 calcium channels, we tested if they 
showed a dominant-negative effect on the activity of functional channels. Being that in 
both isoforms the normal architecture of α2δ subunits is not preserved, these isoforms 
can actually act by negatively counteracting the effect of a functional α2δ4. To test this 
hypothesis we transfected tsA-201 cells with constructs encoding for Cav1.4 α1, β3 and  
α2δ4. In addition to the full length α2δ4, we added in the transfection mix the same 
amounts of constructs encoding for α2δ4 ΔE16 or α2δ4 E25b, and measured current 
densities obtained from transfected cells stimulated with the same protocol described 
before. None of the isoforms tested showed an ability to significantly impair α2δ4 
activity of stimulating current density levels trough Cav1.4 calcium channels (Fig. 30 
A,B). Therefore a possible dominant-negative effect of the different isoforms on α2δ4 
was excluded. 
 To complete the characterization of α2δ4, we finally tested its effect on inactivation of 
Cav1.4. At first we analysed voltage-dependent inactivation of Cav1.4 in presence of 
α2δ4 and compared it to that observed with α2δ1. For this purpose we utilized an 
inactivation protocol consisting in a 50ms test-pulse before and after 5s pulses at 
different potentials (from -98 to 22 mV). The calculated parameters of the inactivation 
slope were comparable between α2δ4 and α2δ1, showing that  α2δ4 and α2δ1 have similar 
effects on voltage-dependent inactivation of Cav1.4 (Fig. 31 B, Tab 4). We also looked 
at a possible effect of α2δ4 on calcium-dependent inactivation. We therefore applied  
300ms pulses at different potentials in presence of Ca2+ and Ba2+. Expression of α2δ4 did 
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not induce an increased inactivation rate of Cav1.4 over 250 ms (r250) in presence of 
Ca2+ compared to Ba2+ over a voltage range from -40 to +40 mV, and results were 
comparable to those obtained with α2δ1 by Burtscher and collaborators using the same 
settings (Burtscher et al. 2014) (Fig. 31 D). The percentage of remaining current during 
250 ms test pulse to 2 and 12 mV (which was the voltage of the maximum current with 
Ba2+ and Ca2+) was 90% for Ba2+ and 91% for Ca2+, with no significant difference 
observed (P = 0.56). Comparable results were recently reported using human α2δ4 
subunit (Lee et al. 2014). 
 
                                 
FIGURE 30. Effect of the coexpression of full length α2δ4 with other α2δ4 variants. The full length α2δ4 
construct was cotransfected with equal amounts of other α2δ4 variants. No significant differences on maximal 
current density were observed in any of the tested conditions as compared with α2δ4 + α2δ4, or with α2δ4 + 
pIRES. As a result no dominant negative effect of the different variants on α2δ4 activity was observable in the 
employed experimental conditions. 
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FIGURE 31. Characterization of α2δ4 activity on Cav1.4 mediated currents. (A) Voltage-dependent 
activation curve of α2δ1, α2δ4, α2δ4 E25b, α2δ4 MUT (c.2451insC), α2δ4 ΔE16, pIRES (empty vector). (B) 
Voltage-dependent inactivation curve of α2δ1 and α2δ4. Mean values, SEM, and the best fits of the current voltage 
relation are shown. (C) Protocol used for the analysis of calcium-dependent inactivation and sample traces for 
α2δ4 in presence of 15mM Ca2+ (CA) or Ba2+ (BA). (D) Representation of the change in current at the beginning 
and at the end of 250ms depolarization (r250) at different potentials using Ca2+ (CA) or Ba2+ (BA). (E) 
Comparison of the r250 values obtained for α2δ4 at the maximal current with Ca2+ (CA) and Ba2+ (BA).  
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TABLE 4. Calculated biophysical parameters of Cav1.4 calcium channels in the different experiments 
conducted. Experiments were performed in tsA-201 cells using 15mM Ca2+ as charge carrier. Data are given as 
mean ± SEM. CDmax= maximum current density, V0.5, act= half-maximum activation voltage, Kact= slope 
parameter of the activation curve, V0.5, inact= half-maximum inactivation voltage, Kinact= slope parameter of the 
inactivation curve, N= sample size, ND= not determined. Statistically significant differences are indicated by 
asterisks (P<0.001=***). For multiple comparisons (CDmax; V0.5 act; Kact), significance is given in relation to 
Cav1.4 α1 + β3 + pIRES. For single comparison (V0.5 inact; Kinact) significance is given in relation to Cav1.4 α1 + 
β3 + α2δ1. Data for α2δ1 V0.5 inact and Kinact were taken from Burtscher et al (Burtscher et al. 2014) to allow 
comparison.  
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5.3 RPGR 
 
5.3.1 Computational analysis of RPGR exon 9a splicing-relevant sequences  
 The intronic mutation g.26652G>A of RPGR increases the levels of the alternative 
exon 9a. The mutations is located 55 bp upstream of exon 9a 3’ splice site. Aiming at 
the design of an exon-skipping approach which could decrease the levels of exon 9a in 
presence of the mutation, we undertook a bioinformatics analysis of relevant sequences 
important for recognition of the alternative exon. At the same time we tried to 
understand the effect of the mutation on such sequences. We first analysed exon 9a 
splice sites with NNSPLICE 0.9. The results show how exon 9a has a weak consensus 
for its 3’ splice site, whereas its 5’ splice is more similar to the consensus sequence 
(Tab. 5). 
           
TABLE 5 Splice site scores of Cacna2d4 exon 22 to 27. The higher is the score, the stronger is the splice site. A 
perfect match to the splice site consensus sequence is indicated with 1.  
 
 Recognition of a defined ESE sequence on exon 9a can constitute a target site for the 
design of chimeric U1snRNAs able to mediate exon 9a skipping. SpliceAid predictions 
for exon 9a did not show presence of a clear and defined ESE along its sequence, since 
ESEs and ESSs seam to be present in the same regions  (Fig. 32). Moreover, SpliceAid 
analysis of the site of the wild type and mutant sequence did not reveal a change in cis-
acting sequences important for splicing (data not shown). We therefore applied another 
prediction tools, ESEFinder. ESEFinder uses an experimentally-generated matrix to 
weight consensus motif for a set of SR proteins, which mainly act by enhancing exon 
recognition (Smith et al. 2006; Cartegni et al. 2003). This tool predicts a binding site for 
an SR protein, SRSF2 (SC35), to be suppressed by the mutation (Fig. 33). Even if this 
result seems to be inconsistent with the effect of the mutation, which actually increases 
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exon 9a presence, it is known that in some condition SRSF2 can act as a splicing 
silencer, particularly when binding to introns,  therefore the removal of its binding site 
can result in augmented exon recognition (Raponi et al. 2011; Erkelenz et al. 2013; 
Dembowski et al. 2012). If the prediction is correct, the mutation site cannot represent a 
target for chimeric U1snRNAs designed to impair exon recognition, since there are no 
indications that the mutation is creating a new ISE. Another possible effect of the 
mutation could be the creation of a new branch site with a stronger consensus. We 
investigated this possibility using the branch point sequence analysis tool of Human 
Splicing Finder (Desmet et al. 2009). The performed prediction does not show a change 
in the branch sites pattern of intron 9 (data not shown).  
 
FIGURE 32.  Prediction for ESE and ESS in RPGR E9a using SpliceAid. All predicted ESE are overlappig with 
predicted ESS, thus a clear ESE is not defined.   
 
                             
FIGURE 33. ESEFinder prediction of the effect of the intronic g.26652G>A mutation. The last portion of intron 
9a before exon 9a is shown. The site of the mutation is underlined. The mutation is predicted to abolish an ISE 
(boxed).   
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5.3.2 Design of U1snRNAs and reporter minigenes for exon 9a skipping 
 The results of our bioinformatics prediction suggests that exon 9a does not have 
evident ESEs, and that the mutation site can not represent a valid target for inducing 
exon skipping. Therefore we decided to target exon 9a splice sites. Masking these sites 
should in fact result in skipping of exon 9a as a consequence of the failure of the 
splicing machinery to recognize these important cis-acting sequences. In particular we 
generated three chimeric U1snRNAs targeting the 3’ splice site (U1_3’), the 5’(U1_5’) 
splice site, and both sites (U1_3’5’). To test the effect of this U1snRNA on exon 9a 
splicing we designed a minigene reporter system cloning the RPGR genomic region 
around exon 9a in an expression vector. The minigene was designed to contain exon 9, 
the whole intron 9, exon 9a and exon 10 (Fig. 34 C). This construct was subsequently 
mutated to introduce the intronic mutation g.26652G>A. Following transfection of the 
wild type and mutant minigenes in HEK293T cells it is possible to observe how in this 
cell line the effect of the mutation is similar to what observed in human patients, were it 
has been shown to increase the levels of exon 9a (Fig. 34 A, B). The mutation in fact is 
able to significantly increase exon 9a levels of about one fold in the minigene (Fig. 34 
D, E). Similar results were obtained in 661w cells (Al-Ubaidi et al., 1992), a 
photoreceptor-derived cell line (Fig. 34 F, G).   
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FIGURE 34. The intronic mutation g.26652G>A and RPGR minigene. (A) Pedigree of the family of the affected 
patient (from Neidhardt et al., 2007). (B) RT-PCR amplification of transcripts either lacking or including exon 9a of 
RPGR using total RNA from blood.The transcripts including exon 9a are increased in patient II-5, compared to his 
nonaffected brothers (patients II-3 and II-4) (from Neidhardt et al., 2007). (C) Schematic representation (not to scale) 
of the minigene. Position of the mutation is indicated by a star. The binding sites of U1_3’ and U1_5’ are reported. 
Position of the primers used for the analysis of E9a presence are indicated by arrows. (D) RT-PCR of  HEK293T 
cells transfected with wild type or mutant RPGR minigene. (E) Densitometric analysis of the bands (N=3) reveals 
how the mutation increases E9a presence (p<0.001). The mean % of E9a+ is given. (F) RT-PCR of 661w cells 
transfected with wild type or mutant RPGR minigene. (G) Densitometric analysis of the bands (N=3) reveals how the 
mutation increases E9a presence (p<0.001). The mean % of E9a+ is given. 
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5.3.3 Testing different chimeric U1snRNAs for exon 9a skipping 
 We then applied the different chimeric U1snRNAs to HEK293T cells transfected 
with the mutant minigene. From densitometric analysis of the RT-PCR performed in the 
different conditions, using U1_3’ and U1_3’5’ we were able to observe a reduction of 
exon 9a+ mRNAs of about 50% compared to transfection of the minigene alone. 
Interestingly, the U1_5’ is able to stimulate exon 9a recognition, doubling the levels of 
exon 9a presence in mature mRNA. Instead, when both construct were used together, 
the results did not match those observed using U1_3’5’. In fact, presence of both U1_3’ 
and of U1_5’ still promotes exon 9a splicing, even though at a lower degree than U1_5’ 
alone. This suggests that the effect of U1_5’ expression is more pronounced of that of 
U1_3’ and that U1_5’ is in fact not masking the splice site, but actually improving its 
recognition in the same way as the normal U1 snRNA does (Fig. 35). Even if chimeric 
U1snRNAs are normally used to increase exon recognition impaired by different 
mutations, in our case the U1_5’ was designed to have a very long (24 bp) 
complementarity with the 5’ splice site with the objective of impeding its detachment 
thus masking the splice site.  
                                 
FIGURE 35. Effect of different chimeric U1 snRNAs on exon 9a splicing. (A) RT-PCR of HEK293T cells 
transfected with RPGR mutant minigene plus the different U1. U1_SCR: scramble U1. Mini mut: mutant minigene 
alone. (B) Densitometric analysis of the bands (N=3). Statistically significance for exon 9a reduction using U1_3’ or 
U1_5’ is reported (p<0.001) compared to U1 SCR.  
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 We then selected our best-performing chimeric U1 snRNA (U1_3’) and tested it at 
different concentrations in HEK293T cells to assess the dose-dependency of its effect in 
comparison to the scramble U1 (U1_SCR). As expected, while the U1_SCR does not 
affect exon 9a levels at the different tested doses, U1_3’ does, showing a visible 
decrease in exon 9a skipping ability at lower doses (Fig. 36).  
    
FIGURE 36. Dose-dependent skipping effect of U1_3’. (A) RT-PCR of HEK293T cells transfected with the RPGR 
mutant minigene plus different doses of U1 3’ and U1 SCR. (B) Densitometric analysis of the bands (N=2). (C) Fit of 
the dose-response curve for U1_3’ and U1_SCR dilutions. Only datas of U1_3’ dilutions were able to fit a dose-
response curve. 
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5.4 USH2A 
 
 The USH2A gene encodes for usherin, a modular protein found associated with the 
photoreceptor connective cilium. Presence of repetitive domains renders a protein an 
interesting target for exon-skipping therapeutic applications, as is the case of 
dystrophin, one of the first successful targets for splicing-modulating interventions 
(Matsuo, 1996). This is due to the fact that removal of exons coding for one of the 
repetitive domains is unlikely to completely impair protein functionality, as long as an 
ORF is maintained. We therefore started to analyse the known mutations of USH2A to 
find those falling in exons which could be easily targeted by antisense approaches. The 
candidate exon must be located in a region of usherin where repetitive domains are 
present, must be relatively small (less than 300 bp), and must be symmetrical. A 
symmetrical exon has a length in base pairs which is a multiple of 3, and thus its 
removal does not impact the reading frame of the protein. Apart from deep intronic 
mutations, which are an obvious target for splicing–correcting approaches,  the 
candidate mutation is a small insertion or deletion which leads to frameshift, or a 
nonsense mutation. We identified in USH2A a region encoding for repetitive FN3 
domains where different exons have the desired characteristics (Fig. 37). In particular, 
of the 72 USH2A exons, exons number 29, 30, 32, 38, 43, 45, 50, 53, 56, 59, 62 are all 
approachable and have different mutations causing Usher syndrome type 2 (Tab. S3).  
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FIGURE 37. USH2A exons approachable by exon-skipping. All domains of USH2A are represented in scale. The 
region of repeated FN3 domains encoded by exons 29 to 62 is marked.  
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6 Discussion 
 
 The application of antisense-based splicing-correcting therapeutic approaches to 
retinal dystrophies offers great opportunities and challenges. The technique allows a 
highly specific and controlled effect, thanks to the fact that its function relies on base-
pairing, and that it acts only where and when the endogenous target pre-mRNA is 
transcribed. This specificity however comes at a cost, which is that the technique is 
mainly patient-specific and therefore difficult to develop to a clinical setting for a broad 
range of diseases. The successful example of exon-skipping applications for Duchenne 
muscular dystrophy (Douglas and Wood, 2013) teaches us much on the importance of 
selecting a good candidate gene for the implementation of such approaches. Effective 
development of new treatments requires the presence of different factors: a tissue in 
which it is easy to deliver the therapeutic agent, availability of formulations and/or 
vectors able to reach the relevant cell type, selection of genes having mutations which 
would benefit from such approaches, and presence of animal models in which the 
approach can be tested, therefore speeding up the development process. We realized 
that the retina, as tissue, offers many of the requirements needed for a successful 
application of new antisense-based splicing-correcting therapeutic approaches. 
However, among the genes causing retinal dystrophies, the presence of a candidate 
which would have all characteristics important for an optimal application of these 
approaches was not evident. We therefore started a survey of all genes causing retinal 
dystrophies to understand which where those more promising, merging all available 
information from databases as well as from the literature. Thanks to this analysis, we 
focused our attention on three genes, each one having some characteristics which 
rendered it an interesting target for splicing-correcting approaches in the retina: 
CACNA2D4, RPGR and USH2A.  
  
  
76 
6.1 CACNA2D4 
 
 In this work we have studied the applicability of an exon-skipping therapeutic 
approach for CACNA2D4 mutations causing recessive cone dystrophy. This gene was 
selected for two main reasons. First, because of the presence of a spontaneous mouse 
model (Wycisk et al., 2006a) having an insertion on the same exon hosting a nonsense 
mutation in humans (E25). Presence of this model offered a great chance to assess the 
feasibility of an exon skipping approach in vivo in the eye for the first time. Second, 
because the gene encoded a protein of known predicted function, being it part of a 
family of accessory subunits of voltage-gated calcium channels. Even if the murine 
subunit was not characterized, the human counterpart was known to induce calcium 
influx from HVA calcium channels (Qin et al., 2002), a property shared with all others 
known α2δ subunits. This property can be measured electrophysiologically, therefore 
allowing a precise analysis of the functionality of the rescued protein resulting from 
exon skipping. We therefore started designing the possible approach and evaluating its 
applicability to the target gene.  
 During our investigation we realized that E25 was not a constitutive exon in mice. In 
fact we confirmed the presence of an alternatively spliced exon (E25b), which is 
mutually exclusive with E25. This exon is of particular importance for the study of the 
role of Cacna2d4 function, since its incorporation terminates the reading frame of the 
protein after the first Cache domain, in a similar way as the c.2451insC mutation. 
Another important finding that we made is that this mutation on exon 25 has a second 
effect to that of prematurely terminating the reading frame. In fact it acts on splicing as 
well. The mutation is predicted to create a new exonic splicing silencer (ESS) in E25, 
which is recognized by several trans-acting splicing factors mediating inhibition of 
exon recognition. In mouse retinae the mutation mainly affects E25 levels, reducing its 
levels in mature mRNA. This resulted in a dramatic change of the relative ratio between 
E25 and E25b splicing isoforms, changing them from 3:1 in favour of E25, to almost 
1:1. When the effect of the mutation was tested in vitro, it instead mainly increased 
E25b levels in mature mRNA, without affecting E25. Even if the result of the mutation 
is to favour the relative presence of E25b over E25 both in vivo and in vitro, there is a 
difference in how this effect is mediated in the two systems. This difference can be 
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ascribed to two players: trans-acting splicing factors and nonsense-mediated decay. 
Presence of a different subset of trans-acting splicing factors in the mouse retina and in 
HEK293T cells can in fact explain the different mechanism of action of the mutation. 
For example, the family of RNA-binding proteins Fox-1 is exclusively expressed in 
brain, skeletal muscle and heart (Jin et al., 2003; Shibata et al., 2000; Underwood et al., 
2005). Fox-1 is known to recognize a specific intronic RNA sequence (UGCAUG) and 
to promote alternative splicing (Jin et al., 2003). Where Fox-1 is expressed it is possible 
to observe, in different genes, alternative splicing of exons surrounded by the sequence 
recognized by Fox-1 (Kuroyanagi, 2009). Nonsense-mediated decay (NMD), a 
mechanism that targets and degrades mRNAs with a premature stop codon, can 
constitute another important element to consider, especially in vivo where we have 
shown a general reduction of Cacna2d4 transcripts in the mutant. There is an increasing 
amount of evidence that links alternative splicing and NMD as a system used by cells to 
regulate gene expression (Lareau et al., 2007; Lejeune and Maquat, 2005; Sibley, 2014). 
In particular, alternative spliced exons can be included or excluded to generate 
premature termination codons which will trigger the NMD machinery, resulting in a 
decrease of transcript levels. In the fumarylacetoacetate hydrolase (fah) gene, for 
example, skipping of exon 8 generates a splicing isoform with a premature termination 
codon. This isoform is subject to NMD, but a protein product is still present (Dreumont 
et al., 2005). To clarify the role of different splicing factors in the recognition of E25 
and E25b, a possible future approach can consist in the analysis of minigene splicing in 
cells after silencing of relevant factors predicted to bind only in presence of the 
mutation. At the same time, block of NMD in vivo by pharmacological treatment 
(Keeling et al. 2013) can help to assess the contribution of this mechanism on the 
relative abundance of E25 and E25b in the retina of Cacna2d4 mutant mice.  
 
 The effect that mutations in the coding region of genes have on splicing is normally 
underestimated: evidences pinpoint a role in splicing for more than a quarter of these 
mutations (López-Bigas et al. 2005; Sterne-Weiler et al. 2011; Lim et al. 2011). The 
early understanding of how splicing patterns change in response to a mutation is highly 
significant for the successful development of strategies aiming at correcting such 
defects. In this effort, splicing-reporter minigene assays are a fantastic tool which can be 
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of assistance (Cooper, 2005). We have successfully used for the first time a minigene 
system able to properly recall all splicing events across 6.5 Kb and six different exons. 
Following implementation of more efficient gene synthesis services the design and 
application of functional minigenes could become easier and more powerful.  
 By analysis of the electrophysiological properties of Cav1.4 calcium channels in the 
presence of murine α2δ4, we were able to confirm its predicted function of accessory 
subunit. In fact, α2δ4 is able to increase Cav1.4-mediated currents in an heterologous 
expression system. In the presence of α2δ4, current densities were augmented of three-
folds, in line with what described observing calcium influx in cells expressing human 
α2δ4 (Qin et al. 2002). Moreover, we noticed how α2δ4 is less able than α2δ1 to mediate 
such increase, as recently observed in another work (Lee et al. 2014). Regarding 
activation, we noticed no significant effect on Cav1.4 calcium channels in presence or 
absence of α2δ4. In a recent work (Lee et al. 2014) human α2δ4 has been described to 
shift the voltage-dependence of activation to more positive potentials when compared to 
α2δ1. Even if in our analysis the V0.5, act in presence of α2δ4 was more positive than that 
observed with  α2δ1, the difference was not significant. We finally showed how presence 
of α2δ4, in a similar way to what has been found for α2δ1 (Burtscher et al. 2014), does 
not facilitate calcium-dependent inactivation of Cav1.4. Since α2δ4 is highly expressed 
in the retina together with Cav1.4, and both localize to photoreceptor terminals, (De 
Sevilla Müller et al. 2013; Knoflach et al. 2013; Busquet et al. 2010; Specht et al. 2009) 
we can therefore suggest that this is the subunit helping trafficking of Cav1.4 α1 subunit 
to the plasma membrane of photoreceptors, as it is able to mediate the same effect on 
the channel in an heterologous system.  
 Regarding Cacna2d4 c.2451insC mutation, we confirmed its pathophysiological role 
in abolishing α2δ4 ability to mediate an increase in functional Cav1.4 channels at the 
plasma membrane. In fact, no activity of the mutant protein was observed in stimulating 
current density trough Cav1.4 channels. This can definitely result in an impairment in 
connectivity between photoreceptors and second-order neurons in the retina. 
Interestingly, similarly to mutant α2δ4, also the newly identified α2δ4 E25b splicing 
isoform shares the same characteristics. In both cases, the protein ORF is interrupted 
between the two Cache domains, and as a result both proteins lack the δ peptide, 
important for membrane anchoring (Davies et al. 2010; Kadurin et al. 2012). Alpha2-
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delta subunits lacking the membrane anchor have been shown to still be able to enhance 
calcium currents, but they lose this property when the whole δ peptide is deleted 
(Kadurin et al. 2012; Gurnett, De Waard, and Campbell 1996). It is therefore peculiar 
the presence in the retina of a Cacna2d4 splicing isoform which is mimicking the effect 
of a disease-causing mutation. The role of this isoform remains therefore elusive, even 
because, by missing the membrane anchor, the protein would probably be secreted. An 
additional important element to assess would be the presence of a similar isoform in 
humans. Existence or absence of a splicing isoform of CACNA2D4 that resembles the 
effect of murine E25b incorporation would be interesting to better understand the role of 
both murine and human mutations in exon 25. In fact, if an alternatively spliced exon 
which truncates CACNA2D4 ORF between the two Cache domains also exists in the 
human retina, in this case as well the c.2406C→A mutation could potentially favour this 
inclusion. Moreover presence of this isoform also in humans would help understanding 
the role of α2δ4 E25b isoform. We hypothesize that the mutation, by mimicking the 
effect of E25b inclusion, offers a specific advantage in heterozygosity (overdominance) 
in a district where α2δ4 is normally expressed. Specifically, since a truncated version of 
α2δ4 normally exists, its overexpression caused by an allele coding only for this isoform 
(the mutant allele) in a defined moment or tissue can potentially exert a positive 
function, which in heterozygosity is not undermined by the detrimental effects on vision 
of loss of full-length α2δ4. This would allow the conservation of different mutations in 
the same position sharing the same mimicking effect.  
 We have identified an additional splicing isoform of Cacna2d4 which arises from 
skipping of exon 16. The α2δ4 ΔE16 transcript is not present in the retina, but we found 
it in different regions of the brain, where it is the only or the more abundant form 
present. However, Cacna2d4 expression in the brain regions analysed is very low 
compared to what observed in the retina, in line with what found in previous work 
(Schlick, Flucher, and Obermair 2012). Additionally, in a recent study, a smaller 
(~165kDa instead of ~170kDa) α2δ4 was detected by Western blots in mouse brain, 
which could possibly correspond to α2δ4 ΔE16 (De Sevilla Müller et al. 2013). It is 
actually possible that this isoform is expressed by specific cell populations  in the brain. 
Even in this case, the role of this isoform remains elusive, since we have shown it does 
not alter current properties of Cav1.4 channels. Skipping of exon 16 results in a large  
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deletion of the first Cache domain sequence. The corresponding region in α2δ1 is 
known to be subject to alternative splicing in a similar way (Angelotti and Hofmann, 
1996). having two regions, A and B, part of the first Cache domain, which can be 
present in different arrangements in the mature mRNA: A+B, ΔA+ΔB, ΔA+B. Even if 
the ΔA+B isoform is able to mediate an increase of current densities trough HVA 
calcium channels, the functional characterization of the ΔA+ΔB isoform is still missing 
(Lana et al., 2014). It would be therefore interesting to test if this isoform shares with  
α2δ4 ΔE16 the same inability in inducing an increase in HVA calcium channels current 
densities. Analysis of localization, interacting partners, and possible function of this 
isoform would therefore shine a light on the importance of Cache domains for α2δ 
subunits.  
 We have discovered in this work the first two splicing isoforms of an α2δ subunit 
(α2δ4 E25b and α2δ4 ΔE16) which are proven to not mediate an increase in HVA 
calcium channels current densities. These results strengthen the current view (Dolphin 
2012) that α2δ subunits may be involved, in the retina and CNS, in different roles not 
directly related to the enhancement of trafficking of functional calcium channels on the 
plasma membrane. Present literature suggest that they can be involved in synaptic 
formation and organization independently from their role in HVA calcium channel 
trafficking (Kurshan et al., 2009). Work conducted in Drosophila showed that α2δ3 null 
flies were not able to properly form the synaptic bouton of motor neurons, which is 
instead correctly formed in α1-null animals. Moreover, the presence of an allele coding 
for α2 but not for the δ peptide was able to revert the phenotype. This suggests that α2δ4 
E25b, which lacks the δ peptide as well, may be fundamental for similar functions. In 
this perspective, we can speculate a role for α2δ subunits as secreted and membrane-
associated signalling molecules likes semaphorins, a class of proteins important for 
axonal guidance. Since α2δ are not exclusive of neural tissues, additional functions are 
also highly possible. Further analysis of the role of this subunits should therefore be 
undertaken, first of all identifying the cell types in which they are expressed and their  
subcellular localization. It is also possible that they play an important role during 
development, when the organization of neural circuits takes places, and therefore their 
expression should be followed over time in relevant model organisms.  
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 Aiming at validating a possible exon-skipping therapeutic approach for CACNA2D4, 
we found out that the region encoded by exons 23 to 26 is of fundamental importance 
for the function of α2δ4. The removal of this portion is indeed enough to impair α2δ4 
activity of promoting calcium currents mediated by Cav1.4 α1 subunits. The same is true 
for the deletion of exons 23, 24 and 25 only. The region encoded by these exons is 
located between the two Cache domains and it is not known to be part of any domain of 
the protein. Moreover, in an α2δ1 paralogue, insertion of an HA tag in the corresponding 
region did not cause any defect in the protein ability to mediate an increase in currents 
(Kadurin et al. 2012). This region may be important for hosting glycosylation sites 
necessary for functionality of the accessory subunit (Gurnett, De Waard, and Campbell 
1996). These findings render inapplicable our therapeutic strategy aimed at correcting 
the retinopathy caused by c.2451insC mutation. This strategy was relying on the 
therapeutic skipping of exon 23 to 26 or 23 to 25 from pre-mRNA in order to eliminate 
the frameshift mutation on E25 and restore the downstream ORF.  
 
 
6.2 RPGR 
 
 Intronic mutations affecting splicing and not altering the consensus sequence of 
splice sites are an optimal target for splicing-modulating approaches. These mutations 
mainly act by: creating or deleting ISS and/or ISE, creating new cryptic splice sites or 
changing the strength of the consensus sequence of the branch point (Cooper et al., 
2009; Lewandowska, 2013; Tazi et al., 2009), The advantages of targeting these 
mutations instead of mutations leading to frameshifts are two. First, since they act on 
splicing, achieving correction of the splicing pattern is enough to have a therapeutic 
benefit: since constitutive exons are not skipped, there is no need  for testing the 
functionality of the rescued proteins which results from exon-skipping approaches 
directed towards mutations terminating the proteins ORF. Second, when the mutations 
effect is to create new cis-acting sequences, the disease can be easily addressed by 
masking those sequences with antisense approaches. For these reasons we selected the 
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intronic mutation g.26652G>A of RPGR (Neidhardt et al., 2007) as a potential target for 
splicing-correcting approaches in the retina. Even if the effect of this mutation is to 
increase levels of the alternatively spliced exon 9a (Neidhardt et al., 2007), from our 
bioinformatics analysis it is not clear if it acts by creating or deleting cis-acting 
sequences. We therefore decided to design chimeric U1snRNAs directed towards both 
splice sites of exon 9a, aiming at reducing its recognition in presence of the mutation.  
 Using an U1 snRNA directed towards the 3’ splice site in HEK293T cells transfected 
with splicing-reporter minigenes we were able to show a significant decrease of exon 9a 
levels. On the contrary, the U1 snRNA directed towards the 5’ unexpectedly caused a 
significant increase in exon 9a levels. U1 snRNA normally recognize the 5’ splice site 
during splicing by binding with its 5’ end to the -3/+6 exon/intron consensus sequence. 
This binding needs to be reversible, since U1 snRNA is required to detach from the 5’ 
splice site for the splicing reaction to take place. It follows from this observation that 
rendering the U1 unable to easily detach from the 5’ splice site by increasing the length 
of the region it recognises (24 base pair for our U1_5’ ) is a strategy that can be used to 
achieve exon skipping (De Angelis et al., 2002). In our case instead the chimeric U1 
snRNA increased exon 9a recognition by binding to the 5’ splice site, probably acting in 
a similar way as  adapted  U1s, which are normally designed with shorter 
complementarity (around 10 bp) (Glaus et al., 2011; Sánchez-Alcudia et al., 2011). This 
effect was not present when the bifunctional U1_5’3’ was used, since  U1_5’3’ caused 
exon 9a skipping, at a comparable level of that induced by U1_3’.Contrary to the effect 
of U1_5’3’, the use of both U1_3’ and U1_5’ induced exon 9a levels which lay in 
between those observable by using U1_3’ or U1_5’ alone, a sign of competition of the 
two snRNA to skip (U1_3’) or include (U1_5’) exon 9a.  Given the current knowledge 
on bifunctional U1 snRNAs it is difficult to predict the reason for this difference in 
action. The results suggest that in the bifunctional U1_5’3’, the region which is 
complementary to the 5’ slice site of exon 9a is not able to exert its function of helping 
exon 9a recognition. This can be caused by its position at the 5’ end of the chimeric U1, 
when instead the antisense region for the 3’ splice site lays between the U1 stem-loop 
structure and the antisense region for the 5’ splice site. In this direction it could be of 
interest to test the effect of a  U1_5’3’ where position of the antisense sequence for the 
5’ splice site is exchanged with that for the 3’ splice site, and observe if in this case the  
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U1_5’3’ behaves like the U1_5’ alone and no more like the U1_3’ alone. 
 Assessment of the effect of the different engineered U1s in 661w cells, investigation 
of exon 9a presence and consequent application of the best U1snRNAs (U1_3’ and U1 
5’3’) in patient-derived fibroblasts would allow additional validation of the designed 
therapeutic approach. The use of patient-derived fibroblasts would also allow other 
important analysis. Since RPGR isoforms containing exon 9a have been shown to 
interact with a different subset of isoforms of its interacting partner RPGRIP1 
(Neidhardt et al. 2007), correction of this effect can be potentially checked in patients 
fibroblasts. Moreover, investigation of restored RPGR localization along the primary 
cilium of patient fibroblasts can be analysed as a surrogate model of the photoreceptor 
connective cilium, in a similar way to what has been recently done for other RPGR 
isoforms (Da Costa et al. 2015).  
 
 
6.3 USH2A 
 
 We identified the USH2A gene as a particularly interesting target for splicing-
modulating therapeutic interventions. Its modular domain architecture is in fact a 
peculiar property of this gene, and can represent a great advantage for exon-skipping 
approaches aiming at preventing the inclusion in the mature mRNA of exons hosting 
mutations leading to truncation of the protein ORF. In line with what has been observed 
with dystrophin (Matsuo, 1996), it is possible that the removal of selected exons 
encoding for some of the repetitive domains of the protein does not significantly impair 
protein functionality, thus permitting the application of such therapies. We have 
identified, in the second region of the protein encoding for FN3 domains, eleven exons 
which can constitute a starting point for the application of exon skipping in the cure of 
Usher syndrome type 2. Overall, 5% of all USH2A mutations known today are 
approachable by skipping of these exons. Currently, the development of  assays able to 
investigate the functionality of the different rescued proteins originating from exon 
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skipping is the main challenge for further development of such therapies. These assays 
should investigate protein localization and protein-protein interactions during and after 
ciliogenesis, using for example patient fibroblasts as a model. 
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7 Materials and Methods 
7.1 Computational analysis of Cacna2d4 E25 splicing 
 Mouse eye RNA-seq samples were downloaded from the Gene Expression Omnibus 
(Edgar et al., 2002) (dataset ID GSE38359: sample IDs GSM945628, GSM945631 and 
GSM945634; dataset ID GSE29752: samples GSM737548 and GSM737550). Reads 
were trimmed at the 3’ end by removing nucleotides having Q score < 30 by means of 
Trimmomatic(Bolger et al., 2014), and then mapped to the mouse genome (mm10 
assembly) by means of TopHat2 (Kim et al., 2013). The resulting alignment and the 
observed exon-exon junctions were eventually visualized with Integrative Genomic 
Viewer (IGV) (Thorvaldsdóttir et al., 2013). 
 The genomic sequence from Cacna2d4 E22 to E27 was analysed using NNSPLICE 
0.9. (Reese et al., 1997) Resulting scores for the different splice sites were reported. 
 Cacna2d4 E25 sequence was analysed using SpliceAid (Piva et al., 2009) in presence 
and absence of c.2451insC  mutation. Differentially predicted splicing regulatory 
elements were showed.  
 
7.2 Computational analysis of RPGR exon 9a splicing 
 The genomic sequence from RPGR exon 9 to exon 10 was analysed using 
NNSPLICE 0.9.(Reese et al., 1997) Resulting scores for the different splice sites were 
reported. RPGR intron 9 and exon 9a were analysed using SpliceAid and ESEFinder in 
presence and absence of the g.26652G>A mutation.  
 Cacna2d4 E25 sequence was analysed using SpliceAid (Piva et al., 2009) in presence 
and absence of c.2451insC  mutation. Differentially predicted splicing regulatory 
elements were showed. The sequence of intron 9 preceding exon 9a was analysed using 
the branch point sequence analysis tool of Human Splicing Finder.  
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7.3 Animals  
 Experiments were conducted in conformity with the European Community Directive 
2010/63/EU and the ARVO Statement for the Use of Animals in Ophtalmic and Vision 
Research and were approved by the Italian Ministry of Health. Cacna2d4 mutant and 
wild-type mice of C57BL/10 background (Wycisk et al., 2006a) were used for 
extraction of retina tissue. C57BL/6 mice were used for analysis of Cacna2d4 ΔE16 
expression in the CNS. 
 
7.4 Cloning of different constructs 
 Cacna2d4 ΔE16 clone (GenBank: BC141091.1; IMAGE ID 9055703) was ordered 
from Source Bioscience, amplified by PCR using primers For: 5’-
GACTGCTAGCCACTTGCATGC and Rev: 5’-CTTGTCGACGTCAGATGGGAT, 
and cloned into pIRES2-EGFP (Clontech, Mountain View, CA) using NheI and SalI 
restriction sites. Exon 16 was subsequently amplified from murine genomic DNA using 
primers  For: 5’-AGCTGGCACCCCGATATAAGCTTGGGGTGCATGGC and Rev: 
5’-AGCTTCTTGCCTTCTCTGTACAAAGGTCGGAGGTCAG. The resulting PCR 
fragment was used as megaprimer (Wang and El-Deiry, 2010) for site-directed 
mutagenesis (Quickchange II site-directed mutageneis kit, Agilent, Santa Clara, CA) 
and added to Cacna2d4 ΔE16 to generate Cacna2d4 full-length (Cacna2d4). The 
c.2451insC mutation on E25 was introduced by site directed mutagenesis of Cacna2d4 
using primers For: 5’-GAGCAGCCCCCCCGGCAGCTTTGTCTTC and Rev: 5’-
GAAGACAAAGCTGCCGGGGGGGCTGCTC. The obtained construct was named 
“Cacna2d4 MUT”. E25b was amplified from murine retina cDNA using primers For: 
5’-AGAGTCAGAGCCTGGCGTGG and Rev: 5’-CTGCTGCAATGGCCGTCTTCC. 
The PCR product was extracted from gel to avoid E25-containing transcript and 
purified. The product was then used as megaprimer for site-directed mutagenesis to 
obtain E25b inclusion in place of E25 (Cacna2d4 E25b). The Cacna2d4 full-length 
construct had been subsequently utilised as template for the generation of Cacna2d4 
ΔE23-25. For this intent a PCR using primers For: 5’-atagcccaggcaagccagt and Rev: 5’-
actccaggtctggatccac was performed, followed by ligation of the PCR product. The 
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Cacna2D4 ΔE23-26 cDNA construct was obtained from overlapping PCR on Cacna2d4 
template. For this purpose two different primer pairs were used to originate the two 
overlapping fragments: For: 5’-CTACGTGACTGCTAGCCACTTGCATGCCCAGGA, 
and Rev: 5’-ATCTGGATGCCCACAGACTCCAGGTCTGGATCC for first reaction; 
For: 5’-GATCCAGACCTGGAGTCTGTGGGCATCCAGATG and Rev: 5’-
CTACGACTCTTGGATCCGTCAGATGGGATGGAGTC for the second reaction. The 
two generated fragments were then purified and used together with the primer pair For: 
5’-GACTGCTAGCCACTTGCATGC and Rev: 5’-CTTGTCGACGTCAGATGGGAT 
in a different PCR reaction to generate Cacna2D4 ΔE23-26.  
 The Cacna2d4 minigene construct was assembled from four fragments amplified 
from murine genomic DNA and digested with specific restriction enzymes. The first 
fragment was amplified using primers For: 5’-
CTAAAGCTTATGATCTACTGTATCACAGA and Rev: 5’-
GTCGCTAGCAGTAATGTCACTCGG and digested with HindIII + NheI; the second 
with primers For: 5’-CGCACTAGTGTTTGGAAAGGAGTGATGGT and Rev: 5’-
TATGCGGCCGCAGTCTGGTTTTCCTC and with SpeI + NotI; the third with primers 
For: 5’-CTAGCGGCCGCACAGTCTTGATTGTTA and Rev: 5’-
CAGACTAGTTCTTACATGAGACTTTGGAT and with NotI + SpeI; the fourth using 
primers For: 5’-GTAGCTAGCGCGTGTGAACATGGACTGG and Rev: 5’-
CGTCTCGAGTCTGCTGCATGGCTGCC and NheI + Xho. The resulting digested and 
purified fragments were ligated together with a pCDNA3-Luc2 vector digested with 
HindIII + XhoI. The c.2451insC mutation  was inserted on the minigene by site-directed 
mutagenesis using the same primer pair utilized for Cacna2d4 MUT.  
 Cacna1f clone (encoding for murine Cav1.4 α1) was ordered from Source Bioscience 
(GenBank: BC156573.1), amplified using primers For 
CCACCATGTCGGAATCTGAAG, and Rev CCATGAGGCCTTAGAGGGC, and 
cloned into pIRES2-mCherry vector using SmaI restriction enzyme. Cacnb2 clone 
(encoding for murine β2 subunit) was ordered from Source Bioscience (GenBank: 
BC115871), amplified using primers For GCTAGATCTTTTTGCCGATGGTCC and 
Rev GACGGATCCTGCAGCTGTACTAG, and cloned into pIRES2-BFP vector using 
BamHI and BglII restriction enzymes. 
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 RPGR minigene was obtained by amplification of human genomic DNA with primer 
For CTAGGTACCCACAGAGACCATAGAGAGTG and Rev 
CTACTCGAGAAGTTTGTTAGCACTCAACTCTAA and cloned into a pCDNA 
plasmid using KpnI and XhoI restriction enzymes. The g.26652G>A mutation was 
added by insertional mutagnensis using primers For 
GCTGAATTAAATGTTAAACTCTCAAATCCTGCACAACAG and Rev 
CTGTTGTGCAGGATTTGAGAGTTTAACATTTAATTCAGC.  
 The four chimeric U1 constructs for RPGR were obtained by ligation of two different 
inverse polymerase chain reaction (PCR) products, the first containing the U1 promoter, 
and the second containing the U1 sequence plus the chimeric sequence. to generate the 
U1_5’, U1_3’ and U1_SCR constructs, .a first PCR was performed on the human U1 
snRNA gene using as forward primer U1cas-up: 5’-
CTAGCTAGCGGTAAGGACCAGCTTCTTTG  and three different reverse primer: 
(U1_5’rpgr-1: 5’-caaaaattagccaggtatgatggcatgagatcttgggcctctgc, U1_3’rpgr-1: 
cgttttggcagggcacggtggatgagatcttgggcctctgc, U1_SCRrpgr-1: 
tcaattattccgcgagacgcagcatgagatcttgggcctctgc was performed. Each of the three obtained 
PCR fragment was then ligated with the product of a PCR on the human U1 snRNA 
gene performed using primers U1-univ For: 5’-GGCAGGGGAGATACCATGATC and 
U1cas-down Rev: 5’-CTAGCTAGCGGTTAGCGTACAGTCTAC. For the generation 
of the U1_5’3’ constructs a first PCR product obtained using primers U1cas-up  and U1 
5’rpgr-1  was ligated with a second PCR product obtained using primer U1 3’rpgr-2 
For: 5’-ccaccgtgccctgccaaaacgggcaggggagataccatgatc and U1cas-down. All the ligation 
product were subsequently amplified by PCR using primer U1cas-up and U1cas-down 
and cloned into pAAV2.1-CMV-EGFP plasmid at the NheI restriction site upstream of 
the CMV promoter.  
All obtained clones have been fully checked by sequencing. 
 
  
  
 
89 
 
 
7.6 RNA extraction and cDNA synthesis  
 Adult mice tissues were dissected and omogenized using a plastic pestel. Total RNA 
was extracted from each tissue from a pool of three different animals using Trizol 
(Trizol Reagent, Life Technolgies, Carlsbad, CA) according to manufacturer’s 
instructions, treated with DNase (Roche,) and purified using columns (NucleoSpin 
RNA, Macherey-Nagel, Düren, Germany). cDNA synthesis was performed using 
random examers (SuperScript VILO cDNA Synthesis Kit, Life Technolgies, Carlsbad, 
CA), according to manufacturer’s instructions. RNA extraction of transfected cells was 
performed two days after transfection with Trizol and RNA was treated with DNase 
(TURBO DNA-free Kit, Life Technologies, Carlsbad, CA). cDNA synthesis was 
performed using oligo(dT)18 (RevertAid First Strand cDNA Synthesis Kit, Thermo 
Scientific, Waltham, MA).  
 
7.7 Cell culture and transfection conditions  
 Hek293T, tsA-201, and 661W cells were maintained in DMEM supplemented with 
10% FBS, 2mM Glutammine, 100 U/ul Pen/Strep, and grown at 37°C, 10% CO2.  
 For transfection with minigenes and chimeric U1 snRNAs, Lipofectamine 2000 
(Life-Technologies, Carlsbad, CA) was used, according to manufacturer’s instructions, 
on 24 well plates. For Cacna2d4 minigenes, 600 ng of each construct were used. 
Regarding RPGR, 400 ng of minigene, plus 200 ng of each different chimeric U1 
snRNAs were used, unless specifically mentioned.  
 For electrophysiological recordings tsA-201 cells were split into 6cm dishes one day 
before transfections. Transfection was performed using Turbofect transfection reagent 
(Thermo Scientific, Waltham, MA) with 0.5 µg of Cav1.4 α1 (Sinnegger-Brauns et al., 
2009), 0.5 µg of β3 (Castellano et al., 1993), and 0.5 µg of different α2δ constructs in 
pIRES2-EGFP expressing vectors and 1 µg pUC,. Data α2δ1 for were taken from (Ellis 
et al., 1988). One day after transfection cells were seeded at low confluence on 3 cm 
dishes coated with poly-D-lysine and stored over night at 30°C, 5% CO2. Recordings 
were performed the following day. In experiments were different α2δ constructs were  
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present in the same transfection, the following amount were used: 0.5 µg of Cav1.4 α1 
(Sinnegger-Brauns et al., 2009), 0.5 µg of β3 (Castellano et al., 1993), 0.5 µg of each 
different α2δ subunit, and 0.5 µg pUC.  
 
7.8 Luciferase activity assay 
 For the luciferase assay, 600 ng of the Cacna2d4 minigene encoding for Luc2 were 
transfected together with 100 ng of pRL-SV40 encoding for Renilla. As positive 
control, 600 ng  of pGL3 vector were used. Two days after transfection, luciferase 
activity was measured using the Dual-Glo Luciferase Assay System (Promega) in a 
Tecan infinite 200 PRO microplate reader. 
 
7.9 RT-PCR and densitometric analysis 
 For all amplifications we used a protocol consisting in:  a 1 min denaturing step at 
94°C, 35 amplification cycles (30 sec at 94°C, 30 sec at 58°C, and 1min at 72°C), and a 
final 7 min step at 72°C . For utilised primer pairs see Tab. S4. Densitometric analysis 
of obtained bands was conducted using software Imagelab 2.0 (Biorad, Hercules, CA). 
Bands intensities, corrected for background, were normalized to the corresponding 
Gapdh values.  
 
7.10 RT-qPCR 
 RT-qPCR was performed in a C1000 thermal cycler with a CFX384 real-time 
detection system (Biorad, Hercules, CA), using the KAPA SYBR FAST master mix 
(Kapa Biosystems, Cape Town, South Africa). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH/Gapdh) was used as a reference gene for normalization, using 
the ΔCt method. All used primer pairs are reported in Table S4. Data were analysed 
using the CFX Manager 2.1 software (BioRad, Hercules, CA). For direct comparison of 
E25 and E25b transcripts levels, amplification efficiency and y-intercept with the two 
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primer pairs was compared using serial dilutions of plasmid containing E25 or E25b. 
Equivalence of the obtained slopes and y-intercept was assessed with extra sum-of-
square F test (Fig. S1). Data are shown as 2^(- ΔCt(E25)) /2^(- ΔCt (E25b)).  
 
7.11 Protein extraction and Western blot 
 tsA-201 cells transfected with all the constructs used for electrophisiological 
analyisis as described above were detached from 6 cm dishes using PBS, centrifuged 
briefly to remove PBS, and lysed with 100 µl of lysis buffer (50 mM Tris-HCl pH 8, 
150 mM NaCl, NP40 1%, Na-deoxycholate 0,25 %, 1mM EDTA, 2mM PMSF, 2mM 
sodium orthovanadate 0,1M protease inhibitors cocktail (Sigma Aldrich, St. Louis, 
MO)). Protein concentration was assessed using Pierce BCA portein assay kit (Thermo 
Scientific, Waltham, MA). 100 ug of proteins (50 ug in the case of transfections with 
human α2δ4) were run on a precast 3-8% Tris-Acetate gel (life technologies, Carlsbad, 
CA). Proteins were transferred to a Hybond ECL nitrocellulose membrane (Sigma 
Aldrich, St. Louis, MO) using a transfer buffer (25 mM Tris-HCl, 192 mM glycine, 
20% methanol, 0.1% SDS). The membrane was blocked for 1 h at room temperature by 
exposure to 5% non-fat dry milk in 20mM Tris-HCl pH 8, 0.5M NaCl, 0.1% Tween-20 
(Sigma Aldrich, St. Louis, MO). The membrane was then incubated overnight at 4 °C 
with rabbit polyclonal anti human CACNA2D4 antibody, 1:400, (Sigma Aldrich, St. 
Louis, MO) or for 1 h at RT with mouse monoclonal anti rat β-Tubulin antibody, 
1:10000 (Santa Cruz, Dallas, TX). As secondary antibody a goat anti rabbit IgG-HRP or 
a goat anti-mouse IgG-HRP, 1:10000 (Santa Cruz, Dallas, TX) were used for 1h at 
room temperature. A chemiluminescence-based kit (Amersham ECL Select Western 
Blotting Detection Reagent, GE Healthcare, Little Chalfont, UK) was used for 
detection.  
 
  
  
92 
7.13 Electrophysiological recordings 
 Whole-cell patch-clamp experiments were performed using an Axopatch 700B 
amplifier (Molecular Devices, Sunnyvale, CA). Borosilicate glass pipets (external 
diameter 1.5 mm; wall thickness 0.32 mm; Science Products, Frankfurt/Main, 
Germany) were pulled using a micropipette puller (P97, Sutter Instruments, Novato, CA) 
to obtain electrodes with a resistance of 1.5-3 MΩ. pClamp10.2 (Molecular Devices, 
Sunnyvale, CA) and Prism 5 (Graphpad, La Jolla, CA) softwares were used for data-
analysis. For recordings were used: a pipet internal solution at pH 7.4 containing 135 
mM CsCl, 10 mM HEPES, 10 mM EGTA, 1 mM MgCl2, and a bath solution adjusted 
to pH 7.4 (with CsOH) containing 15 mM CaCl2 or BaCl2, 10 mM HEPES, 150 mM 
Choline-Cl, 1 mM MgCl2. Recording were performed at room temperature (19-22 °C). 
All voltages were corrected for a liquid junction potential of -8mV. In all protocol used 
a holding potential of -98mV was applied. Current-voltage (IV) relationship was 
analysed by applying 50 ms pulses at different potentials from -78mV to 52 mV using 
15mM Ca2+ as charge carrier. To determine current densities (CD), peak current 
amplitudes were normalized to the membrane capacitance (Cm). For each analysed cell, 
the maximum observed current density  (CDmax) was reported. The following equation 
was used for fitting the IV curves for CD: 
CD = Gmax(V-Vrev)/(1+exp((V0.5, act-V)/kact), 
where Gmax is the maximum slope conductance V is the applied potential, Vrev is the 
reverse potential, V0.5, act is the half-maximum activation voltage, and kact is the slope 
parameter of the curve. To study the voltage-dependence of activation, peak current 
amplitudes were normalized to the maximum current (Imax). The derived  Inorm values 
were fitted using the previous formula to calculate Gmax and Vrev parameters. Those 
parameter were used to convert the Inorm values into points of an activation curve using 
the formula:  
Act(%) = Inorm/(Gmax x (V-Vrev)) 
The obtained values of the activation curve were fitted using the Bolzmann equation: 
Act(%) = ISS + (1 – ISS)/(1 + exp((V0.5, act – V)/kact) 
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to obtain V0.5, act and  kact parameters. ISS is the non activating fraction. To analyse the 
voltage-dependence of inactivation, 50ms test pulses were applied before (initial pulse) 
and after (final pulse) a 5s pulse at potentials from -98 to 22 mV. Final peak currents 
were normalized to the initial ones and reported as % of inactivation (Inact(%)). 
Obtained data were fitted using the Bolzmann equation to extrapolate the half-
maximum inactivation voltage (V0.5, inact) and the slope parameter of the curve (kinact). 
Calcium-dependent inactivation (CDI) was investigated using the same protocol applied 
for the IV curve, but with 300 ms pulses instead of 50 ms. Experiments were conducted 
using 15mM Ca2+ or 15mM Ba2+ as charge carriers. Inactivation was measured as the 
ratio between the current after 250 ms from the peak current and the peak current itself 
at the different voltage applied (r250).  
 
7.14 Statistics 
 Statistical analysis was performed with Prism 5 and statistical significance set at 
P<0.05 for all conducted tests. RT-PCR densitometric analysis, RT-qPCR, and r250 
data are represented as means ± SD, and compared using unpaired two-tailed student-t 
test. Electrophysiological data are represented as mean ± SEM, and analysed by 
Kruskal–Wallis test followed by Dunn’s post-hoc test for multiple comparisons. Mann–
Whitney U-test was used for single comparisons. The fit of the dose-response curve 
(Y=Bottom + (Top-Bottom)/(1+10^((X-LogIC50))) for U1_3’ and U1_SCR was 
performed using Prism 5 with the least square method and no constrains.   
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Running Title: Activity of α2δ4 splicing isoforms. 
Precis: We describe a novel splicing isoform of Cacna2d4 found in mouse retina. This 
isoform lacks activity on L-type calcium channels and truncates the gene open reading 
frame in the same position as the c.2451insC mutation does. 
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ABSTRACT  
Purpose. Mutations in CACNA2D4 exon 25 cause photoreceptor dysfunction in humans 
(c.2406C→A mutation) and mice (c.2451insC mutation). We investigated the feasibility 
of an exon-skipping therapeutic approach by evaluating the splicing patterns and 
functional role of targeted exons.  
Methods. Splicing of the targeted α2δ4 (CACNA2D4) exons in presence and absence of 
the mutation was assessed by RT-PCR in vivo on mouse retinae and in vitro in 
HEK293T cells using splicing-reporter minigenes. Whole-cell patch-clamp recordings 
were performed to evaluate the impact of different Cacna2d4 variants on the 
biophysical properties of Cav1.4 L-type calcium channels (CACNA1F). 
Results. Splicing analysis revealed the presence of a previously unknown splicing 
isoform of α2δ4 in the retina which truncates the gene open reading frame (ORF) in a 
similar way as the c.2451insC mutation. This isoform originates from alternative 
splicing of exon 25 (E25) with a new exon (E25b). Moreover, the c.2451insC mutation 
has an effect on splicing and increases the proportion of transcripts including E25b. Our 
electrophysiological analyses showed that only full-length α2δ4 was able to increase 
Cav1.4/β3 mediated currents while all other α2δ4 variants did not mediate such effect.  
Conclusions. The designed exon-skipping strategy is not applicable because the 
resulting skipped α2δ4 are non-functional. α2δ4 E25b splicing variant is normally present 
in mouse retina and mimics the effect of c.2451insC mutation. Since this variant does 
not promote significant Cav1.4 mediated calcium current, it could possibly mediate a 
different function, unrelated to modulation of calcium channel properties at the 
photoreceptor terminals. 
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INTRODUCTION 
 
Exon skipping therapeutic approaches offer a unique opportunity for intervention in 
patients affected by retinal dystrophies, as different types of mutations can be 
potentially treated in a patient-specific way.(Bacchi et al., 2014) Among the potential 
applications, it is possible to use different antisense molecular tools to induce 
intronization of selected exons. This strategy can be beneficial where the targeted exons 
are carrying nonsense mutations or insertions/deletions leading to frameshift. However 
the precise splicing pattern of the mutated target exon(s) and the functionality of the 
skipped protein need to be carefully evaluated. We selected the CACNA2D4 gene as a 
potential therapeutic target in the retina: this gene encodes for α2δ4, a member of α2δ 
accessory subunits of high voltage activated (HVA) calcium channels.(Qin et al., 2002) 
HVA calcium channels are multiprotein complexes composed of an α1 subunit, which 
constitutes the channel pore, and different accessory subunits (α2δ, β, and in some cases 
γ). α2δ subunits are known to regulate HVA calcium channels mainly by increasing 
channel presence on the cell membrane, and by modulating channel gating 
properties.(Dolphin, 2013) They are translated as a single protein but then cleaved into 
α2 and δ peptides, which are subsequently joined together by a disulphide bond. The α2 
peptide is extracellular, while the δ mediates membrane anchoring.(Davies et al., 2010) 
In the retina α2δ4 is the main accessory subunit(Knoflach et al., 2013; Wycisk et al., 
2006a, 2006b) where it is suggested to form a complex with Cav1.4 α1 and β2 
subunits,(Lee et al., 2014) since mutations in all these genes are linked to retinal 
dystrophies.(Ball et al., 2002; Burtscher et al., 2014; Knoflach et al., 2013; Wycisk et 
al., 2006a) So far, two mutations in Cacna2d4 exon 25 were reported to cause cone and 
cone-rod dystrophies in humans and mice respectively.(Wycisk et al., 2006a, 2006b) 
Both mutations are expected to result into a truncated protein, likely to be non-
functional due to the loss of the δ peptide and other functional domains downstream of 
the mutation (Fig. 1A). Since the skipping of the sole mutation-carrying exon 25 in α2δ4 
would result in frameshift, skipping of exon 23-24-25-26 (α2δ4 ΔE23-26) or of exons 
23-24-25 (α2δ4 ΔE23-25) is needed to restore the reading frame downstream of the 
skipped exons. We hypothesized that this strategy would result in a rescued protein 
missing the skipped exons, but retaining the δ peptide and other structural elements. 
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Moreover the targeted exons do not contain any known domain important for α2δ 
function. The presence of a mouse model and ability to test the functionality of the 
skipped protein by electrophysiology offer a clear advantage in assessing the feasibility 
of this exon-skipping approach. We thus generated constructs lacking these exons and 
tested their functionality by electrophysiology in cells in which the whole channel 
complex had been reconstituted.  
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METHODS  
 
Computational analysis of Cacna2d4 E25 splicing 
Mouse eye RNA-seq samples were downloaded from the Gene Expression 
Omnibus(Edgar et al., 2002) (dataset ID GSE38359: sample IDs GSM945628, 
GSM945631 and GSM945634; dataset ID GSE29752: samples GSM737548 and 
GSM737550). Reads were trimmed at the 3’ end by removing nucleotides having Q 
score < 30 with Trimmomatic(Bolger et al., 2014), and then mapped to the mouse 
genome (mm10 assembly) with TopHat2(Kim et al., 2013). The resulting alignment and 
the observed exon-exon junctions were eventually visualized with Integrative Genomics 
Viewer (IGV).(Thorvaldsdóttir et al., 2013) 
The genomic sequence of Cacna2d4 between E22 and E27 was analysed using 
NNSPLICE 0.9.(Reese et al., 1997) and scores for the different splice sites were 
reported. 
Cacna2d4 and CACNA2D4 E25 sequences were analysed using SpliceAid(Piva et al., 
2009) in presence and absence of the c.2451insC mutation obtaining predictions of 
differentially binding splicing regulatory elements. 
 
Animals  
Cacna2d4 mutant and wild type (WT) mice with C57BL/10 background(Wycisk et al., 
2006a) (2 months old) were used for retinal tissue extraction. C57BL/6 mice (3-5 
months old) were used for analysis of Cacna2d4 ΔE16 expression in the CNS. 
Experiments were approved by the Italian Ministry of Health and conducted in 
conformity with the European Community Directive 2010/63/EU and the ARVO 
Statement for the Use of Animals in Ophthalmic and Vision Research.  
 
Cloning  
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Cacna2d4 ΔE16 clone (GenBank: BC141091.1; IMAGE ID 9055703) was ordered 
from Source Bioscience, amplified by PCR using primers For: 5’-
GACTGCTAGCCACTTGCATGC and Rev: 5’-CTTGTCGACGTCAGATGGGAT, 
and cloned into pIRES2-EGFP (Clontech, Mountain View, CA) using NheI and SalI 
restriction sites. Exon 16 was subsequently amplified from murine genomic DNA using 
primers For: 5’-AGCTGGCACCCCGATATAAGCTTGGGGTGCATGGC and Rev: 
5’-AGCTTCTTGCCTTCTCTGTACAAAGGTCGGAGGTCAG. The resulting PCR 
fragment was used as megaprimer(Wang and El-Deiry, 2010) for site-directed 
mutagenesis (Quickchange II site-directed mutageneis kit, Agilent, Santa Clara, CA) 
and added to Cacna2d4 ΔE16 to generate Cacna2d4 full-length (α2δ4). The c.2451insC 
mutation on E25 was introduced by site directed mutagenesis of Cacna2d4 using 
primers For: 5’-GAGCAGCCCCCCCGGCAGCTTTGTCTTC and Rev: 5’-
GAAGACAAAGCTGCCGGGGGGGCTGCTC. The obtained construct was named 
“α2δ4 MUT”. E25b was amplified from mouse retina cDNA using primers For: 5’-
AGAGTCAGAGCCTGGCGTGG and Rev: 5’-CTGCTGCAATGGCCGTCTTCC. The 
PCR product was extracted from gel to avoid E25-containing transcript and purified. 
The product was then used as megaprimer for site-directed mutagenesis to obtain E25b 
inclusion in place of E25 (α2δ4 E25b). The α2δ4 full-length construct has been 
subsequently utilised as template for the generation of α2δ4 ΔE23-25. For this intent a 
PCR using primers For: 5’-atagcccaggcaagccagt and Rev: 5’-actccaggtctggatccac was 
performed, followed by ligation of the PCR product. The α2δ4 ΔE23-26 cDNA construct 
was obtained from overlapping PCR on Cacna2d4 template. For this purpose two 
different primer pairs were used to originate the two overlapping fragments: For: 5’-
CTACGTGACTGCTAGCCACTTGCATGCCCAGGA, and Rev: 5’-
ATCTGGATGCCCACAGACTCCAGGTCTGGATCC for first reaction; For: 5’-
GATCCAGACCTGGAGTCTGTGGGCATCCAGATG and Rev: 5’-
CTACGACTCTTGGATCCGTCAGATGGGATGGAGTC for the second reaction. The 
two generated fragments were then purified and used together with the primer pair For: 
5’-GACTGCTAGCCACTTGCATGC and Rev: 5’-CTTGTCGACGTCAGATGGGAT 
in a different PCR reaction to generate α2δ4 ΔE23-26. The Cacna2d4 minigene construct 
was assembled from four fragments amplified from mouse genomic DNA and digested 
with specific restriction enzymes. For a detailed list of utilized primers and restriction 
enzymes see Table S1. The resulting digested and purified fragments were ligated 
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together with a pCDNA3-Luc2 vector digested with HindIII and XhoI. The introduction 
of c.2451insC mutation into the minigene was performed by site-directed mutagenesis 
using the same primer pair utilized for α2δ4 MUT. All obtained clones were checked by 
sequencing.  
 
RNA extraction and cDNA synthesis  
Tissues from adult mice (n=3) were dissected and  total RNA was extracted using Trizol 
Reagent (Life Technolgies, Carlsbad, CA), treated with DNase (Roche, Basel, 
Switzerland) and purified using NucleoSpin RNA columns (Macherey-Nagel, Düren, 
Germany). cDNA synthesis was performed using random examers (SuperScript VILO 
cDNA Synthesis Kit, Life Technolgies, Carlsbad, CA). RNA extraction of transfected 
HEK293T cells was performed two days after transfection as described above. 
 
Cell culture and transfection conditions  
HEK293T or tsA-201 cells were maintained in DMEM supplemented with 10% FBS, 
2mM glutammine, 100 U/ul Pen/Strep, and grown at 37°C, 10% CO2. For transfection 
with minigenes, Lipofectamine 2000 (Life-Technologies, Carlsbad, CA) was used. For 
electrophysiological recordings tsA-201 cells were split into 6 cm dishes one day before 
transfections. Transfection was performed using Turbofect transfection reagent (Thermo 
Scientific, Waltham, MA) with 0.5 µg of Cav1.4 α1(Sinnegger-Brauns et al., 2009), 0.5 
µg of β3(Castellano et al., 1993), and 0.5 µg of different α2δ constructs in pIRES2-
EGFP expressing vectors and 1 µg pUC. The α2δ1 sequence utilized was described 
previously.(Ellis et al., 1988) For α2δ1(Ellis et al., 1988) transfections, 0.05 µg of a GFP 
expressing plasmid were cotransfected. One day after transfection cells were seeded at 
low confluence on 3 cm dishes coated with poly-D-lysine and stored over night at 30°C, 
5% CO2. Recordings were performed the following day. In experiments where different 
α2δ constructs were present in the same transfection, the following amounts were used: 
0.5µg of Cav1.4 α1(Sinnegger-Brauns et al., 2009), 0.5µg of β3(Castellano et al., 1993), 
0.5µg of each different α2δ subunit, and 0.5 µg pUC.  
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RT-PCR and densitometric analysis 
PCR protocol consisted in denaturation (94°C; 1 min), 35 amplification cycles (94°C, 
30 sec; 58°C, 30 sec; 72°C, 1 min) and final extension (72°C, 7 min); primers are 
reported in Table S2. Densitometric analysis was conducted using Imagelab 2.0 
software (Biorad, Hercules, CA). Band intensities, corrected for background, were 
normalized to the corresponding Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) 
values.  
 
RT-qPCR 
RT-qPCR was performed in a C1000 thermal cycler with a CFX384 real-time detection 
system (Biorad, Hercules, CA), using the KAPA SYBR FAST master mix (Kapa 
Biosystems, Cape Town, South Africa).  Gapdh was used as a reference gene for 
normalization, using the ΔCt method. Primers are reported in Table S2. Data were 
analysed using the CFX Manager 2.1 software (BioRad, Hercules, CA). For direct 
comparison of E25 and E25b transcripts levels, amplification efficiency and y-intercept 
with the two primer pairs was compared using serial dilutions of plasmid containing 
E25 or E25b. Equivalence of the obtained slopes and y-intercept was assessed with 
extra sum-of-square F test. Data are shown as 2^(-ΔCt(E25)) /2^(-ΔCt (E25b)).  
 
Electrophysiological recordings 
Whole-cell patch-clamp experiments were performed using an Axopatch 700B 
amplifier (Molecular Devices, Sunnyvale, CA). Borosilicate glass pipets (external 
diameter 1.5 mm; wall thickness 0.32 mm; Science Products, Frankfurt/Main, 
Germany) were pulled using a micropipette puller (P97, Sutter Instruments, Novato, 
CA) to obtain electrodes with a resistance of 1.5-3 MΩ. pClamp10.2 (Molecular 
Devices, Sunnyvale, CA) and Prism 5 (Graphpad, La Jolla, CA) softwares were used 
for data-analysis. Recordings were executed at pH 7.4 (with CsOH). In [mM], the 
internal solution contained 135 CsCl, 10 HEPES, 10 EGTA, 1 MgCl2, and the bath 
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solution 15 CaCl2 or BaCl2, 10 HEPES, 150 Choline-Cl, 1 MgCl2. Recording were 
performed at room temperature (19-22 °C). All voltages were corrected for a liquid 
junction potential of -8mV. In all protocols used a holding potential of -98mV was 
applied. To determine current densities (CD), peak current amplitudes were normalized 
to the membrane capacitance. For each analysed cell, the maximum observed current 
density (CDmax) was reported. Protocols for the voltage-dependence of activation and 
inactivation, as well as calcium-dependent inactivation were used as described in 
Burtscher and colleagues(Burtscher et al., 2014)  
 
Statistics 
Statistical analysis was performed with Prism 5 and significance set at P<0.05 for all 
tests. PCR data are represented as mean ± SD, and compared using unpaired two-tailed 
student-t test. Electrophysiological data are represented as mean ± SEM, and analysed 
by Kruskal–Wallis test followed by Dunn's post-hoc test for multiple comparisons. 
Mann–Whitney U-test was used for single comparisons.  
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RESULTS  
 
Computational analysis of Cacna2d4 exon 25 splicing 
We first investigated the feasibility of an exon-skipping approach for the c.2451insC 
mutation (previously annotated as c.2367insC) in exon 25 of Cacna2d4(Wycisk et al., 
2006a) (registered sequence (NM_001033382.2). We first analysed the splicing pattern 
of this and surrounding exons by an in-silico approach using RNA-seq data from four 
eyes and one retina of C57BL/6 mice. Datasets showed that the canonical exon 25 (128 
bp) was not always included in the final transcript. In these cases it was substituted by a 
new exon included between exon 24 and 26 (Fig. 1B). This putative exon of 205 bp, 
named E25b, is located in intron 25 in close proximity to exon 25. If E25b is included 
instead of E25, it terminates the open reading frame of Cacna2d4 in a way similar to the 
known mutation c.2451insC, as it carries a stop codon. E25b was present in less reads 
compared to E25, suggesting that it may be included in a smaller fraction of Cacna2d4 
transcripts. To further corroborate the existence of this new exon we undertook a 
bioinformatics analysis of the 5’ and 3’ splice sites of E25b (Table 1) and discovered 
that the putative E25b showed higher prediction scores with respect to the canonical 
E25. In particular, the 3’ splice site of E25 is very weak, while the 3’ splice site of E25b 
is relatively strong. This strengthens the idea that E25b may be included in place of 
E25, thereby generating an alternatively spliced variant of Cacna2d4. Moreover, it 
suggests that nucleotide variations in E25 sequence may significantly affect its 
inclusion levels in mature transcripts, favouring E25b containing transcripts. We 
hypothesized that the c.2451insC insertion could have such an effect, and 
computationally tested whether it might increase E25b inclusion using the SpliceAid 
webserver.(Piva et al., 2009) The output of the comparisons between WT and mutant 
E25 revealed how the insertion in E25 mainly establishes new exonic splicing silencers 
(ESS) (Fig. 1C). In fact, the prediction showed 7 new ESS with scores between -4 and -
7 in the mutant and only one new exonic splicing enhancer (ESE) with a score of 4 
(Table S3), all absent in the wt sequence. We thus predict a change in the ratio of E25 
and E25b containing transcripts between WT and mutant alleles, with the c.2451insC 
insertion favouring E25b inclusion. These results were supported by analysing the effect 
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of human c.2406C→A mutation in E25, where a predicted ESE is abolished and 
substituted with an ESS (Fig. S1). 
 
 
In vivo and in vitro characterization of exon 25 splicing 
We then verified our above hypothesis by analysing E25 splicing in retinae of 
Cacna2d4 WT and mutant mice.(Wycisk et al., 2006a) We performed an RT-PCR using 
primers on exon 24 and 26 to confirm the presence of E25b along with E25 thanks to a 
clear difference in size (Fig. 2A). Densitometric analysis of PCR products revealed that 
E25b is less abundant than E25 in mature transcripts found in WT retinae. A significant 
decrease in E25 containing transcripts was instead observed in the mutant retina (Fig. 
2B), while E25b levels remained constant. RT-qPCR performed with specific primers 
for exon 25 and exon 25b confirmed that E25-containing transcripts were significantly 
diminished in mutant mice compared to WT; E25b-containing mRNAs were also 
reduced, although to a much lower extent (Fig. 2C). Quantification of E25 and E25b 
containing transcripts revealed that the ratio between the two isoforms changed in 
favour of E25b in mutant animals (Fig. 2D). 
 
We next assessed the effect of the mutation using a minigene reporter system, generated 
by cloning the exons surrounding E25 (exons 22 to 27) together with portions of 
intronic sequences (introns 22 to 26) in an expression cassette (Fig. 2E). Following 
minigene transfection in HEK293T cells, proper splicing between the different exons 
was observed by RT-PCR using primers on E22 and on the plasmid downstream of E27 
(Fig. 2F). Minigene analysis also showed alternative splicing between E25 and E25b, as 
previously described in vivo. Interestingly, in HEK293T cells the effect of the mutation 
was to increase E25b inclusion without affecting E25 levels, as observed by 
densitometric analysis of the RT-PCR (Fig 2G) and confirmed by RT-qPCR (Fig. 2H) 
for the two isoforms. The ratio of E25 over E25b levels revealed that the ratio between 
the two isoforms tended to change in favour of E25b in mutant animals (Fig. 2I). 
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Analysis of α2δ4 ΔE16 splicing isoform expression in the CNS and neuroendocrine 
system. 
By databases analyses, we found the presence of another putative splicing isoform of 
Cacna2d4, obtained from the sequencing of a whole brain cDNA library. This isoform 
is characterized by the absence of exon 16 (α2δ4 ΔE16, GenBank: BC141091.1), an 
exon that encodes for a portion of the first Cache domain of α2δ4, which is conserved in 
all known α2δ subunits.(Davies et al., 2010) We thus investigated the presence of this 
isoform in retina, CNS, and neuroendocrine system by RT-PCR (Fig. 3A). The ΔE16 
isoform was absent in the retina and in the pituitary gland, where all Cacna2d4 
transcripts contained E16. Instead, ΔE16 mRNA was the predominant isoform 
expressed in cerebellum, hippocampus, occipital cortex and somatosensory cortex; both 
variants were present in hypothalamus. Densitometric analysis showed that Cacna2d4 is 
highly expressed in the retina, while lower levels were detected in other areas of the 
CNS (Fig. 3B).  
 
Functional characterization of different α2δ4 variants 
The α2δ accessory subunits have different effects on HVA calcium channels: they 
primarily increase calcium influx by increasing the number of channels on the plasma 
membrane; (Dolphin et al., 1999; Hobom et al., 2000; Jones et al., 1998; Klugbauer et 
al., 2000) in addition, they fasten the inactivation kinetic of some HVA calcium 
channels.(Felix et al., 1997; Hobom et al., 2000; Sipos et al., 2000) To identify how 
α2δ4 subunit modulate Cav1.4 L-type calcium currents, we undertook whole-cell patch-
clamp recordings in tsA-201 cells transfected together with β3 subunits and compared its 
biophysical properties with the more investigated α2δ1.(Burtscher et al., 2014; Koschak 
et al., 2003) Co-expression of full-length α2δ4 resulted in a three-fold increase in current 
density, similarly to α2δ1 (Fig. 4A, 4B, 4D). In addition, α2δ4 and α2δ1 displayed 
comparable voltage-dependent activation and inactivation properties (Fig. 4C and Table 
2). We finally tested the effect of α2δ4 on calcium-dependent inactivation of Cav1.4, and 
identified no differences in the inactivation kinetic between Ba2+ and Ca2+ driven 
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currents. The percentage of remaining current during 250 ms test pulse to 2 and 12 mV 
(which was the voltage of the maximum current with Ba2+ and Ca2+) was 90% for Ba2+ 
and 91% for Ca2+, with no significant difference observed (P = 0.56). No difference was 
found over a voltage range from -40 to +40 mV, as also previously noted with α2δ1 
using the same experimental settings.(Burtscher et al., 2014) Similar results were fairly 
recently reported also for human α2δ4 subunits.(Lee et al., 2014)  
Since our primary aim was to test the feasibility of exon skipping as a potential 
therapeutic approach for α2δ4 mutant subunits, we assessed the functionality of proteins 
missing either three (E23-24-25) or four (E23-24-25-26) exons. Neither construct 
increased current densities and were comparable to our negative control (Cav1.4, β3 
and pIRES vector) (Fig 4D and Table 2). We also characterized the electrophysiological 
properties of the E25b isoform, which we expected to mimic the c.2451insC mutant, 
and the ΔE16 variant: none of these variants evoked a change in current density levels 
(Fig. 4A, 4B, 4D, Table 2), and activation gating properties of Cav1.4 were not altered 
with any of the variants for which we were able to obtain an activation curve (Fig 4C, 
Table 2). We finally tested whether we could exert a possible dominant negative effect 
of the different splicing isoforms or the mutant by expressing them together with full 
length α2δ4 in a 1:1 ratio. We ruled out a possible dominant negative effect of the 
different splicing isoforms as no changes in current densities were appreciated if 
compared to α2δ4 alone (Fig. 5). 
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DISCUSSION 
 
We discovered that the previously described c.2451insC mutation,(Wycisk et al., 
2006a) causing retinopathy in mice, apart from truncating the ORF of the gene after the 
first Cache domain, also affects splicing. The mutation favours inclusion of a newly 
identified alternatively spliced exon, E25b, which also terminates the ORF. The 
mutation created new ESSs on E25, and promoted E25b inclusion in place of E25. In 
vivo, the mutation mainly affected E25, impairing its incorporation in mature mRNA. 
When using a minigene reporter system in HEK293T cells, its effect is instead to favour 
E25b inclusion, without significantly affecting E25 levels. The observed difference of 
action could be due to the presence of different trans-acting splicing factors in the two 
analysed systems: HEK293T cell line and mouse retinae. Differences in the impact of 
nonsense mediated decay on the overall levels of transcripts(Nicholson et al., 2010) 
might also be involved, especially in vivo where we see a general reduction of 
Cacna2d4 mRNA.  
Our findings are also pathophysiologically relevant, since we confirmed the predicted 
role of murine α2δ4 as an accessory subunit of Cav1.4 by characterizing its biophysical 
properties. This subunit is able to increase current densities by three-fold in an 
heterologous expression system, in accordance with the changes in calcium influx 
previously described using human α2δ4.(Qin et al., 2002) Moreover α2δ4 has no effect on 
the activation properties of Cav1.4 and is comparable to α2δ1 when inactivation is 
investigated. We therefore suggest that, since α2δ4 is highly expressed in the retina 
together with Cav1.4, where both localize to photoreceptor terminals,(Busquet et al., 
2010; Knoflach et al., 2013; De Sevilla Müller et al., 2013; Specht et al., 2009) this is 
likely the subunit helping trafficking of Cav1.4 to the plasma membrane of 
photoreceptors, as it is able to mediate the same effect on the channel in an heterologous 
system.  
The α2δ4 isoform resulting from E25b inclusion completely lacks the δ peptide, 
important for membrane anchoring.(Davies et al., 2010; Kadurin et al., 2012) Even if 
α2δ subunits lacking the membrane anchor site are still able to enhance calcium 
currents, they lose this ability when the whole δ peptide is deleted.(Gurnett et al., 1996; 
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Kadurin et al., 2012) Indeed, α2δ4 c.2451insC and α2δ4 E25b did not increase current 
densities. Therefore, the role of the α2δ4 E25b splicing isoform in the retina remains 
elusive, as the protein would be secreted. Elucidation of the presence of a splicing event 
in human CACNA2D4, that resembles the effect of murine E25b incorporation, would 
be important. Specifically, if an alternatively spliced exon truncating CACNA2D4 ORF 
between the two Cache domains exists also in the human gene, also in this case the 
c.2406C→A mutation could favour this inclusion. 
We show that the region encoded by exons 23 to 26 is of fundamental importance for 
the functionality of α2δ4. The removal of this portion indeed impairs α2δ4 ability to  
promote calcium currents mediated by Cav1.4 a1 subunits. The region encoded by these 
exons spans between the two Cache domains and it is not part of any known domain of 
the protein. Moreover, in an α2δ1 paralogue, insertion of an HA tag in the corresponding 
region did not affect the protein ability to mediate an increase in currents.(Kadurin et 
al., 2012) This region may host glycosylation sites important for its 
functionality.(Gurnett et al., 1996) This impairs our therapeutic strategy aiming at 
correcting the retinopathy caused by c.2451insC mutation, since this strategy was 
relying on the therapeutic skipping of exon 23 to 26 or 23 to 25 from transcripts in order 
to eliminate the frameshift mutation on E25 and restore the ORF downstream of it.  
We described the presence of two newly identified splicing isoform (Cacna2d4 E25b 
and Cacna2d4 ΔE16) that were unable to influence Cav1.4 currents. In keeping with 
previous studies, (Schlick et al., 2012) Cacna2d4 ΔE16 is present at low levels in the 
analysed CNS areas. Moreover, in a recent study, a smaller (~165kDa instead of 
~170kDa) α2δ4 was detected by Western blots in mouse brain, possibly being α2δ4 
ΔE16.(De Sevilla Müller et al., 2013) These results strengthen the current 
hypothesis(Dolphin, 2012) that α2δ subunits may fulfill, in the retina and CNS, different 
functions not directly related to trafficking of calcium channels on the plasma 
membrane. The reason for occurrence of two different frameshift-causing mutations 
both on E25 in humans and mice and the presence of a splicing isoform that 
recapitulates the effect of the mutation in mice remains elusive. It is likely that the 
mutation, by mimicking the effect of E25b inclusion, offers a specific advantage in 
heterozygosity (overdominance) in the eye or in other districts where α2δ4 is normally 
expressed. This would allow the conservation of different mutations sharing the same 
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mimicking effect. 
The effect that mutations in the coding region of genes have on splicing is generally 
underestimated: it is today believed that more than a quarter of these mutations interfere 
with proper splicing.(Lim et al., 2011b; López-Bigas et al., 2005; Sterne-Weiler et al., 
2011) As we showed in this work, early investigation of how splicing patterns change in 
response to a mutation is of pivotal importance for the implementation of therapies 
involving antisense-mediated splicing-correcting approaches. To this end, splicing-
reporter minigene assays can constitute a precious ally in this effort: we described here 
for the first time the design and use of a minigene system able to properly recall all 
splicing events across 6.5 Kb and six different exons. With the implementation of more 
efficient gene synthesis services this powerful approach could become relatively easy to 
use.  
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TABLES 
TABLE 1. Splice-site sequences and scores for Cacna2d4 exons 22 to 27.  
 
Score Sequence 5' > 3' 
E22 5'splice site 0.52 ctggagtgtgagttc 
E23 3'splice site 0.92 ttcctgtgactttaccctcaggtgacgaggaactggtgcgg 
E23 5'splice site 0.85 tctctgagtacgtac 
E24 3'splice site 0.93 tgttgttgctttgcctcgcagagagtcagagcctggcgtgg 
E24 5'splice site 0.99 ctgacaggtgagccc 
E25 3'splice site 0.43 acatcaatcctactctcacaggaagttcctgacccctgaag 
E25 5'splice site 0.92 ggaccaggtaacgga 
E25b 3'splice site 0.93 cctctctgtgctcttccccagagtggaaaaagggagatgtg 
E25b 5'splice site 0.99 tcccaaggtgagatc 
E26 3'splice site 0.98 caataattctcatttttccagatagcccaggcaagccagtg 
E26 5'splice site 1.00 gcagcaggtaagagc 
E27 3'splice site 0.98 cctccttcctgtttcctgcagctgtgggcatccagatgcaa 
 
A perfect match with the canonical 3’ or 5’ splice site sequence is indicated by 1. E25b 
scores are higher than those of E25, reflecting stronger splice sites. 
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TABLE 2. Biophysical parameters of different α2δ constructs coexpressed with Cav1.4 
α1 and β3.  
 
 
Experiments were conducted in tsA-201 cells using 15mM Ca2+ as charge carrier. Data 
are given as mean ± SEM. CDmax= maximum current density, V0.5, act= half-maximum 
activation voltage, Kact= slope parameter of the activation curve, V0.5, inact= half-
maximum inactivation voltage, Kinact= slope parameter of the inactivation curve, N= 
sample size, ND= not determined. Statistically significant differences are indicated by 
asterisks (P<0.001=***). For multiple comparisons (CDmax; V0.5 act; Kact), significance is 
given in relation to Cav1.4 α1 + β3 + pIRES. For single comparison (V0.5 inact; Kinact) 
significance is given in relation to Cav1.4 α1 + β3 + α2δ1. Data for α2δ1 V0.5 inact and 
Kinact were taken from Burtscher et al.(Burtscher et al., 2014) 
  
  
144 
FIGURE LEGENDS 
 
FIGURE 1. Scheme of Cacna2d4 transcript and computational analysis of exon 25 
splicing. (A) Schematic representation of Cacna2d4 transcript (not in scale). The 
various exons are numbered. Positions of the von Willebrand factor A (VWF-A) 
domain(Springer, 2006; Whittaker and Hynes, 2002) and of the two Cache(Vivek and 
Aravind, 2000) domains of the protein are shown. The murine c.2451insC mutation site 
and of the resulting nonsense codon are indicated by black arrowheads. (B) IGV 
visualization of the RNA-seq eye sample GSM737548 aligned to Cacna2d4 genomic 
sequence. Position of E25b has been included. Junctions represent reads spanning over 
two exons: alternative splicing of E25 and E25b can be observed. (C) SpliceAid 
prediction of E25 exonic splicing enhancers (ESE, positive scores) and silencers (ESS, 
negative scores). Predictions present only on the mutant E25 are boxed. The mutation 
mainly creates ESSs with high scores. The location of the insertion on E25 is underlined 
in black. 
 
FIGURE 2. Qualitative and quantitative analysis of exon 25 alternative splicing in 
presence and absence of c.2451insC mutation. (A) Representative RT-PCR of WT and 
mutant mouse retinae. Plasmids containing Cacna2d4 sequence with E25 (pE25) or 
with E25b (pE25b) were used as controls. Presence of both E25 and E25b can be 
observed. (B) Densitometric analysis of the RT-PCR on WT and mutant mouse retinae 
reveals a reduction of E25 containing plasmid (P<0.05). (C) Quantification of 
Cacna2d4 E25, E25b and 3’ UTR using RT-qPCR of WT and mutant mouse retinae 
(n=3). A more pronounced reduction of E25 (p<0.001) compared to E25b (p<0.05) 
containing transcripts was observed. (D) Relative abundance of E25 over E25b 
containing transcripts in mouse retinae. The mutation favours E25b presence (p<0.001). 
(E) Schematic representation of Cacna2d4 splicing-reporter minigene. The length of the 
different exons (boxes) and introns (straight lines) is shown. Alternative splicing events 
leading to E25b inclusion are reported with dashed lines. The position of primers used 
in RT-PCR is shown with arrows. (F) Representative RT-PCR of HEK293T cells 
transfected with WT (WT MINI) and mutant (MUT MINI) minigenes. The first line 
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shows the occurrence of proper splicing between all exons included in the minigene. 
Two bands, close to 850 bp, are distinguishable. The lower is caused by E25 inclusion, 
the upper by E25b. The second line confirms the presence of E25b-containing 
transcripts alongside E25-containing ones. (G) Densitometric analysis of the RT-PCR 
on WT and mutant minigenes. The mutation acts on minigene splicing by favouring 
E25b inclusion. (H) Quantification of the two splicing isoforms (E25/E25b) in presence 
or absence of the mutation, by means of RT-qPCR in cells transfected with the 
minigenes (n=2). Data confirms that the mutation causes an increase in the levels of the 
splicing isoform including E25b (p<0.01). (I) Relative abundance of E25 over E25b 
containing transcripts in HEK293T cells transfected with minigene splicing reporter 
systems. The mutation favours E25b presence. 
 
FIGURE 3. Analysis of α2δ4 ΔE16 splicing isoform presence in the CNS and 
neuroendocrine system. (A) RT-PCR with primers flanking E16 on mouse hippocampus 
(HC), pituitary gland (PG), hypothalamus (HPT), occipital cortex (OC), somatosensory 
cortex (SSC), cerebellum (CB), WT (RET WT) and mutant (RET MUT) retina. (B) 
Densitometric analysis of RT-PCR.  
 
FIGURE 4. Effect of different α2δ4 variants on Cav1.4 mediated current density. (A) 
Scheme of the recording protocol and representative sample traces for some of the 
different tested conditions. (B) Representation of the changes in current density at the 
different voltages tested for α2δ1, α2δ4, α2δ4 E25b, α2δ4 MUT (c.2451insC), α2δ4 ΔE16, 
pIRES (empty vector). Mean values, SEM, and the best fits of the current voltage 
relation are shown. The total number of cells considered for each curve is reported in 
parentheses. (C) Voltage-dependent activation curve of α2δ1, α2δ4, α2δ4 E25b, α2δ4 MUT 
(c.2451insC), α2δ4 ΔE16, pIRES (empty vector). (D) Maximal current densities of cells 
measured in the presence of different α2δ4 subunits in comparison to α2δ1 and pIRES. 
For each condition mean and SEM are shown. Selected pairs of conditions were 
compared using Kruskal-Wallis test followed by Dunn’s multiple comparison post-test 
(p < 0.001 = ***). 
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FIGURE 5. Effect of the coexpression of full length α2δ4 with other α2δ4 variants. The 
full length α2δ4 construct was cotransfected with equal amounts of other α2δ4 variants. 
No significant differences on maximal current density were observed in any of the 
tested conditions as compared with α2δ4 + α2δ4, or with α2δ4 + pIRES. As a result no 
dominant negative effect of the different variants on α2δ4 activity was observable in the 
employed experimental conditions. 
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SUPPLEMENTARY MATERIAL 
 
Figure S1. 
 
 
LEGEND TO FIGURE S1. SpliceAid prediction of human mutation c.2406C→A 
effect on CACNA2D4 E25. The position of the mutation is underlined with a black bar. 
Abolished ESE is crossed, while the new ESS is boxed.  
 
TABLE S1. Primers and restriction enzymes used for minigene assembly. 
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TABLE S2. Primers used for RT-PCR and RT-qPCR 
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TABLE S3. SpliceAid complete prediction of splicing factor binding to the mutant 
murine E25 only.  
Protein Name Position in E25 mut Recognized Sequence Score Function 
hnRNP E1 83-89 CCCCCCC -7 ESS 
hnRNP E2 83-89 CCCCCCC -7 ESS 
hnRNP K 83-89 CCCCCCC -7 ESS 
HuR 83-89 CCCCCCC -7 ESS 
hnRNP I (PTB) 83-89 CCCCCCC -7 ESS 
hnRNP A1 83-89 CCCCCCC -5 ESS 
RBM5 83-89 CCCCCCC -5 ESS 
hnRNP U 83-89 CCCCCCC -4 ESS 
Nova-1 83-89 CCCCCCC 3 ESE 
 
Exonic splicing silencer (ESS) or enhancer (ESE) are reported, together with their 
sequence and the computed prediction score. SpliceAid predicts target sequences of 
splicing enhancers and silencers: it gives positive scores for sequences bound by factors 
helping exon recognition and negative ones for sequences repressing exon recognition. 
The higher the score, the stronger is the ESE prediction; the lower the score, the 
stronger is the ESS prediction.  
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Splicing is an important and highly regulated step in gene expression. The ability to modulate
it can offer a therapeutic option for many genetic disorders. Antisense-mediated splicing-
correction approaches have recently been successfully exploited for some genetic diseases,
and are currently demonstrating safety and efficacy in different clinical trials. Their
application for the treatment of retinal dystrophies could potentially solve a vast panel of
cases, as illustrated by the abundance of mutations that could be targeted and the versatility of
the technique. In this review, we will give an insight of the different therapeutic strategies,
focusing on the current status of their application for retinal dystrophies.
Keywords: splicing correction, antisense oligonucleotides, retinal dystrophy, gene therapy
Retinal dystrophies are an extremely diversified group ofgenetic diseases all characterized by visual dysfunctions
that can lead to blindness in the worst cases. Today there are
more than 200 genes responsible for syndromic and non-
syndromic retinal dystrophies,1 each of them carrying several
types of mutations leading to very different clinical phenotypes.
The development of different gene therapy approaches has
given a hope for the implementation of therapies for these
otherwise incurable conditions. Messenger RNA splicing is an
extremely complex and fundamental cellular process that has
been so fare barely considered as a therapeutic target,2,3 even if
it can be seen as a highly appealing one for its importance in
the cell context. The ability to modulate splicing can in fact
offer several advantages over other conventional gene replace-
ment approaches, especially in the context of retinal dystro-
phies. By definition, antisense-based therapeutic approaches
act following base-pairing with their mRNA target, thus giving
the possibility of obtaining a great specificity of action. Since
they act at the mRNA level, the endogenous transcriptional
regulation of the target gene is always maintained. This means
that the therapeutic effect is obtained only where and when the
target pre-mRNA is present. In a highly specialized and
organized tissue like the retina, it is particularly important to
maintain endogenous gene regulation. Therapeutic interven-
tions for delicate processes like the phototransduction cascade
would require the preservation of this control for desirable
outcomes.4 Splicing-correction approaches also allow a fine-
tuning over the relative abundance of splicing isoforms
because, by acting at a pre-mRNA level, it is relatively easy to
modulate their ratio. The availability of several different
molecular tools that can be used to manipulate splicing renders
these approaches a versatile and promising strategy for the
multitude of retinal dystrophies known today. Moreover, the
retina has some characteristics that make it a perfect target
tissue for those therapies. First of all, it is an easy tissue to
access, and different drug delivery routes are in use today.5,6
Being that the eye is relatively small, enclosed, and separated
from the rest of the body by the blood-brain barrier, it
minimizes the required dose and systemic dissemination of
the therapeutic agent, thus avoiding possible complications due
to systemic side effects of the therapy.7 The eye is also an
immune-privileged organ, limiting potential immune response
to the delivered agent.8 The retina is composed by nondividing
cells, thus it is easier to induce prolonged effects or transgene
expression, without the need of using integrating vectors.
Regarding gene delivery, the presence of different adeno-
associated viral (AAV) vector serotypes able to efficiently and
Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
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stably transduce all retina layers9 is a great advantage for
splicing-modulating genetic tools.
THE MRNA SPLICING PROCESS
Once transcription of a gene begins in the nucleus, the
transcript undergoes a complex series of cotranscriptional
processes all devoted to the production of a mature mRNA,
collectively dubbed ‘‘mRNA processing.’’ One of these events,
called mRNA splicing, consists in the removal of intervening
sequences (‘‘introns’’) and the joining of the coding portions of
the transcript (‘‘exons’’). Messenger RNA splicing is a major
way by which the cell can induce transcriptional diversity,
mainly through alternative splicing, and apply a fine control on
this diversity. The proper recognition of introns and exons is
mediated by cis-acting sequences and trans-acting factors. The
principal cis-acting elements that spatially organize the splicing
reaction, consist in the splice donor (DS) site, the polypy-
rimidine tract (Py), the branch-site (BS), and the splice
acceptor (AS) site. There are also other cis-acting sequences
that are fundamental for mRNA splicing10: exonic splicing
enhancers (ESE) or silencers (ESS) that enhance or inhibit
recognition of the exon in which they lay; intronic splicing
enhancers (ISE) or silencers (ISS), intronic sequences that
promote or suppress recognition of the nearby exons. Trans-
acting factors are instead several proteins and ribonucleopro-
teins able to recognize the different cis-elements. Small nuclear
RNA (snRNA) are constitutive components of the small nuclear
ribonucleoproteins (snRNP) U1, U2, U4, U5, U6, and allow
them to base-pair with different cis-acting sequences mediating
the cascade of events leading to the splicing reaction. For
example, the U1 snRNP recognizes the DS site, whereas U2
binds to the branch site. The other two groups of trans-acting
splicing factors are represented by heterogeneous nuclear
ribonucleoproteins (hnRNPs), that have mainly a repressive
function, and by serine- and arginine-rich (SR) proteins, that
play an important role in splicing regulations by mainly binding
to ESE and ISE, thus promoting splicing.11–15 All these factors
assemble together in a precise temporal sequence in a complex
called spliceosome, the cellular machinery devoted to the
TABLE. List of Genes Causing Retinal Diseases
Disease Category Involved Genes
Cone or cone-rod dystrophy/dysfunctions ABCA4 ADAM9 AIPL1 BBS12 C2orf71 C8orf37 CA4 CABP4 CACNA1F CACNA2D4
CDHR1 CERKL CNGA3 CNGB3 CNNM4 CRB1 CRX GNAT2 GUCA1A GUCY2D
KCNV2 MERTK MKS1 NR2E3 NRL OPN1LW OPN1MW PDE6C PDE6H PITPNM3
PROM1 PRPH2 RAB28 RAX2 RDH12 RIMS1 RLBP1 RPE65 RPGRIP1 TULP1
UNC119
Retinitis pigmentosa ABCA4 ARL2BP ARL6 BBS1 BEST1 C2orf71 C8orf37 CA4 CEP290 CERKL CLRN1
CNGA1 CNGB1 CRB1 CRX CYP4V2 DHDDS EMC1 EYS FAM161A FSCN2 GPR125
GRK1 GUCA1A GUCA1B GUCY2D IDH3B IMPDH1 IMPG2 KIAA1549 KLHL7
LCA5 LRAT MAK MERTK MFRP MYO7A NR2E3 NRL OFD1 PDE6A PDE6B PDE6G
PRCD PROM1 PRPF3 PRPF31 PRPF6 PRPF8 PRPH2 RBP3 RDH12 RGR RHO
RLBP1 RP1 RP1L1 RP2 RP9 RPE65 RPGR RPGRIP1 SAG SEMA4A SNRNP200
SPATA7 TOPORS TULP1 USH2A VCAN ZNF513
Leber congenital amaurosis AIPL1 BBS4 BEST1 CABP4 CEP290 CNGA3 CRB1 CRX DTHD1 GUCY2D IMPDH1
IQCB1 KCNJ13 LCA5 LRAT MERTK MYO7A NMNAT1 NRL RD3 RDH12 RPE65
RPGRIP1 RPGRIP1L SPATA7 TULP1
Macular dystrophy/degeneration ABCA4 ABCC6 BEST1 CNGB3 CRX EFEMP1 ELOVL4 GUCY2D PAX2 PROM1 PRPH2
RP1L1 TIMP3
Stargardt disease ABCA4 ELOVL4 PRPH2 CFH HMCN1
Age-related macular degeneration ABCA4 ARMS2 BEST1 C3 CFH ELOVL4 ERCC6 FBLN5 HMCN1 HTRA1 RAX2
SLC24A1
Stationary night blindness CACNA1F CABP4 GNAT1 GPR179 GRK1 GRM6 LRIT3 NYX PDE6B RHO SAG
SLC24A1 TRPM1
Color blindness CNGA3 CNGB3 GNAT2 OPN1LW OPN1MW OPN1SW PDE6C PDE6H
Usher syndrome ABHD12 CACNA1F CDH23 CIB2 CLRN1 DFNB31 GPR98 GUCY2D HARS LRAT
MYO7A PCDH15 PDZD7 TRIM32 USH1C USH1G USH2A
Chorioretinal atrophy/degeneration ABCA4 CRB1 TEAD1
Retinal dystrophies/dysfunctions/degeneration ABCC6 ABCA4 ADAMTS18 AIPL1 BEST1 C1QTNF5 CAPN5 CDHR1 CERKL CHM
CRB1 CYP4V2 FZD4 GUCA1B KCNV2 LRAT LRP5 MERTK NDP NR2E3 NRL OTX2
PANK2 PLA2G5 PROM1 PRPH2 RD3 RDH12 RDH5 RGS9 RGS9BP RLBP1 RPE65
SLC24A1 TSPAN12
Retinopathy of prematurity LRP5 NDP FZD4
Optic atrophy/aplasia MFN2 OPA1 OPA3 OTX2 SLC24A1 TMEM126A WFS1
Wagner syndrome VCAN COL2A1
Bardet-Biedl syndrome ARL6 BBS1 BBS10 BBS12 BBS2 BBS4 BBS5 BBS7BBS9 CEP290 LZTFL1 MKKS MKS1
RPGRIP1L SDCCAG8 TRIM32 TTC8 WDPCP
Other systemic/syndromic diseases involving the retina ABCC6 ABHD12 ADAMTS18 AHI1 ALMS1 ATXN7 CC2D2A CDH3 CEP290 CISD2
CLN3 COL11A1 COL2A1 COL9A1 ERCC6 FLVCR1 GNPTG IFT140 INPP5E IQCB1
ITM2B JAG1 KIF11 LRP5 NPHP1 NPHP4 OFD1 OPA3 OTX2 PANK2 PAX2 PEX1
PEX2 PEX7 PHYH RBP4 RPGRIP1L SDCCAG8 TIMM8A TMEM237 TREX1 TTPA
TTPA USH1C WFS1
All RetNet identified genes have been searched and allocated to disease categories according to HGMD Professional entries from December
2013.
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splicing process. For a more exhaustive description of the
splicing process, we refer the reader to more detailed
reviews.16–18
MUTATIONS LEADING TO RETINAL DISEASES
Retinal dystrophies are caused by mutations in many different
genes, leading to a multitude of disease conditions1,19 (Table).
Today there are 219 genes identified as causative of retinal
diseases, and the number is still growing.1 The total number of
known mutation for 208 of this genes, annotated in the Human
Gene Mutation Database (provided in the public domain by
HGMD Professional, http://www.hgmd.cf.ac.uk/ac/index.
php), is 13.668.20 The large majority of those are represented
by missense mutations, accounting for 34% of the total (Fig. 1).
Small deletions follow as the second most abundant type of
genetic defect (16%). Bona fide splicing mutations represent an
11% of the total. Generally, mutations residing in introns are
categorized as splicing mutations because the amino acid
sequence of the protein is not altered, thus the problem most
likely concerns proper splicing. These mutations can be
located in any of the cis-acting elements present in introns.
But splicing mutations can also be found in the exons, altering
or not the coding sequence. In this case, their identification as
a splicing mutation is much more difficult, as it requires
analysis of the splicing pattern. Today it is believed that more
than 25% of mutations, normally categorized as missense,
nonsense, or silent, actually act by altering the splicing
pattern.21–23 Their effect can be the disruption of a cis-acting
sequence, or the formation of a new one, resulting in exon
skipping, intron retention, or use of alternative DS and AS sites.
Correct identification of these mutations is of pivotal
importance for the development of therapeutic approaches.
Aside from splicing mutations, antisense-mediated splicing-
correction approaches can potentially be utilized for the
correction of missense and nonsense mutations, as well as for
small insertions and deletions. In all cases where a mutation
causes the introduction of a stop codon or frameshift leading to
a premature termination of the transcript, the possibility to
interfere with the proper recognition, by the splicing
machinery, of the exon carrying the mutation (therapeutic
exon skipping) can be the right strategy to follow. The result of
this approach is a shorter mature mRNA, missing the portion
encoded by the skipped exon, but resulting in a restored ORF.
It is then necessary to assess the functionality of the rescued
smaller protein. This strategy is more easily applicable to genes
where the mutated exon encodes for a repetitive structural
element whose loss in the final protein product is less likely to
cause structural and functional defects of the protein itself,
whereas it is a riskier approach in other cases, where proper
function of the skipped protein is less predictable.
ANTISENSE OLIGONUCLEOTIDES
A versatile tool to target splicing is represented by antisense
oligonucleotides (AONs). These are chemically synthesized
molecules, generally around 20 nucleotides long, able to mimic
the RNA structure and bind, by reverse complementarity, to
specific cellular RNA targets. Even if they are normally used to
block mRNA translation or to degrade mRNA by RNase H-
mediated cleavage, these effects are unwanted when the goal is
to interfere with splicing. By the use of several different
chemistries24,25 available today for their design, it is in fact
possible to direct AONs toward splicing relevant sequences on
the pre-mRNA, masking them, and to avoid RNase H activity
after binding. The first splice-switch oligonucleotides used a
phosphothioate linkage to join nucleosides (DNA-PS).26 How-
ever, these AONs were retaining undesired RNAse H activity.24
A second generation of oligonucleotides was created from the
DNA-PS structure. Inclusion at the 20 oxygen of a methyl
(20OMe) or a methoxyethyl (20MOE) protecting group to
increase oligonucleotides resistance to degradation and block
RNAse H activity originates 2 0OMe-PS27 and 2 0MOE-PS28
ribonucleosides, respectively. The third generation comprised
locked nucleic acids (LNA), peptide nucleic acids (PNA), and
phosphorodiamidate morpholino oligonucleotides (PMO).
Locked nucleic acids derive from the addition of a methylene
bridge between the 20 oxygen and the 50 carbon on a DNA-PS
backbone.29,30 Locked nucleic acids have an increased affinity
to target RNA and do not activate RNAse H. In PNAs the DNA
backbone is instead substituted by a peptide-like mimicry.31
Peptide nucleic acids do not cause RNAse H degradation of
their target and show strong affinity to it. Since they are
neutrally charged, addition of a lysine residue is commonly
used to increase their water solubility and cell-uptake.
Phosphorodiamidate morpholino oligonucleotides derive from
the substitution of the ribose rings with morpholine ones, and
their joining by phosphorodiamidate groups.32 Phosphorodia-
midate morpholino oligonucleotides are neutrally charged
oligonucleotides that do not activate RNAse H and are lowly
susceptible to degradation. For a comprehensive understand-
ing of these chemistries, we refer the reader to more specific
reviews.24,25,33,34
In order to be able to regulate splicing, AONs must gain
access to the cell nucleus. There are different splicing
regulatory sequences that have been so far targeted with
AONs on pre-mRNA to achieve splicing modulation (Fig. 2). For
example, by targeting splicing enhancers or silencers, it is
possible to induce respectively exon skipping or exon
retention by blocking access of splicing factors to their target
sites. Another common target of AONs are splice sites that,
when bound by an AON, are no longer free to take part in the
splicing reaction, thus obliging the spliceosome to use
alternative ‘‘downstream’’ sites, again inducing exon skipping.
In few cases, AONs have been also engineered to carry an
additional tail containing cis-acting sequences that can be
bound by splicing factors able to enhance35–39 or silence40–43
splicing of specific exons. In this way, apart from their
antisense activity toward a splicing-relevant sequence, these
bifunctional AONs can induce additional effects depending on
FIGURE 1. Mutation pattern of genes causing retinal diseases.
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the sequence they carry on the tail. Since AONs act by base-
pairing, they are generally believed to allow a high specificity
of action for their desired target. No undesired misspliced
products of the target gene or of chosen unrelated genes were
in fact detected when investigated after therapeutic applica-
tion of AONs.44,45 Even if these findings are not generalizable
and proper design of the antisense molecule should always be
considered, they underline the potentiality of AONs in the
context of target selectivity. Splicing modulation finds its more
advanced application in the cure of Duchenne muscular
dystrophy (DMD). Duchenne muscular dystrophy is an X-
linked recessive disease caused by mutations in the dystrophin
gene. Dystrophin is an important cellular protein whose main
role in muscle fibers is the connection of the cellular
cytoskeleton with the extracellular matrix. Different mutations
in the 79 exons of the gene cause protein truncation due to the
loss of the open reading frame. The majority of these mutations
can be addressed by exon skipping.46 The commonly mutated
exon 51 has been the first target for exon skipping. In the
clinical trials completed so far for exon 51 skipping, the
different chemistries applied (2 0OMe-PS, PMOs) showed
overall efficacy and absence of serious adverse effects.44,47–49
A phase I clinical trial using a 20MOE-PS oligonucleotide for
splicing modulation has also been recently completed for
spinal muscular atrophy (SMA), and a phase II trial has recently
started.50 Mutations in the survival motor neuron 1 (SMN1)
gene are causative of the disease. In humans, SMN1 has a
paralogous, named SMN2. The two genes are identical, apart
from a silent mutation in exon 7 of SMN2. This mutation,
however, causes exon 7 of SMN2 to be less recognized by the
splicing machinery. If exon 7 is not included, the protein is
truncated. So a therapeutic strategy is to mask exon 7 ESS using
AONs, thus promoting exon 7 inclusion, which results in the
production of a functional full length SMN protein from SMN2
that can compensate for mutations on SMN1.
Antisense oligonucleotides are known to be able to target
all retinal layers following intravitreal, subretinal, or topical
administration.51–56 They have long been used to elicit RNAse
H degradation or to block transcription in the eye for several
different diseases, having been applied, for example, against
cytomegalovirus (CMV), herpes simplex virus (HSV), vascular
endothelial growth factor (VEGF), transforming growth factor-
b (TGF-G), fibroblast growth factor (FGF).5,57
An example of the use of splice-switch oligonucleotides in
the eye is that of vascular endothelial growth factor receptor 2
(KDR). The KDR gene has two distinct products: membrane-
bound KDR (mbKDR), that is prohemangiogenic, and soluble
KDR (sKDR), antilymphangiogenic. Soluble KDR needs the
recognition of an alternative polyadenilation site on KDR
intron 13 to be translated. By intravitreal administration of
PMO directed against murine Kdr exon 13 DS site, it was
possible to increase the sKDR/mbKDR ratio at mRNA and
protein level in the retina and vitreous, interfering with the
spliceosome ability of mediating intron 13 splicing58 (Fig. 3).
This resulted in a block of hemangiogenesis and lymphangio-
genesis in a model of choroidal neovascularization and corneal
injury.58 Another recent example of the use of AONs as splicing
regulators to treat a retinal dystrophy is the one of the gene
centrosomal protein 290kDa, (CEP290). Centrosomal protein
FIGURE 2. Possible AONs targets to induce splicing modulation. Schematic representation of cis-acting sequences that are possible target of AONs.
Cis-acting sequences that promote exon recognition are reported in green, whereas sequences that suppress it are highlighted in red. Antisense
oligonucleotides designed to induce exon skipping are shown in the bottom part. Antisense oligonucleotides designed to promote proper exon
inclusion are shown in the upper part.
FIGURE 3. Antisense oligonucleotides approach for KDR. Scheme of
action of AON against KDR exon 13 DS site: normally mbKDR,
originating from intron 23 splicing, is more abundant than sKDR—that
is, instead generated by the use of an alternative polyadenylation site in
the retained intron 13. By interfering with the E13 DS site it was
possible to increase the sKDR form, and decrease the mbKDR one.
FIGURE 4. Antisense oligonucleotides approach for CEP290. (A)
Proper joining of CEP290 exon 26 and 27 (green lines and arrow) is
impaired by a mutation in intron 26 (red star). The mutation causes the
aberrant inclusion of a cryptic exon in a portion of the mature mRNA
(red arrows). (B) Using different AONs (black lines) it was possible to
increase the fraction of correctly spliced mRNA (black arrows).
Splicing Correction of Retinal Dystrophies IOVS j May 2014 j Vol. 55 j No. 5 j 3288
  
 
159 
 
 
  
290kDa mutations are responsible for ~15%59,60 of Leber
congenital amaurosis cases, as well as for other genetic diseases
such as Joubert syndrome, Senior-Løken syndrome, Meckel-
Gruber syndrome, and Bardet-Biedl syndrome. A transition on
intron 26 (c.2991þ1655A>G) is among the most common
mutations of CEP290.61 The mutation introduces a new DS site
on intron 26, causing an aberrant exon to be included in the
mature messenger RNA between exon 26 and 27. This aberrant
exon carries a stop codon, resulting in a premature truncation
of the protein. By the design of 20OMe-PS directed toward
predicted ESE sequences at the 30 of the aberrant exon it was
possible to demonstrate, on patient fibroblast, its skipping
from the mature mRNA, so to efficiently restore proper
splicing between exon 26 and 2762 (Fig. 4). Another study
by Gerard X and colleagues,63 by using 20OMe-PS targeting a
different predicted ESE sequence, came to a similar result.
Moreover, they were able to show an increase of full length
protein levels in patient fibroblast following AON administra-
tion, as well as a faster ciliation.
CHIMERIC AND ADAPTED SNRNAS
The use of AONs as a therapeutic approach for genetic diseases
poses one major problem. Their effect is time-limited, so to
have a durable effect, repeated administration is required. In
this view, the use of engineered snRNAs offer a major
advantage, as they can be delivered in expression cassettes in
the same way as it is done in conventional gene replacement
therapies. By using viral or nonviral delivery systems, it is in
fact possible to transduce or transfect target cells, and then
produce the snRNA exploiting endogenous transcription. Like
for AONs, one of the advantages of this class of RNA molecules
is their specificity of action, as undesired activity of snRNAs has
not been reported so far.64,65 Today there are two classes of
snRNAs that have been successfully modified to be able to
modulate splicing: U1 and U7. The first step of spliceosome
assembly is mediated by U1 recognition of the DS site.66 U7
snRNA is instead not involved in splicing, but in the processing
of the 30 end of histone mRNA.67 They both can be used to
manipulate splicing exactly as AONs. Antisense U1 and U7
snRNA have been applied for masking cis-acting sequences,
thus inducing therapeutic exon skipping, for Duchenne
muscular dystrophy.68–70 Bifunctional U7 snRNA, acting in a
similar way as bifunctional AONs, have also been designed for
DMD71 and SMA.72,73
Small nuclear RNAs can also be applied to a specific set of
mutations not targetable by AONs. When a mutation disrupts a
DS site, it leads to complete or partial loss of the splicing
machinery’s ability to recognize it. The design of mutation-
adapted U1 snRNA able to interact by base-pairing with the
mutated splice site can reestablish spliceosome recogni-
tion.64,74 This is possible by exploiting U1 natural function in
splicing. Unfortunately, the same strategy is so far not applicable
in a similar way to mutations of the AS site, It is also possible to
engineer any viral vector with even a combination of different
snRNAs, by taking advantage of their limited size.70 Tanner and
colleagues75 applied mutation-adapted U1 snRNAs to rhodopsin
(RHO), one of the genes responsible for autosomal dominant
retinitis pigmentosa. An exonic point mutation interfering with
the DS site was found responsible for exon 4 missplicing. By
using minigenes as reporter systems in COS 7 cells, they were
able to show rescue of exon 4 proper recognition with an
efficiency of around 90% after treatment with mutation-adapted
U1 snRNAs75 (Fig. 5). The same strategy was used for a splice
donor mutation of RPGR inducing exon 10 skipping. Proper
inclusion of exon 10 was achieved in patient fibroblast using
mutation-adapted U1snRNAs76 (Fig. 5). Mutations in Bardet-
Biedl syndrome (BBS) 1 result in more than 20% of cases of BBS,
a ciliopathy characterized by retinal dystrophy, cognitive
impairment, obesity, polydactyly, hypogonadism, and renal
disease.77 Bardet-Biedl syndrome 1 is a member of a protein
complex called BBSome, involved in trafficking of vesicles to
the cilia.78 Schmidt and collaborators79 identified in a family
affected by BBS a splice donor mutation on exon 5 of BBS1
causing missplicing. They were able to show, after administra-
tion of mutation-adapted U1 snRNAs, restoration of proper
splicing in COS-7 cells, using minigenes as splicing reporter.
Similar results were obtained in patient-derived fibroblast
transduced with lentiviral vectors encoding for the modified
U1-snRNAs (Fig. 6). A recent innovative approach has been
developed for the treatment of mutations occurring at position
þ5 of DS sites.65 The synergic use of both mutation-adapted U1
and U6 snRNAs was sufficient to achieve efficient correction of
aberrant splicing caused by BBS1 mutations, whereas the only
use of mutation-adapted U1 snRNAs resulted in low levels of
splicing correction.
TRANS-SPLICING
Another correction approach that acts at the splicing level is
spliceosome-mediated RNA trans-splicing (SMaRT). This tech-
nology is based on a cellular process, called trans-splicing. First
discovered in trypanosome,80,81 trans-splicing has been also
described in mammals.82,83 It consists in the ability of two
different pre-mRNAs to originate a chimeric mature mRNA
following a recombination event during splicing. Trans-
splicing can be exploited to correct aberrant mRNA by using
an artificial RNA sequence, called pre–trans-splicing molecule
(PTM). The PTM consists of a correct portion of the cDNA of
the gene of interest, flanked by a region containing all
important element for splicing and the binding domain (BD),
important for specific binding of the PTM to the target
endogenous pre mRNA, mainly on an intronic sequence. There
are three types of PTMs that can be exploited to achieve 50
trans-splicing, 30 trans-splicing or internal exon replacement,
correcting respectively the 50, the 30, or a central region of a
transcript (Fig. 7). Pre–trans-splicing molecules are delivered
in expressing vectors as in a normal gene transfer approach.
They have been administered in vivo using different viral
vectors,84–86 or nonviral delivery sistems.87–89 The peculiarity
of this technique, compared with other splicing-correction
approaches, is the fact that it is mutation-independent, thus the
FIGURE 5. Mutation-adapted U1 snRNA for RHO and RPGR DS site
mutations. The altered splicing pattern caused by the different
mutations is reported in red. The correct splicing pattern is reported
in green. The antisense sequence of the best U1 snRNA used to correct
the effect of each mutation is reported. (A) Mutation at the last base of
exon 4 of RHO causes skipping of the exon or missplicing due to the
use of an alternative DS site. (B) An intronic mutation affecting the DS
site of exon 10 of RPGR leads to exon 10 skipping.
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same PTM can be used to treat different mutations located in
the same region of the transcript.
Even if SMaRT has never been applied so far for the
correction of a genetic disease of the retina, it has been
successfully tested in several in vivo models for spinal muscular
atrophy,88 hemophilia A,90 hyper-IgM X-linked immunodefi-
ciency,86 and tauopathy.84 As there are already exhaustive
reviews91,92 about the first three in vivo approaches, to give an
example of possible application of SMaRT, we spend a few
words on the last and more novel one regarding tauopathy
caused by mutations in MAPT, the gene encoding tau protein.
Tau, a protein important for microtubule stabilization in the
CNS, is subject to active alternative splicing as it is present in
humans with six different isoforms.93 Tau exon 10 encodes for
a tandem repeat and by alternative splicing originates two sets
of different tau isoforms: with 4 (4R; þE10) or 3 (3R; "E10)
tandem repeats. Splicing mutations that lead to a change in the
levels of E10 containing transcripts cause an imbalance in the
4R/3R isoform ratio, and lead to frontotemporal dementia with
parkinsonism linked to chromosome 17 (FTDP-17). Avale and
colleagues84 designed a PTM for 30 trans-splicing with the BD
binding to intron 9, and carrying the cDNA of the last three
exons of tau (E10-E11-E12). They applied the PTMs to Htau
mice that express only human MAPT, resulting in equal
amounts of 4R and 3R.94 Since normal adult mice express
only the 4R isoform, the model recapitulates the effect of a
FIGURE 6. Mutation-adapted U1 snRNA for BBS1 DS site mutations. (A) Normal splicing of BBS1 (green) is altered (red) by a mutation at the end of
exon 5. The mutation causes exon 6 skipping (bottom left) or intron 5 retention (bottom right). (B) Black arrows represent the correcting effect of
the best mutation-adapted U1 snRNA, able to partially restore proper splicing. Arrows dimension represent the amount of the different splicing
products.
FIGURE 7. Schematic representation of the three possible trans-splicing approaches. The different PTMs are constituted by a region harboring:
splicing cis-acting sequences, shown in green; the coding sequence in blue; and the BD. The mature mRNA resulting from the three trans-splicing
approaches is shown with the endogenous sequence in orange, and in blue the sequence introduced by the PTMs.
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splicing mutation abolishing E10 inclusion. Following delivery
of the PTM in the prefrontal cortex of Htau mice by stereotaxic
injection using lentiviral vectors, they were able to show
effective trans-splicing at RNA and protein level.
RNA INTERFERENCE
RNA interference (RNAi) is a regulatory mechanism used by
the cell to silence specific transcripts at the posttranscriptional
level. The endogenous effectors of this mechanism are micro
RNAs (miRNAs). They are transcribed into primary precursors
(pri-miRNA) that are then cleaved first by Drosha into a ~70-bp
precursor hairpin (pre-miRNA), and then by Dicer into a ~22-
bp RNA/RNA duplex.95 One of the two strands (the guide
strand) is then loaded into the RNA-induced silencing complex
(RISC) as a mature miRNA, where it can recognize comple-
mentary mRNAs. Silencing by RISC is caused by translational
repression if the complementarity between the miRNA and its
target mRNA is not perfect. When the miRNA perfectly
matches its target, silencing is instead mediated by cleavage
and subsequent degradation of the mRNA. Small interfering
RNAs (siRNAs) are double-stranded RNA molecules that result
from processing by Dicer of exogenous double-stranded RNAs.
Alternatively, they can be chemically synthetized and delivered
as such for therapeutic purposes. Small interfering RNAs are
directly loaded into RISC. Another class of interfering RNA is
composed by short hairpin RNA (shRNAs), stem-loop struc-
tures that enter the miRNA processing pathway as substrates
for Dicer. Short hairpin RNAs are often obtained from the
transcription of a delivered DNA transgene hereby guarantee-
ing stable expression. On the contrary, the effect of siRNA is
transient, even if different chemistries are today available to
improve their stability. Small interfering RNAs have already
been used to treat retinal diseases for a few years. The first
RNAi therapeutic applications to enter the clinical phase have
in fact been two naked siRNAs developed for the treatment of
AMD: Bevasiranib, directed against VEGF; and AGN211745,
targeting VEGF receptor (VEGFR1). Clinical development of
these two drugs has been discontinued during the last years,
mainly because of their failure in meeting efficacy endpoints.96
Even if other clinical trials are in progress for other naked
siRNA,97 the lessons that we can learn from the two described
trials is that it is a challenge to deliver naked siRNA into cells,
even in an easy system such as the eye, and that their efficacy is
not mediated by RNAi, but via an off-target sequence
independent effect on cell surface Toll-like receptor-3
(TLR3).98,99 New chemistries seem to overcome these limita-
tions,100 and the availability of different types of formulations
(polymer- or lipid-coated nanoparticles, oligonucleotide nano-
particles, and conjugates delivery systems97) can potentially
help in improving cellular uptake in the retina. However, the
current trend for in vivo applications is to utilize viral vectors
to deliver shRNAs to different retinal layers.101–106
By exploiting the mechanism of RNAi-mediated gene
silencing, it is possible to solve different situations in which
correct splicing is compromised. Mutations that cause impair-
ment in the splicing process can lead to misspliced products
that in some cases can show a dominant negative or a gain of
function effect. If this is the case, the simple decrease of the
misspliced mRNA, without affecting the correctly spliced
counterpart, can revert the pathological condition. This is
possible using RNAi.107 A recent example of the application of
this strategy in the retina has been shown for retinitis
pigmentosa.108 Mutations in rhodopsin (RHO) are the most
prevalent cause of autosomal dominant retinitis pigmentosa
(adRP), accounting for 25% of the cases.109 Two mutations
causing adRP (c.531-2A>G and c.937-1G>T) generate mis-
splicing products. They abolish the proper recognition of the
DS site of exon 3 and 5, respectively. Mutation c.531-2A>G
originates two misspliced mRNAs with a partial intron 2
retention or a partial deletion of exon 3. Mutation c.937-1G>T
results in a partial deletion of exon 5. Using RNAi against the
misspliced mRNA, it was possible to successfully decrease their
level without affecting the properly spliced isoform, with the
exception of the second product of c.531-2A>G mutation,
where the RNAi was not able to distinguish between the wild
type (WT) and the aberrant mRNA (Fig. 8).
CONCLUSIONS AND FUTURE PERSPECTIVES
Antisense-mediated, splicing-correction approaches, after their
first and successful application for DMD, acquired a momen-
tum that prompted the efforts for their application to several
disease conditions. Citing only some of the main applications
in the CNS, splicing modulation therapies have been imple-
mented for ataxia telangiectasia (AT), frontotemporal demen-
tia, and parkinsonism linked to chromosome 17 (FTDP-17),
Alzheimer disease (AD), spinocerebellar ataxia (SCA), neurofi-
bromatosis type 1 (NFT1), and many others.110
So far their application in the eye has just begun, showing
great promise. However, there are some limitations that need
to be faced for a successful implementation of such therapies.
The first drawback is that, apart from trans-splicing, all other
approaches are patient-specific. Even if the shift toward
personalized medicine offers great advantages in a long-term
frame, its development poses many challenges in the
immediate future. The limited number of patients treatable
with each antisense molecule raises questions on the feasibility
FIGURE 8. RNA interference for adRP splicing mutations. Left: the effect on splicing of the two RHO mutations c.531-2A>G and c.937-1G>T is
shown. Mutation c.531-2A>G originates two misspliced products (A, B). Right: The different misspliced products can be selectively recognized by
siRNA (black lines) targeting sequences or exon-exon junctions absent in the WT transcript. Small interfering RNA directed toward misspliced
product b of c.531-2A>G mutation was not able to discriminate between the WT mature mRNA and the aberrant one. Adapted from Hernan et al.108
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of normal clinical trials. Moreover, the current need to consider
antisense therapies, even of the same class and for the same
disease, as different drugs if they are targeting different
mutations, creates a great economic obstacle to their
development. Luckily a debate between researchers and
regulatory agencies has already started on these issues.111
Another problem regarding the retina is the difficulties of
having relevant animal models that would allow splicing
manipulation of the gene of interest. The implementation of
such models will definitely foster clinical application of
splicing-correction approaches for retinal dystrophies.
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FIGURE S1. Alignment of human and mouse CACNA2D4 exons 23-24-25-26. ClustalW2 alignment is visualized 
with Jalview. The sequence corresponding to the different exons is highlighted.  
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FIGURE S2. Alignment of human and mouse CACNA2D4 proteins. ClustalW2 alignment is visualized with 
Jalview. Conservation score and consensus are reported. The homology is of 85%.  
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FIGURE S3. Equivalence of the standard curve for pE25 and pE25b plasmids RT-qPCR.  Each point of the two  
fitted curve is represented as mean ± SD (N=5). The two curves for pE25 and pE25b can be represented by a single 
straight line with y-intercept = 8.48 and slope =  -3.23 (Extra sum-of-square F test). 
 
               
TABLE S4. List of primers utilized for RT-PCR and RT-qPCR. 
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